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ABSTRACT 
Over 1.4 million American’s have been diagnosed with an Inflammatory 
Bowel Disease (IBD).  The etiology of IBDs is unknown, however, it is believed 
that these diseases develop due to an inappropriate immune response to the 
microbiota driven by the complex interactions of an individual’s genetics, 
environment and immune system.   The research presented here evaluates one 
aspect from each of the three susceptibility categories (genetics, environment 
and immune system) utilizing the H. hepaticus mouse model for IBD. In this 
model of IBD, the opportunistic bacterium H. hepaticus induces a TH1 mediated 
inflammation in the ceca of susceptible mouse strains such as A/J mice.  All 
described experiments utilized cytokine mRNA expression and histologic 
evaluation.   
First, the effects of estrogen signaling on the development of IBD were 
evaluated in the A/J mouse.  Previous studies within our laboratory have 
demonstrated increased severity of disease in female mice.  Here, experiments 
utilized estrogen receptor (ER) α and β knock-out mice, ERα and ERβ specific 
agonists and the adoptive transfer of CD4+ lymphocytes into RAG2-/-, RAG2-/-
ERα-/- and RAG2-/-ERβ-/- mice.  Collectively these experiments suggest when 
estrogen signaling is limited to ERβ on a non-CD4+ cell population, disease 
severity is decreased.    
Next, the use of a helminth based therapy in this microbiota driven IBD 
disease model was evaluated.  A/J mice with ongoing H. hepaticus induced 
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disease were treated with Trichuris muris.   The data demonstrate that disease 
severity is acutely exacerbated and chronically unaltered by T. muris therapy.  
Additionally, we demonstrated that the response to T. muris , including the A/J 
mouse’s ability to clear worms, is altered when ongoing TH1 mediated 
inflammation exists.   These data collectively suggest that helminth therapeutics 
should be used with caution to treat chronic TH1 mediated inflammation.   
Lastly, the role T regulatory cells in the resistance to H. hepaticus induced 
inflammation was examined.  By utilizing neonatal thymectomies and diphtheria 
toxin treatments, natural T regulatory cells and Foxp3+ T regulatory cells were 
selectively depleted in the C57BL/6 mouse.  As this strain of mice is resistant to 
H. hepaticus induced disease, depletion of these cellular populations allowed for 
evaluation of their role in protection from disease.  We demonstrate that neither 
the depletion of natural or inducible T regulatory cells at the time of H. hepaticus 
inoculation results in disease development in the C57BL/6 mouse.  Additionally 
we present data that suggests H. hepaticus, in this mouse strain, drives a 
protective immune response which may include the induction of inducible T 
regulatory cells.    
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Chapter 1 - Inflammatory Bowel Disease  
Disease Presentation 
Members of the medical community identified the two major forms of 
Inflammatory Bowel Disease (IBD) over 150 years ago - Ulcerative Colitis (UC) 
was first described in 1859 by Sir Samuel Wilks1, followed by Crohn’s Disease 
(CD) in 1932 by Dr. Burril Crohn2.  Unfortunately, despite major advances in 
diagnostics and pharmacological treatments available, neither the etiology nor 
cure for IBD has been discovered.   Presently, the focus of IBD research is 
extremely variable and includes investigations into the influence of genetics, the 
microbiota, the environment and the immune system on disease development, as 
well as the identification of viable treatment options. Overall, the scientific and 
medical communities agree that IBD is the result of an exaggerated and 
inappropriate immune response, most likely instigated by the commensal 
microbiota population3.  
The Crohn’s and Colitis Foundation of America (CCFA) estimates that 
there are approximately 1.4 million people living with an IBD in the United States.  
While IBDs are typically diagnosed early in adulthood4, it has been estimated that 
approximately 10% of those patients living with an IBD in the United States are 
children5.  As there is no cure for IBDs and the response to available 
therapeutics is unpredictable, the associated fiscal and emotional costs 
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throughout an individual’s life are high.  It is estimated that in the United States 
alone approximately 1.7 billion dollars a year are spend on IBD associated health 
care expenses5.   Furthermore, individuals living with active IBDs have been 
reported to have a high incidence of depression6,7,  and an overall lower quality 
of life8-11 than those not living with an IBD. 
Although both CD and UC are described as IBDs, their clinical 
presentations are quite dissimilar.  The hallmark clinical sign for an UC patient is 
presentation with bloody diarrhea with or without accompanying abdominal pain 
and tenesmus.  The clinical presentation of a CD patient is less specific; the most 
common clinical signs associated with CD are abdominal pain, weight loss and 
diarrhea.  CD patients are more likely to experience fever, malaise and anorexia 
than their UC counterparts.4 
Making a diagnosis of either CD or UC can be a long and frustrating 
process, as the etiology of IBD is unknown and there is not a specific test for 
diagnosis.  Before a diagnosis is made, a general examination of the patient, 
including blood counts and the evaluation of general organ function must be 
done.  Additionally the patient must be screened for infectious agents such as 
Clostridium difficile which can cause similar clinical signs as those seen in IBD.  
Often, patients undergo radiography and endoscopic imaging to evaluate the 
extent of intestinal dilation, to perform tissue biopsies, and to check for strictures, 
fistulas and abscesses.4   The development of serologic marker diagnostics for 
IBD patients which test for the presence of specific antibodies shown to be up-
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regulated in either CD or UC has allowed for more exact disease diagnoses and 
may eventually aid in the development of a more individualized treatment 
regimen for patients12.   
Histology and anatomic location of disease can further help distinguish a 
diagnosis of CD from UC. In general, CD lesions are found predominately in the 
ileum and proximal colon, but can be found anywhere in the gastrointestinal (GI) 
tract between the mouth and anus.  Lesions are transmural and found in patchy 
distributions with healthy bowel interspersed with diseased bowel.  The 
development of fisulas between the GI tract and itself, other organs or the skin is 
almost exclusively found in CD patients.  The inflammation found in CD patients 
is characterized by lymphocytic infiltration and the development of 
granulomatous inflammation.  In contrast the inflammation found in most UC 
patients usually begins and extends proximately from the rectum and is 
predominated by neutrophils within the lamina propria (LP) and intestinal 
crypts.3,4,13   
 Defining the type of inflammatory response can also help distinguish 
between CD and UC.  Historically it was thought that CD was mediated by a TH1 
type inflammatory response with the over production of IL-12 p40 and IFN-γ13-16, 
while UC was driven by a TH2 type inflammatory response including increased 
production of IL-1313,14,17.   Recent data demonstrate that the immune response 
driving the development of CD also includes the TH17 inflammatory axis18-21.  Of 
vast importance was finding that IL-23, which is involved in the maintenance of 
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TH17 mediated inflammation14, is composed of the p19 and p40 subunits22,23.  
Previous IBD research which demonstrated the therapeutic effects of IL-12 p40 
subunit neutralization in human IBD patients24-26 and in animal IBD models27, 
which were thought to be acting upon IL-12 alone, had to be re-evaluated. 
Recent literature has demonstrated that TH17 inflammation, plays a substantial 
role in human IBD patients28,29.   To further complicate matters, the vast reports 
documenting the apparent involvement and influence of multiple cell populations 
such as dendritic cells, T regulatory cells, epithelial cells, and T effector cells.  
The role of these cell populations are further discussed later on in this chapter.     
The Triad of Susceptibility 
As previously stated, the etiology of IBD is unknown; however, medical 
and scientific communities alike agree that the development of IBD is due to the 
interaction of multiple factors and not the result of one particular dysfunctional 
gene, molecular incident or pathogen exposure.  Instead, it is suspected that the 
interplay between factors such as an individual’s sex, microbiota, overall hygiene, 
early-exposure to antigens, genetics, lifestyle, and physical environment can all 
affect the likelihood disease development3,18,30-32.    For the purposes of this 
discussion, these factors have been grouped into three main categories:  (1) 
genetics, (2) environment, and (3) the immune system (Figure 1-1).    
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Genetics  
The genetic inheritance from your ancestors can dictate your sex, 
appearance, anatomical attributes and your susceptibility to the development of 
diseases, including IBD.  The evidence for a genetic influence on the 
development of UC and CD has been demonstrated repeatedly through 
epidemiologic studies which evaluated the importance of sex33,34 and ethnicity35.  
Furthermore, identification of numerous susceptibility loci for IBD in general and 
for UC and CD specifically, has solidified the role of genetics in disease 
development36.   
Familial Predispositions  
 The influence of race and ethnicity on IBD has been extensively studied in 
many regions of the world37.  Within the United States, Caucasians have the 
highest incidence of IBD; they are closely followed by African Americans, then 
Hispanics and Asians35,38.  Interestingly, individuals of Hispanic or Asian origin 
were more likely to develop UC, and African Americans and Caucasians were 
more likely to develop CD35,39,40.  A study done in British Columbia supports 
these findings – Caucasians were more frequently diagnosed with an IBD and 
were more likely than either of the Asian populations (Pacific and South Asian) 
evaluated to develop CD41.  Interestingly, the authors identified differences in 
disease presentation between the two Asian populations – the South Asian 
population was more likely to be diagnosed with UC than their Pacific 
counterparts41. The occurrence of IBDs within families has also been shown to 
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be variable dependent on the ethnicity of the family for example, within 
Caucasians those of Jewish descent are more likely to develop either CD and 
UC than non-Jewish individuals42.      A compounding factor of these studies are 
the environmental factors which may predispose to the development of IBD; 
because of this the region of the world from which study samples are taken must 
be considered.  This concept is further explored in the “Environmental Influences” 
section of this chapter.   
In regards to familial inheritance of an IBD, it was shown in the early 
1990s that your risk of developing IBD was ten times greater than the general 
population if you had a relative with either UC or CD, suggesting a genetic 
component to disease development43.  Studies done in twins have demonstrated 
a higher incidence of IBD as a whole in both individuals when the twins are 
monozygotic, as opposed to dizygotic44,45.  Overall, twins have proven to be an 
invaluable resource for the division of environmental and genetic influences on 
IBD development46. 
Sex Bias  
Although not nearly as severe as the female sex biases reported in many 
autoimmune diseases such as Sjogren’s syndrome, rheumatoid arthritis or 
multiple sclerosis47-50, a slight female sex bias has been reported for CD33.  
Furthermore, when severity of disease is evaluated, it has been shown that 
female IBD patients are more likely to experience severe disease than their male 
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counterparts34.   Interestingly, more female than male patients are affected by 
other diseases which involve the deregulation of the gastrointestinal (GI) mucosal 
immune system, such as Irritable Bowel Syndrome51, colon cancer52  and  
microscopic colitis53,54. Furthermore there are reports of IBD severity being 
influenced by gonadal hormone related events such pregnancy 55,56, estrogen-
based hormone replacement therapy57 or either the use or cessation of oral 
contraceptives58-61.  Overall the literature has presented evidence that gonadal 
sex hormones could be involved in the development and regulation of IBDs, 
particularly CD.   
Susceptibility Loci  
Since the early 2000s when the first CD susceptibility gene NOD2 
(CARD15)62,63 was identified, the existence of IBD susceptibility loci, has been 
extensively evaluated. To date, over 160 distinct genetic loci have been identified 
which can influence the development of IBDs36,64-68.   One-hundred and ten of the 
163 identified loci are associated with both UC and CD patients, with the 
remaining 53 split relatively equally between CD (30) and UC (23)65.   
Interestingly, about 70% of the susceptibility loci identified for IBD have also been 
identified as susceptibility loci for other immune modulated diseases36,69.  This 
overlap supports the influence of other factors such as the environment and 
microbiota on disease when a genetic modification which has the potential to 
predispose for IBD development, is present.  
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Further complicating the matter was the realization that different ethnicities 
may have different IBD susceptibility loci.  The infamous NOD2 loci identified in 
Caucasian IBD patients, is not important in Asian patients62,63.  Research 
focused on Japanese IBD patients has identified novel susceptibility loci in 
Asians not previously identified in Caucasian case studies70,71.  
Environment  
The environment in which you choose to live contains a variety of factors 
which may affect you immune system in a positive or negative way.  Exposure to 
helminths, cigarette smoking, your microbiota and overall hygiene all have the 
potential to affect the development of IBD.30,32,72    
Microbiota  
When discussing IBD, the role of microbiota in disease development is 
undisputed.  For the purposes of this discussion, microbiota is defined as all the 
bacteria living within the GI tract of an individual person or mouse73.  As the 
number of bacteria living within us vastly outnumber the number of cells in our 
own bodies73, it is not unexpected that they have the capability to alter intestinal 
homeostasis74-76.   The influence of the microbiota has been documented in both 
IBD patients77,78 and in mouse models79-81 of IBD.    In general, the microbiota 
has been shown to be integral in the  development of a functional immune 
system82.  Interestingly, several of the genetic susceptibility loci identified for IBD, 
such as NOD2 and ATG16L1 are involved in the recognition and response to the 
9 
 
microbiota78.  A recent publication which has correlated the use of antibiotics in 
children with the development of IBDs also lends support to the need for an 
unaltered and healthy microbiota for proper immune development31.   
 The microbiota has been shown to interact with multiple cell types 
involved in the maintenance of GI homeostasis.  For example, the induction of 
inducible T regulatory cells, a set of regulatory cells which can suppress 
inflammatory processes such as colitis, has been shown to be influenced by the 
microbiota83-86.  Furthermore, adoptive transfer experiments in germfree mice 
have demonstrated that the microbiota is necessary for the induction of T cells 
responsible for colitis development87-89.  The discovery that dendritic cells (DC) 
penetrate the epithelial barrier to sample luminal contents further solidified the 
involvement of the microbiota in gut homeostasis90,91.  As the gut epithelium is 
the physical barrier between members of the microbiome and the immune 
system, is not surprising that the expression of cytokines by the epithelium can 
influence dendritic cell luminal sampling92.  
It is likely that the influence of microbiota on the development of IBD is 
dependent upon the pre-existence of other risk factors however, the possibility of 
pathogenic bacteria being responsible for IBD cannot be completely ruled out at 
this time.   The development of advanced microbiome analysis techniques will 
help shed light on these unanswered questions.   
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The hygiene hypothesis  
In the early 1990s it was proposed that excessive cleanliness can deprive the 
developing immune system of the antigen exposure needed to prime appropriate 
immune responses.  This phenomenon is now known as the hygiene hypothesis 
and simply suggests that lack of antigen exposure early in life can predispose 
children to the development of immune-related diseases, such as IBD93.   In the 
time since, the hygiene hypothesis has been extensively evaluated and not yet 
been disproved94-97.   
Developed versus Developing Countries  
As previously mentioned, IBDs are a diagnosis historically made in the 
developed countries of North America and Europe18 however, the rate of 
diagnosis in other regions of the world such as Asia and Africa has slowly 
increased 37,98.  It was once believed that race, due to familial genetics, was an 
important factor in the development of IBD however, recent studies have 
provided data that lifestyle and environment may have more of an influence than 
genetics as incidence of disease appears to be altered with a change in 
geography.  For example, a study that compared the incidence of UC in South 
Asian immigrants to the United Kingdom demonstrated that second generation 
immigrants had a higher incidence of UC, in comparison to first generation 
immigrants99.  Furthermore the incidence of UC in the second generation 
population was comparable to that seen in the indigenous European population, 
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further lending support to the hygiene hypothesis and the importance of 
environment in development of IBD99. 
Helminths  
When considering exposure to antigens capable of affecting gut 
homeostasis in developed and developing countries, gastrointestinal parasites 
immediately come to mind.  In developed countries where the incidence of IBD is 
high, Westernized living’s hygiene standards have included the eradication of 
gastrointestinal parasites95,96.   Interestingly, reports have emerged that suggest 
the integration of western lifestyle practices, such as the use of anti-helmintics, 
could be linked to increased IBD diagnosis rates in regions such as Asia, Africa 
and South America37.   For example, in South Africa, where western hygiene 
standards are being practiced by some individuals, exposure to helminths during 
childhood appears to be protective against IBD development100.  Similar trends 
have been noted in China, where a rise in IBD diagnoses correlates with the 
introduction of Westernized living practices98.  
Smoking 
 A relationship between IBD development and tobacco use has been 
identified101-104.  As approximately 1 out of every 5 adults in westernized 
countries smoke, the effects on the immune system and inflammation in general 
have been extensively researched102.  As cigarette smoking has been repeatedly 
shown to having systemic pro-inflammatory effects, it is not surprising that it has 
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an effect on the development of IBD.  What was surprising, however, was the 
finding that while smoking increases the risk for CD, it is protective for the 
development of UC101-104.   
Interestingly, a recent publication demonstrated that cessation of cigarette 
smoking correlated with a considerable shift in the microbiota population, that 
include an increase in bacterial diversity105.  Findings such as these demonstrate 
the complex relationship between factors previously thought to independently 
effect disease development.  It is yet to be determined if the protective effects of 
cigarette smoking seen in UC are due to the decreased stimulation by a less 
complex microbiota or decreased levels a particular microbe responsible for 
inciting inflammation.         
The Immune System 
Although IBDs are believed to develop when a disturbance in normal 
immune function occurs106, they are not classified as an autoimmune disease as 
the immune response is not targeted towards self-antigens107.  Rather, the 
immune response is most likely targeted towards endogenous, non-pathogenic 
bacteria.  Mouse models and human research have identified many members of 
the immune system as being involved in the development and resulting 
inflammation seen in IBDs36. 
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Effector T cells  
 Following thymic development and selection, naïve T cells capable of 
differentiating into effector T cell populations, migrate to the periphery108.  Their 
differentiation into TH1, TH2, or TH17 effector cells is mediated by the expression 
of IL-12, IL-4 and IL-6/TGFβ, respectively14,109-112.  Originally it was thought that 
CD was driven by the expansion of TH1 T cells and UC by TH2 T cells.  However, 
recent advances in the understanding of TH17 inflammatory pathways suggest 
the involvement of these effector cells in CD as well14,113,114.   
 Following differentiation, T effector cells secrete pro-inflammatory 
cytokines such as IFN-γ, IL-13 and IL-17.  It has been shown in IBD that the 
elevated levels of these cytokines are predominately produced by activated T 
cells3,14,17,108.  Mouse models of IBD have demonstrated the importance of 
lymphocytes in the development of colitis and general intestinal inflammation 
through adoptive transfer experiments and studies utilizing lymphocyte deficient 
mice16,115-119.  Elevated production of the TH2 cytokine IL-13 in UC patients15-17,120 
and the TH1 and TH17 cytokines IFN-γ and IL-17 in CD patients3,14-16,21,121 has 
further supported the involvement of lymphocytes in disease progression.  
Antibody neutralization therapies which target the actions of lymphocytes by 
inhibiting IFN-γ and IL-12/23 have had promising results25,122-124.  T effector cells 
are suppressed endogenously by IL-10 and TGFβ which are secreted and 
expressed by T regulatory cells. 
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T regulatory cells  
T regulatory cells are a type of lymphocyte generally identified by the 
expression of the transcription factor Foxp3 and are capable of suppressing the 
immune system through the secretion of anti-inflammatory cytokines such as IL-
10 and TGFβ125-137.  The concept of a suppressive cell that could control the 
immune system had existed within the scientific community for decades138 and 
was truly implied in the mid-1900s with the observation that removal of the 
thymus causes an uncontrolled immune response which ultimately results in 
autoimmunity139-142.  Since this time, thousands of articles attempting to 
characterize and describe this cell population have been published, including one 
in 2003 by Bluestone and Abbas which suggested the existence of not one but 
two distinct CD4+ regulatory cell populations: a natural and an inducible T 
regulatory cell143.  Their speculations have since been proven132,133,143-153 and it is 
now known that inducible T regulatory cells can develop from CD4+ naïve T cells 
in the periphery127,128,138-148154-158.  Interestingly, the microbiota which is believed 
to be involved in IBD development, has been shown to play an important role in 
the induction of inducible T regulatory cells which can control the development of 
colitis84,86.    
Humans without a functional Foxp3 gene lack T regulatory cells and many 
develop severe intestinal inflammation due to the uncontrolled infiltration of 
lymphocytes159-162.  In a similar fashion, mice without functional T regulatory cells 
have been shown to develop colitis163,164.  It has not been shown that those with 
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IBD have dysfunctional T regulatory cells.  However, it has been demonstrated 
that a decreased proportion of T regulatory cells are present in IBD patients 
compared to healthy controls165, which may be due to an increased rate of T 
regulatory cell apoptosis166.   As T regulatory cells have been shown to suppress 
lymphocyte proliferation in vitro via IL-10 and TGFβ167-169, it is not surprising that 
they can suppress colitis development in vivo118,170,171.   Furthermore, T 
regulatory cells have been shown to be capable of both preventing and reversing 
colitis in mouse IBD models116-119,155,172-178.   
Dendritic Cells  
Dendritic cells (DCs), are an antigen presenting cell (APC) which are 
present in the lamina propria of the gut and are responsible for directing immune 
responses to pathogens.  DC have been shown to penetrate the epithelium in 
order to monitor the microbiotia makeup90,91.  Following antigen recognition, 
either an inflammatory immune response or the induction of tolerance can be 
orchestrated by DCs179-181.  In CD patients, intestinal DC have been shown to 
produce elevated levels of the cytokine IL-12, which drives TH1 lymphocyte 
differentiation, in comparison to healthy controls182.  Additionally, the expression 
of toll-like receptors (TLRs) on DCs has been shown to be elevated in IBD 
patients compared to controls182.   
Mouse models of IBD have further demonstrated the involvement and 
importance of DC in the maintenance of intestinal homeostasis.  In the dextran 
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sulfate sodium (DSS) mouse model of colitis, selective depletion of dendritic cells 
decreases inflammation, while the adoptive transfer of DC increases disease 
severity183.  Clustering of DC and lymphocytes has been observed prior to the 
onset of colitis and suggests these two cell types interact during disease 
development184.  Interestingly, in both adoptive transfer and DSS mouse models 
of IBD, active colitis resulted in a decreased number of CD103+ DCs185, which 
have been reported to be required for the induction of inducible T regulatory cells 
in the periphery186-188.   
The Epithelium 
 The gastrointestinal epithelium is not only a physical barrier between the 
gut lumen and the body, but also a highly dynamic system intricately involved in 
the maintenance of gut homeostasis in which commensal bacteria are tolerated 
and pathogens incite an immune response189.  Epithelial cells routinely utilize 
pattern recognition receptors (PRR), such as toll-like receptors, to survey luminal 
contents189-192.  Although specific TLR defects have not been identified in IBD 
patients, several susceptibility loci contain TLR signaling components and some 
believe alterations in TLR capabilities may contribute to differences in disease 
severity between patients193.   NOD2 mutations identified in IBDs62,63 can affect 
the PRR activity of a specialized epithelium cell known as the Paneth cell, which 
in addition to pathogen recognition also secrets defensins that have antimicrobial 
activities194.   
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In addition to pathogen recognition, epithelial cells are capable of directing 
dendritic cell activities through the production of cytokines92 and have been 
shown to play a role in the activation of T cells195.  Disruption of the nuclear 
factor-ΚB (NF-KB) signaling pathway, which drives the transcription of cytokines 
when unaltered, within epithelial cells has shown to disrupt GI homeostasis and 
can result in increased susceptibility to colitis in mouse IBD models196,197.   
Not to be overlooked is the mucus component of the GI epithelium, which 
is secreted by goblet cells, and covers the epithelial cell luminal surface serving 
as an additional layer of defense against bacteria198.  While UC patients have 
been shown to have decreased colonic mucus layers, CD patients do not appear 
to share this defect199.   
Therapeutics for IBD  
While not classified as a disease with high mortality, IBDs require life-long 
medical attention as there is no known cure.  In general, the treatment options 
available to patients are designed to suppress clinical signs and include surgery, 
pharmaceutics and alternative therapies.  Special consideration in treatment 
plans must be made for children5,200-202, the elderly203,204 and women currently or 
planning on becoming pregnant4,205.  Additionally, the mental health of IBD 
patients must be taken into consideration when a treatment plan is being 
developed206,207.  Overall the treatment of IBD is complicated by the “sub-groups” 
of patients which respond differently to treatment, suggesting the need for 
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personalized medicine in which treatment is tailored to each patient individually, 
rather than to the disease diagnosis in general208-210.   
Surgery 
Today, there is a high surgical recession rate among IBD patients, 
approximately 20-30% of UC patients and 70-80% of CD patients will undergo a 
surgical resection during their lifetimes as a result of uncontrolled disease4.  The 
decision to undergo surgery for an IBD patient is most often due to the 
persistence of uncontrollable clinical signs.  UC patients are typically treated 
more aggressively in regards to surgical recession of the bowel due to the 
consistent anatomical location of lesions4. Often, those with UC, will have a total 
proctocolectomy instead of a partial colectomy due to the high probability that 
disease will re-develop in the remaining colon203.  While UC patients who have 
undergone a total proctocolectomy will often live disease free postoperatively, 
this is not the case for CD patients who have undergone bowel resections203.      
For a CD patient, surgical resections are more conservative and are 
recommended to be limited to areas of symptomatic macroscopic disease4 such 
as obstructions, abdominal abscesses, bleeding, the development of cancer, and 
extreme cases of stricture or dilation203.  The use of laproscopic surgery has 
made IBD related procedures less invasive, thus making surgery a viable option 
for patients who would not be considered surgical candidates due to the risks 
associated with traditional surgery techniques203.   
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Pharmaceuticals  
Pharmaceutical treatment for IBD patients include the use of: 
aminosalicylates, corticosteroids, immune modulators and biological 
therapies4,211-214.  Unfortunately, widely variable remission rates are reported with 
these treatments211,215 and can be difficult to interpret due to IBD’s cyclic patterns 
of exacerbation and remission4.    Also, many IBD clinical trials lack evaluation of 
a true placebo group, which further complicates the ability to identify the true 
efficacy of proposed  treatments215.     
Aminosalicylate treatment utilizes 5-ASA derivatives for the treatment of 
mild to moderate UC and CD216.  Its main target are GI epithelial cells4 where it is 
suspected to limit the release of inflammatory mediators such as prostaglandins 
and leukotrienes which ultimately, through decreased release of cytokine and 
reactive oxygen metabolities, inhibit activation of NF-KB216.    
Corticosteroids can be administered orally (prednisolone, prednisone and 
budesonide), intravenously (hydrocortisone or methylprednisolone) or topically 
(hydrocortisone and prednisolone)4.  These drugs are generic anti-inflammatories 
that suppress the induction of inflammatory pathways such as IΚB, which is 
upstream of NF-KB activation.  Additional mechanisms of action include: 
decreased interleukin transcription and the induction of lymphocyte apoptosis 
within the GI lamina propria.4  The side effects associated with corticosteroid use 
and their lack of efficacy beyond suppression of acute inflammation limit their 
long-term use in IBD patients4,216,217.  Immune modulators which target either 
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particular cell populations or mechanisms required for cell life can also be used in 
IBD patients.  Examples include methotrexate which inhibits DNA and RNA 
synthesis through dihydrofolate reductase inhibition and ciclosprin (CsA) which 
inhibits calcineurin which limits lymphocyte expansion4.   As with corticosteroids, 
generic immunosuppression can occur with long term treatment216. 
Tailored biological therapies target specific signaling molecules and 
receptors involved in the IBD inflammatory response.  Treatments which 
neutralize TNFα are popular and include adalimumab, certolizumab pegol and 
infliximab4,122,212,216.  Therapies targeting CD3+ and CD25+ T cell populations 
utilize the antibody based drugs visilizumab and daclizumab, respectively122,212.   
Also available are treatments which neutralize or block the receptors of IL-12, IL-
6, IFN-γ and IL-2122.  Interestingly, responses to supplemented recombinant IL-
10, which was thought to be integral in the suppression of IBD development, 
have been contradictory and sometimes unsuccessful in clinical trials218-221. 
Alternative Therapies  
The pharmaceuticals previously described have not been developed to 
target the etiology of IBD but rather the resulting inflammatory processes 
associated with disease and clinical signs.  As previously stated, the remission 
rates achievable with these therapeutics are low211 and has led to investigations 
into non-traditional therapeutic options for the treatment of IBD such as 
helminths, cell based therapeutics and the use of probiotics or antibiotics to alter 
the microbiota212.   
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Helminths  
As previously discussed, the hygiene hypothesis suggests that in an 
attempt to achieve cleanliness, people are depriving their immune systems of 
antigen stimulation needed for a balanced immune system.  One such exposure 
situation is helminths.  As a result, the use of helminths as a therapeutic is 
currently being examined in IBD patients222-226.  Preliminary data generated in 
clinical trials which administered Trichuris suis to patients with active IBD 
demonstrates a decrease in disease related symptoms and/ or the induction of 
remission in approximately 70% of patients227,228.  A study documenting the long-
term effects of T. suis in humans without IBD demonstrated that within four 
months of continued treatment there was a lack of clinical signs associated with 
helminthosis229.  Although results from these clinical trials have been promising, 
patient reluctance to be treated with worms and the documented negative effects 
of acute parasitism with T. suis, has limited this method of treatment229.  Further 
complicating the use of helminths as a therapeutic option is the lack of quality 
control protocols for the generation of medical-grade helminths230,231.  To 
circumvent the negative attributes of helminth therapy, worm derived proteins 
and/or molecules is also being considered230-232.   
Antibiotics & Probiotics  
As the microbiota has been repeatedly demonstrated to be integral in the 
development of IBD, it is logical that antibiotics and probiotics, both of which 
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have the potential to alter the microbiota population, would be considered 
therapeutically.  Like antibiotics, which are drugs that target specific 
classifications of bacteria, the administration of probiotics, which typically consist 
of live bacteria, to the IBD patient has the potential to alter the microbiota 
makeup by preventing the overgrowth of pathogenic bacteria74,77,233,234.     
It has been demonstrated that both antibiotics and probiotics can have 
positive effects in UC patients with pouchitis77,235.   In practice, the antibiotics 
metronidazole and ciprofloxacin are often used in conjunction with the traditional 
pharmaceuticals discussed earlier, and their use in CD patients seems to be 
beneficial in achieving and maintaining remission77,216,235.  Whether antibiotics 
and probiotics have the capability to act upon a specific bacterial population 
which, unbeknownst to us, is responsible for disease development or are merely 
beneficial in restoring a healthy microbiome is unknown.  Controlled clinical trials 
are needed to further evaluate the effects of both in IBD patients.   
Cell-Based Therapeutics  
Cell based therapeutics are an interesting alternative to traditional 
therapeutics for IBD and involve treatment with or targeting of a particular cell 
population.  Treatment with T regulatory cells is currently being examined as an 
IBD therapy and involves the isolation and/or induction of T regulatory cells from 
a patient to be used in their own treatment regimen208,236,237.  Supporting the 
possible applications of this new therapy, is the recent discovery that T regulatory 
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cells can be isolated from patients with CD, cultured, propagated in vitro and then 
used to suppress T cell proliferation238.  Despite the political controversy 
associated with stem cell therapy, preliminary clinical trials have produced 
promising results in IBD patients122,208,212.  
Clinical trials involving selective cell depletion, accomplished with 
apheresis through either centrifugation or column filtration appear to have 
beneficial effects in IBD patients122.   Granulocytes, monocytes, lymphocytes and 
platelets can all be removed from IBD patients with this technique; the cells 
targeted and extent of depletion depends upon the apheresis technique 
utilized122,212. 
Unfortunately, despite the extensive array of traditional and non-traditional 
therapeutic options available for IBD patients, a panacea has not been found.  
Overall, managing IBD is a difficult task considering the extreme variations in 
remission rates reported within IBD patients211,215, the unpredictable cyclic 
patterns of exacerbation and remission4 and the general lack of balanced clinical 
trials utilizing placebo controls215.  As previously stated, the need for a 
personalized medicine approach in which patients undergo  treatments 
specifically tailored for them following biomarker and genetic analysis, rather than 
to the disease diagnosis in general, is needed208.   
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The Helicobacter hepaticus model of IBD  
Attributes of the model 
There are a multitude of mouse models utilized to study IBD, all of which 
utilize different “triggers” to induce IBD-like inflammation; examples of which 
include: adoptive cell transfers, the administration of haptenating agents and 
genetically modified mice239-241.  The trigger used in our model of IBD is the 
bacterium Helicobacter hepaticus.   The genus Helicobacter includes multiple 
bacteria, all of which are motile, gram-negative, microaerophlic organisms.  This 
genus is most known for H. pylori which has been repeatedly shown to be 
associated with the development of gastritis, gastric ulcers and gastric cancer, 
such as adenocarcinoma, in humans242-244.  Multiple helicobacter species have 
been identified which infect mice including, but not limited to: H. hepaticus, H. 
mastomyrinus, H. bilis, H. ganmani, H. felis, H. muridarum and H. thyphonius245-
250.  As many rodent vendors and institutional research colonies have been 
shown to harbor Helicobacter spp., the role these bacteria play in disease 
modeling and overall animal health has been questioned245,247,251.   
When the prevalence of H. hepaticus, the species utilized in our IBD 
model, was evaluated it was found that many wild-type mice harbor the bacteria 
but do not exhibit disease245.   Because of the overall lack of pathogenic 
evidence in most mouse strains, H. hepaticus it is not thought of as an infectious 
pathogen, but rather as an opportunistic member of the murine microbiota.  In the 
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genetically susceptible A/J mouse, however H. hepaticus is capable of inducing 
inflammation of the cecum which can be utilized as an IBD model25,252-254.   
Although the exact mechanism of action is unknown, the presence of H. 
hepaticus is thought to catalyze an immune response towards other members of 
the microbiota, which results in the development of inflammation.  The presence 
of Helicobacter spp. in general, and H. hepaticus specifically, has been 
demonstrated to have immune modulating capabilities within the GI system89,255-
264.  Furthermore, several models of IBD, have reported the need for H. 
hepaticus, in combination with the endogenous microbiota, for the development 
of consistent, severe disease79,265-267.   Although the role of the microbiota is 
undisputed in human IBD, helicobacters have not been linked to disease 
development to date268.   
Overall, the A/J H. hepaticus model for IBD recapitulates the hypothesized 
dysfunctional interaction between an individual’s immune system and microbiota, 
which may or may not contain pathogenic members75,80.   As previously 
discussed, a genetic susceptibility loci has not been identified that is consistent 
for all IBD patients, thus suggesting the importance of other factors such as the 
microbiota74,75,80 and environmental influence30,32. Unlike other mouse IBD 
models which require a genetic modification or exposure to a haptenating 
agent239-241, this model is triggered by a microbiota member.    
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One distinction of the  H. hepaticus IBD model is that it incorporates a 
genetic susceptibility component as many inbred mouse strains infected with H. 
hepaticus exhibit no evidence of disease development25,245,247.  For example, A/J 
mice administered H. hepaticus develop histologic inflammatory lesions in the 
cecum three months post inoculation while C57BL/6 mice do not25,254.  It is 
unknown as to why these two mouse strains ultimately respond differently to the 
addition of H. hepaticus to the endogenous microbiome.  Despite knowing that 
both strains are persistently colonized, data on the effect of H. hepaticus 
bacterial loads on the immune response has been contradictory25,269.  
Differences in genetics between the two strains has also been evaluated with 
Quantitative Trait Loci (QTL) and loci have been identified on chromosomes 3 
and 17 which are thought to be linked to disease susceptibility, as identified by 
the production of IL-12/23 p40.  Several of the potential genes identified in this 
QTL analysis have been shown to be involved in disease development in human 
IBD patients, thus giving further support for the use of this mouse model for the 
study of IBD.270      
An additional shared attribute of the H. hepaticus IBD model and IBD is 
the existence of both a sex bias and differences in disease severity between the 
sexes.  CD has a documented slight female sex bias33  and, female IBD patients 
are more likely to experience severe disease than their male counterparts34.   In 
a similar fashion, female A/J mice inoculated with H. hepaticus develop a more 
severe histologic disease than inoculated male A/J mice252.  Lastly, the 
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inflammation seen in female A/J mice recapitulates several aspects of that seen 
in CD including the the up-regulation of IL-12/23 p40 and IFN-γ25,253.   
Disease Presentation  
Acute Immune Response (4 days post-inoculation)  
Four days following inoculation with H. hepaticus both A/J and C57BL/6 
mice have elevated expression of pro-inflammatory cytokine and chemokine 
genes25.  At this time point, no histologically detectable changes exist.   Included 
in the list of elevated cytokines are the anti-inflammatory cytokine IL-10 and the 
pro-inflammatory cytokines IL-12/23 p40 and IFN-γ25,252-254.   
The cytokine IL-12 is comprised of two subunits: p40 and p70 and is 
produced by APCs such as DCs and other phagocytotic cells, like macrophages, 
which are involved in the initial immune response to bacteria271.  The production 
of IL-12 drives TH1 differentiation of naïve T cells, while simultaneously inhibiting 
TH2 differentiation, which is typically mediated through IL-4110,114,272,273.   Naïve T 
cells differentiate into TH1 lymphocytes following stimulation with IL-12 and IFN-γ; 
the initial production of IFN-γ is attributed to NK cells following bacterial 
stimulation108.  The resulting TH1 lymphocytes, after activation of the JAK/STAT1 
and T-bet signaling pathways, secrete more IFN-γ108,274,275, which acts in a 
positive feedback fashion to further induce the production of IL-12 by APCs276.  
This perpetuates the differentiation of more naïve T cells into TH1 lymphocytes108.   
This positive feedback loop could potentially be involved in the uncontrolled 
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inflammation seen in IBD, as neutralization of IFN-γ can prevent disease 
development in the H. hepaticus IBD mouse model25,123,124. 
IL-10 involvement in IBD development is also logical, as IL-10 knock-out 
mice exhibit cecal inflammation265,277,278, as do humans with IL-10 production or 
receptor defects220.  IL-10 is produced by multiple cell types, including T 
regulatory cells and suppresses inflammation by inhibiting the differentiation of 
lymphocytes through the down regulation of IL-12 production by dendritic cells 
and macrophages108,172.  H. hepaticus IBD mouse models have repeatedly 
demonstrated the importance of T regulatory cells and IL-10 in abrogation or 
prevention of disease development118,123,124,176.  
Chronic Immune Response and Disease Development (90 days post-inoculation)  
Despite both mouse strain’s immediate response to H. hepaticus¸ only the 
A/J mouse has a detectable immune response 90 days post-inoculation.  At this 
time, in addition to the elevations in mRNA expression seen 4 days post-
inoculation, A/J mice inoculated with H. hepaticus will have detectable typhlitis 
(inflammation of the cecum).   This inflammation can be described as an 
infiltration of lymphocytes within the lamina propria of the cecum25,252-254 and is 
characterized by a chronic TH1 (IL-12/23 p40 and IFN-γ) driven intestinal 
inflammation25,253 which is similar to the distribution and degree of inflammation 
seen in CD patients15,16.   C57BL/6 mice evaluated at this time point will not have 
elevations in mRNA gene expression, nor will they have histologic disease8.   
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Prologue to Chapters 2-4   
The research presented here evaluates one aspect from each of the 
three susceptibility categories (genetics, environment and immune system) 
utilizing the H. hepaticus mouse model for IBD. First, in Chapter 2, the effects 
of estrogen signaling on the development of IBD is evaluated.  Previous studies 
within our laboratory have demonstrated increased severity of disease in female 
mice.  The experiments described in Chapter 2 utilized estrogen receptor (ER) 
knock-out mice, ER specific agonists and adoptive transfers to demonstrate that 
decreased severity of disease occurs when estrogen signaling is limited to ERβ 
on a non-CD4+ cell population.  This data was generated through the 
collaborative efforts of both the author and Dr. Andrew Hillhouse.     
In Chapter 3, the use of a helminth based therapy in this microbiota 
driven IBD disease model was evaluated.  Our results suggest that the use of 
helminths, when disease is driven by a particular member of the microbiota, is 
not recommended and has the potential to exacerbate disease severity.  
Furthermore, we demonstrated that the ability to clear the helminth T. muris is 
hindered by the presence of H. hepaticus, thus suggesting that an individual’s 
immune response to helminths can be altered by their microbiota.  
 
Next, in Chapter 4, we evaluated the role of natural and inducible T 
regulatory cells in immune response to H. hepaticus, which serves as our 
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model’s trigger for IBD-like inflammation.  With the use of neonatal thymectomies 
and selective depletion of Foxp3+ cells the role of inducible and natural T 
regulatory cells were evaluated.  We demonstrated that inducible T regulatory 
cells, but not natural T regulatory cells, have a protective function in microbial 
driven inflammation.   The final chapter briefly outlines the author’s unpublished 
experiments which often served as preliminary data for those experiments 
described in Chapters 3-5.  
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Figure 1-1. The Inflammatory Bowel Disease Triad of Susceptibility. 
The development of IBD has not been linked to any one particular pathogen, gene or exposure 
incidence.  The development of this disease is believed to be driven by the complex interactions 
of an individual’s environment, immune system and genetics.   
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Chapter 2 - The Role of Estrogen Signaling in a Mouse 
Model of Inflammatory Bowel Disease: A Helicobacter 
hepaticus model 
 
Introduction 
Crohn’s disease (CD) and ulcerative colitis (UC) are classified as 
inflammatory bowel diseases (IBDs) and are diagnosed primarily in North 
America and northern Europe3.  There are approximately one million people in 
the U.S. living with IBDs5, and while the cause is unknown, differences in 
intestinal microbiota, hygiene, genetics, geography, and the environment can 
contribute to disease development3.  There is no known cure for IBDs and 
current treatments are predominantly pharmaceutical, merely suppressing clinical 
symptoms.  When pharmaceutical intervention fails, the final option for treatment 
is bowel resection. 
ERα and ERβ modulate gene expression by directly interacting with 
estrogen response elements or other transcription factors279, and have been 
implicated in the modulation of several immune-mediated diseases48.  For 
example, physiologic events that result in elevated estrogen levels are 
associated with increased disease severity in systemic lupus erythematous (SLE) 
patients, but decreased disease severity in rheumatoid arthritis (RA) and multiple 
sclerosis (MS) patients47,49,50.   Furthermore, there are distinct sex biases in colon 
cancer52 and inflammatory intestinal disorders such as Irritable Bowel Syndrome 
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(IBS)51 and microscopic colitides53,54, suggesting a role for gonadal sex 
hormones (GSHs), including estrogen, in the modulation of intestinal health.  
GSH-related events, such as menopause, pregnancy and the use of oral 
contraceptives can modulate IBD.  In particular, the development of IBD has 
been associated with oral contraceptive use58,59 and the cessation of oral 
contraceptive use has been associated with the resolution of clinical signs and 
symptoms60,61.  Furthermore, women are partially protected from disease flare-
ups during pregnancy55 and estrogen-based hormone replacement therapies are 
associated with decreases in disease severity in post-menopausal patients57. 
 Animal models of IBD also support the use of estrogen therapies to 
modulate disease.  For example, in an IBD model utilizing the HLA-B27 
transgenic rat, estrogen administration decreases diarrhea and intestinal 
inflammation280.  Further work with this model has demonstrated decreased 
disease severity when NF-κB signaling is inhibited by ERB-041, a selective ERβ 
antagonist281-283.  Furthermore, estrogen administration decreases disease in 
other IBD models such as dinitrobenzene sulfonic acid (DNB)-induced and acetic 
acid-induced colitides284,285. Finally, estrogen signaling has also been shown to 
protect against the development of colitis-associated diseases, such as 
neoplasia, in the azoxymethane/dextrane sodium sulfate (DSS)-induced 
colorectal cancer model286.   
In the Helicobacter hepaticus-induced model of IBD, susceptible mouse 
strains, such as the A/J mouse, develop histologically observable disease in the 
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cecum three months post-inoculation25. While the exact mechanism by which H. 
hepaticus initiates disease is unknown, it is believed that H. hepaticus colonizes 
the cecum and serves as a provocateur for a CD-like inflammatory response 
against endogenous microbiota.  Findings by Cahill et al. and Maggio-Price et al. 
demonstrated that the presence of H. hepaticus modulates mucosal immune 
responses89,256-258.  H. hepaticus-induced typhlitis is characterized by lymphocytic 
infiltration of the lamina propria and increased expression of the TH1 cytokine 
genes IL-12/23 p40 and IFN-γ, as well as TNF-α and the chemokines CXCL9 
and CXCL1025,252-254.  H. hepaticus-infected female A/J mice develop more 
severe intestinal inflammation and have significantly higher TH1 cytokine gene 
expression than infected males252.  This data and the previously reported 
associations between estrogen and IBD led to the hypothesis that estrogen 
signaling modulates the development of H. hepaticus-induced inflammation.  To 
test this hypothesis, H. hepaticus-infected ERα- and ERβ-knockout mice and 
mice treated with ER specific agonists were used.  Additionally, an adoptive 
transfer model was used to identify the cell type through which estrogen-
mediated events occur.  
Results 
Estrogen administration decreases disease severity  
To evaluate the role of estrogen, female mice were ovariectomized at 3-4 
weeks of age and implanted with either a placebo (control) or continuous-release 
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hormone pellet (1.5 mg - supraphysiologic dose of 17β-estradiol, E2).  All mice 
were orally inoculated with H. hepaticus one week post-operatively.  Ninety days 
post-inoculation, mice were sacrificed and ceca collected for the evaluation of 
histologic disease and mRNA expression.  
The ceca of placebo-treated animals had an increase in cellular infiltration 
and thickening of the cecal mucosa (Figure 2-1A, top), whereas the E2-treated 
animals had little to no inflammatory infiltrates (Figure 2-1A, bottom).  Evaluation 
of cecal histologic sections revealed that E2-treated animals had significantly 
lower lesion scores than those that received the placebo treatment (Figure 2-1B).   
We previously demonstrated that mRNA expression of IL-12/23 p40, IFN-γ 
and CXCL9 is elevated during H. hepaticus-induced intestinal inflammation25.  
Estrogen treatment significantly reduced the cecal expression of all three 
inflammatory mediators compared to placebo-treated animals (Figure 2-1C).  The 
decreases in inflammation and inflammatory gene expression suggest estrogen 
could effectively reduce disease severity. 
Decreased disease severity when estrogen signaling is limited to ERβ  
To determine the relative role of the two estrogen receptors, ERα and 
ERβ, in modulating disease, A/J ER-/- and ER-/- mice were inoculated with H. 
hepaticus at 3-4 weeks of age.   To serve as controls, heterozygotes (ERα+/- or 
ERβ+/-) and wild-type littermates were also inoculated.  Ninety days post-
inoculation, mice were necropsied and their ceca assessed for histologic 
36 
 
inflammation and mRNA expression.  Mean lesion scores of ER-deficient mice 
did not differ from those of the control mice, however ER deficiency resulted in 
a significant decrease in disease (Figure 2-2A).  Because female IBD patients 
are more likely than male patients to experience severe disease34, the incidence 
of severe disease in this model (defined as a lesion score ≥6) was evaluated.  
When estrogen signaling was limited to ERβ (ERα-deficient mice) a significantly 
lower incidence of severe disease was observed in comparison to control and 
ERβ-deficient mouse groups (Figure 2-2B).  Analyses of the ceca of ERα-
deficient mice showed significantly decreased mRNA expression of CXCL9 and a 
trend of decreased IFN-γ expression levels when compared to littermate controls; 
there were no differences in the expression of IL-12/23 p40 (Figure 2-2C).   
ERβ signaling decreases the development of inflammation and 
inflammatory cytokine expression 
Although data generated using knockout mice suggest that lack of 
functional ERα decreases disease development, it is possible that these changes 
are the result of preferential estrogen signaling through ERβ, rather than the lack 
of ERα.  To better identify the mechanism by which disease development is 
modulated, ER-specific agonists were utilized.    
Wild type A/J mice were ovariectomized at 3-4 weeks of age, implanted 
with an ERβ agonist (DPN), ERα agonist (PPT), or placebo continuous-release 
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pellet, and then inoculated with H. hepaticus one week post-operatively.  Ninety 
days post-inoculation, mice were sacrificed and ceca collected for evaluation.     
Histologic evaluation demonstrated that treatment with the ERβ agonist 
(DPN) was associated with significantly less cecal inflammation compared to the 
control mice (Figure 2-3A), while treatment with the ERα agonist (PPT) did not 
alter intestinal inflammation compared to control mice.  The percentage of mice 
with severe disease (severe lesion score ≥ 6) in the group treated with DPN was 
significantly less than the control group (Figure 2-3B).  Cecal expression of IL-
12/23 p40 and CXCL9 was significantly less than in placebo-treated control mice.  
Again, there was a trend of decreased IFN-γ expression in the DPN-treated mice 
when compared to the control and PPT-treated mouse groups (Figure 2-3C). 
Collectively, these results indicate that signaling through ERβ reduces the 
expression of CXCL9, and IL-12/23 p40, and that this ultimately results in 
reduced intestinal inflammation.  
Estrogen signaling on non-CD4+ lymphocytes suppresses disease 
development and decreases IFN-γ production  
Previous studies in our laboratory have demonstrated that H. hepaticus 
induces a TH1 inflammatory response, suggesting a role for CD4+ T cells in 
disease development.  Administration of the ERβ agonist decreases expression 
of genes expressed in CD4+ and non-CD4+ cellular subsets. To investigate the 
influence estrogen receptors have on  individual cellular subsets, adoptive 
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transfer experiments were carried out using controlled expression of estrogen 
receptors on CD4+ T cells and non-CD4+ T cells.   
In the first experiment, splenic CD4+ lymphocytes were isolated from mice 
deficient for either ERα or ERβ and adoptively transferred to RAG2-/- A/J mice. 
As a control, CD4+ lymphocytes isolated from wild type A/J mice were adoptively 
transferred to RAG2-/- recipients.  Ninety days after adoptive transfers, all mice 
were sacrificed and ceca collected.  Histologic evaluation revealed no significant 
differences in mean lesion scores between mice that received CD4+ lymphocytes 
from wild type, ERα-deficient, or ERβ-deficient donors (Figure 2-4A).  Analysis of 
the cecal expression of IL-12/23 p40, IFN-γ and CXCL9 revealed no significant 
differences between the experimental and control mice (Figure 2-4B-D), implying 
that estrogen signaling on a CD4+cell population is not responsible for altering 
disease development.  
 In the second adoptive transfer experiment, the role of ERα and ERβ on 
non-CD4+ lymphocyte cell populations was examined by adoptively transferring 
CD4+ lymphocytes from wild type donors into mice inoculated with H. hepaticus 
and dually deficient for RAG2 and either ERα or ERβ expression.  Again, H. 
hepaticus-inoculated RAG2-/- mice with functional ERα and ERβ were adoptively 
transferred wild type CD4+ lymphocytes as controls.   
 Adoptive transfer of CD4+ lymphocytes into mice lacking ERα resulted in 
significant decreases in disease severity (Figure 2-5A). Interestingly, among the 
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cecal cytokines and chemokines studied, IFN-γ mRNA levels were significantly 
less in both the group missing ERα and the group missing ERβ on the non-CD4+ 
cellular subsets (Figure 2-5C).  There were no differences in IL-12/23 p40 and 
CXCL9 expression (Figure 2-5B & D).  The reduction in disease development 
along with the decreased expression of IFN-γ in the mice lacking ERα signaling 
capabilities on their non-CD4+ cells provides further support that estrogen 
signaling through ERβ can modulate mucosal inflammation.   
Discussion 
The regulation of autoimmune diseases by gonadal sex hormones (GSHs) 
is complex and multifaceted.  There are many theories as to why women are 
more likely to develop an autoimmune disease.  Many of these recognize the 
influence of GSHs; additionally most acknowledge that females, due to their 
evolutionary role to bear offspring, have an immune system programmed to 
accept exposure to allogeneic antigens, such as a developing fetus during 
pregnancy47,49.  Many diseases, such as MS, RA and SLE, demonstrate a female 
sex bias48,50.  In SLE, elevations in estrogen are associated with increased 
disease severity, while in MS and RA, increases in estrogen levels, such as 
occurs during pregnancy, have been shown to decrease disease severity50,287.  
Additionally, animal models of MS288-290 and RA291 have recapitulated the 
beneficial effects of estrogen therapies.  
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The mucosal immune system of the gastrointestinal track also appears to 
be highly influenced by estrogen signaling.  A female sex bias is seen in both 
IBS51 and Crohn’s disease, a subset of IBD33, although it is small relative to the 
sex-bias of many other autoimmune-related diseases48.   Furthermore, there is 
evidence that estrogen can modulate disease severity in IBD patients55-57 and in 
animal models of IBD280-283.  The influence of gondal sex hormones is also 
apparent in our model as female H. hepaticus-infected A/J mice develop more 
severe intestinal inflammation than their male counterparts252.  Additionally, there 
is a greater increase in the expression of inflammatory TH1 cytokines and 
chemokines in H. hepaticus-infected female mice, relative to male mice252.   In 
light of these observations, we sought to investigate the effects of estrogen 
signaling on disease development and the associated cytokine responses.   
As mentioned, in other animal models of autoimmune diseases such as 
experimental autoimmune encephalomyelitis (EAE), collagen-induced arthritis 
and DNB-induced colitis, high doses of estrogen effectively decrease disease 
severity280,284,285.   Our findings that administration of estrogen decreases 
disease severity are consistent with these reports.  The immune response to H. 
hepaticus infection in A/J mice is a TH1-type immune response characterized by 
an increase in cecal expression of IL-12/23 p40, IFN-γ, TNFα, IP-10 and 
CXCL925,252.  In these studies, we assessed the mRNA expression of IL-12/23 
p40, CXCL9 and IFN-γ as markers for the immune response and demonstrated 
that estrogen administration in H. hepaticus-infected mice was associated with 
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significantly decreased expression of all three.  Decreases in IL-12/23p40, IFN-γ 
and CXCL9 gene expression and histologic disease suggest that estrogen 
therapy affects microbe-induced TH1-type inflammation of the cecum. 
The exact mechanism by which estrogen alters disease has yet to be 
identified and although chronic estrogen treatment reduces disease severity, 
these alterations may be secondary to estrogen’s systemic effects.  Evaluation of 
estrogen-treated animals did confirm the presence of systemic changes.  When 
compared to placebo treated animals, estrogen-treated mice had reduced 
numbers of circulating red blood cells (RBCs), reduced weight gain, and changes 
in urogenital anatomy (data not shown).  Anatomical changes associated with 
estrogen administration included swelling and hardening of the cervix, as well as 
urinary abnormalities such as the inability to urinate normally and bladder 
distension.  Secondarily, urine leakage and perianal swelling and inflammation 
were observed in some mice (data not shown).   Although it is unclear if chronic 
estrogen treatment directly decreases intestinal inflammation or if the change is a 
secondary effect, the other clinical effects associated with chronic estrogen 
therapies negate its therapeutic viability. 
To circumvent the unwanted side effects of chronic estrogen 
administration, while still utilizing the anti-inflammatory properties of an estrogen-
based therapy, selective estrogen receptor (ER) modulation was evaluated.   
Although the signaling pathways initiated by ERs have been shown to elicit 
distinct immune responses in other models of autoimmune disease281,292, the 
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relative expressions of ERα and ERβ vary between the intestinal cellular 
populations and thus induce a variety of immune responses293-299.  Further 
investigation was required to identify both the specific cell type and estrogen 
receptor responsible for decreased disease severity following estrogen 
administration.  
To assess the role of specific ERs, mice lacking either ERα or ERβ were 
inoculated with H. hepaticus.  ERα-/- mice had decreased severity of disease that 
appeared to be mediated through both the innate and adaptive immune response 
as expression of IL-12/23 p40 did not significantly vary, but IFN-γ and CXCL9 
were decreased.  Although these results are somewhat inconclusive, it is 
reasonable to hypothesize that ERα signaling promotes a pro-inflammatory 
immune response, and removal of this signaling pathway decreases disease 
severity.  Alternatively, removal of ERα may simply redirect most estrogen 
signaling through ERβ, and preferential signaling through this receptor modulates 
the inflammatory response and decreases disease severity.   
We subsequently demonstrated decreases in both disease development 
and inflammatory mediator gene expressions when mice were treated with the 
ERβ agonist DPN.  Other studies have also suggested a role for ERβ in 
modulating intestinal inflammation58, in particular the publication by Looijer-van 
Langen et al. that demonstrates decreased ERβ expression in both human IBD 
patients, and in rodent models of IBD, including the IL-10-/- mouse and the HLA-
B27 rat300.  The recent work by Saleiro et al. has further highlighted the protective 
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properties of intestinal ERβ signaling by demonstrating the ability of ERβ 
signaling to inhibit the development of colitis-associated cancers in mice286.  
These findings were further supported by an epidemiological study in which the 
authors demonstrated that females with IBD are less likely to develop colorectal 
cancer than male IBD patients33.  Our results also suggest that ERβ signaling 
may be important in suppressing the development of H. hepaticus-induced 
typhlitis.  ERβ is expressed primarily on intestinal epithelial cells, suggesting its 
signaling would function primarily through the innate immune response.  
Signaling through ERβ increases the development of tight junctions in the 
intestinal epithelium and decreases intestinal permeability300-302, possibly 
resulting in decreased sampling of the luminal bacteria.  Furthermore, treatment 
of colonic cells in culture with either 17β Estradiol or DPN, the ERβ agonist used 
in this study, results in increased epithelial resistance300.  Increased epithelial 
resistance could decrease the ability of bacterial antigens to stimulate the 
immune system and could explain the decreased expression of IL-12/23 p40 
seen in the ERβ agonist (DPN)-treated mice.   
The finding that loss of ERα, which results in preferential signaling through 
ERβ, decreased disease severity, coupled with the finding that an ERβ agonist 
also decreased disease severity, initially suggests that signaling through ERβ 
abrogates the immune response and ultimately prevents development of 
inflammation.  However, given these findings, we expected ERβ-deficient mice to 
have increased disease severity, but this was not the case.  Given the complexity 
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of the mucosal immune system there are several plausible explanations for our 
findings.  The first being that this model’s maximum disease severity had been 
reached and depletion of ERβ was insufficient to further exacerbate disease 
beyond this plateaued level.  Conversely, it is also plausible that the immune 
response, in addition to being down-regulated by ERβ signaling as demonstrated 
by our ERβ agonist treatments, is up-regulated when estrogen signaling occurs 
solely through ERα.  Further experiments were needed to identify the cell types 
in which ERα and β was occurring in our model. Previously published findings 
have shown intestinal epithelial cells express ERβ52,301 and CD4+ T cells express 
ERα303 making it necessary to evaluate the involvement of both CD4+ and non-
CD4+ cellular populations in disease modulation. 
To identify the cell type through which ER signaling modulates disease, an 
adoptive transfer model was utilized.  When estrogen signaling on CD4+ T cells 
was altered, no differences in histologic disease or mRNA expression were 
observed. However, when non-CD4+ cellular populations lacked ERα signaling, 
disease severity was decreased and IFN-γ mRNA expression was lowered.  
These results suggest that the development of H. hepaticus-induced 
inflammation is independent of estrogen signaling on CD4+ T cells, and is 
dependent on estrogen signaling in a non-CD4+ cellular population. Interestingly, 
although the development of inflammation was not affected when there was a 
lack of ERβ signaling on non-CD4+ cells, there was a significant decrease in the 
amount of IFN-γ mRNA present in the cecum.  These results suggest that, 
45 
 
although both ERα and ERβ signaling is linked to IFN-γ production, only 
signaling through ERβ is capable of changing histologic disease development.  
It is possible that, in this experimental model, the changes in IFN-γ gene 
expression are not due to the direct effects of estrogen signaling.  For example, 
estrogen signaling in dendritic cells can decrease antigen presentation and, in 
turn, indirectly affect the resulting immune response.  Reports on the expression 
of ERs on dendritic cells are somewhat contradictory and although it is generally 
accepted that ERα is constitutively expressed on dendritic cells296, there are 
reports of co-expression of ERβ304,305.  Additionally, in vitro studies have shown 
that a lack of ERα results in decreased dendritic cell differentiation.  Furthermore, 
these populations can be restored with high doses of E2, thus demonstrating the 
ability of ERβ to induce dendritic cell differentiation independently of ERα304.   
The findings reported herein also suggest that ERβ-mediated immune 
modulation is occurring through a non-CD4+ cell population which expresses 
ERβ, such as epithelial cells or dendritic cells. Epithelial cells with increased ERβ 
signaling could be increasing tight junctions and consequently decreasing the 
overall antigen pool presented to the immune system.  Alternatively, ERβ 
signaling on dendritic cells may be altering antigen presentation to the overall 
immune system, ultimately resulting in decreased disease development.           
Overall, this research suggests that when estrogen signals solely through 
ERβ in a non-CD4+ cell population, an immunosuppressive effect occurs.  This is 
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supported by data from knock-out animals, ER agonists, and adoptive transfer 
experiments, all of which demonstrated decreased histologic disease 
development when estrogen signaling is limited to ERβ.  This research supports 
further investigation of the potential uses of targeting estrogen signaling 
pathways, particularly ERβ, to modulate the development of pathology in 
diseases such as IBD.   
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Materials & Methods 
Ethics Statement  
This study was conducted in accordance with the Guide for the Care and Use 
of Laboratory Animals and approved by the University of Missouri Animal Care 
and Use Committee [ACUC Protocol Number: 7749].  All surgical procedures 
were performed under isoflurane anesthesia and all mice received post-operative 
buprenorphine for analgesia.   
Mice 
Wild type A/JCr mice were obtained from Frederick National Laboratory for 
Cancer Research. 
Generation of estrogen receptor (ER) and RAG2 deficient A/J Mice 
B6;129-Esr1tmUNC (ERα knockout)306 and B6;129-Esr2tmUNC (ERβ knockout)307 
mice were kindly donated by Dr. Dennis Lubahn of the University of Missouri.  A 
marker-assisted congenic breeding scheme was used to transfer the ER 
mutations to the A/J mouse strain.  Resulting strains (A.129(P2)-Esr1tmKsk/Mmmh 
and A.129P2(B6)-Esr2tmUNC/Mmmh) strain were subsequently submitted to the 
Mutant Mouse Regional Resource Center (MMRRC 029880 and 029908 
respectively).  C57BL/6 mice containing a disruption in the Rag2 (recombination 
activating gene 2) gene were obtained from Taconic laboratories (B6.129S6-
Rag2tm1Fwa).  Again, a marker-assisted congenic breeding scheme was used to 
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generate Rag2-deficient mice on an A/JCr background (A.129S6(B6)-
Rag2tm1Fwa).  The generation of mice with mutations in both Rag2 and either ERα 
or ERβ was accomplished by crossing the A.129S6(B6)-Rag2tm1Fwa strain with 
either A.129(P2)-Esr1tmKsk/Mmmh or A.129P2(B6)-Esr2tmUNC/Mmmh mice.   
ERα, ERβ, and RAG2 PCR  
At 3-4 weeks of age, all mice were ear-tagged (National Band & Tag, 
Newport, KY) and 3-5 millimeter tail snips were collected for genotyping. DNA 
was extracted using a Qiagen DNeasy DNA extraction kit (Valencia, CA) per 
manufacturer’s protocol. The resulting DNA was used in PCR reactions to 
determine each individual mouse’s genotype.  Each reaction contained 0.2 μl 
FastStart Taq (5 U/μl) (Roche, Indianapolis, IN), 0.3 μl of each 25 μM primer (IDT 
Coralville, IA), 3.2 μl of 1.25 mM dNTPs (Roche) and 2 μl 10× PCR buffer with 
MgCl2 (Roche). Thermal cycling conditions were: 1 cycle at 94⁰C for 4 min, 45 
cycles of 15 at 94⁰C , 45 sec at the appropriate annealing temperature (Table 1), 
1 min at 72⁰C and 1 cycle at 72⁰C for 10 min.  PCR reactions were analyzed by 
gel electrophoresis with 3% 1× TBE agarose gels and amplicons were visualized 
with ethidium bromide (Bio-rad Hercules, CA). Primer sequences, product sizes 
and annealing temperatures are listed in Table 2-1.  
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Bacterial Culture 
Culture of Helicobacter hepaticus strain MU-94 was previously described25,252.  
Mice were inoculated via gastric gavage with 0.5 ml of culture containing 
approximately 5 × 108 bacteria/mL. Colonization was confirmed 2-4 weeks post-
inoculation and at necropsy with H. hepaticus-specific PCR of feces247.  
Ovariectomy 
Mice were anesthetized with isoflurane, clipped dorsally, and aseptically 
scrubbed.  A single longitudinal skin incision was made on the dorsal midline.  
The ovaries were visualized, the muscle wall was incised, and ovaries were 
removed.  After a continuous-release hormone pellet (described below) was 
inserted rostrally into the subcutaneous space between the scapulae through the 
initial incision, the incision was closed with sterile skin staples.  Mice were given 
0.0015 mg buprenorphine IP for analgesia and recovered on a heating pad.  
Seven to ten days post-operatively, the skin staples were removed.  At the time 
of necropsy, mice with detectable ovarian remnants were removed from the 
study.   
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Compounds 
In initial studies, a 90-day continuous-release hormone pellet containing 1.5 
mg/pellet of 17β-estradiol (E2) or a placebo (Innovative Research of America, 
Sarasota, FL) was administered.  The secondary studies utilized 90-day 
continuous-release pellets containing either 2.5 mg of the ERα agonist, PPT 
(4,4',4''-(4-Propyl-[1H]-pyrazole-1,3,5-triyl) trisphenol), or 10 mg of the ERβ 
agonist, DPN (diarylpropionitrile 2,3-bis(4-hydroxyphenyl)-propionitrile) (Tocris 
Bioscience Ellisville, MO and Innovative Research of America). At the time of 
necropsy, the presence of a pellet was confirmed and mice without a visible, 
intact pellet were removed from the study.  
Isolation of CD4+ Lymphocytes and Adoptive Transfers  
CD4+ T cells were isolated from the spleens of 8-12 week old donor mice.  
CD4+ T cells were negatively selected using a CD4+ T Cell Isolation Kit (Miltenyi 
Biotec, Auburn, CA), and purified with a Miltenyi Biotec autoMACS cell separator.  
After isolation, cells were suspended in sterile PBS and 5 × 105 cells were 
injected into the tail vein of recipient mice.  All mice were monitored for weight 
loss; loss of more than 20% of the starting body weight resulted in removal from 
the study.  
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Necropsy  
In all experiments, the cecum was removed and cecal contents collected 
to confirm H. hepaticus colonization.  The cecum was then sectioned 
longitudinally into two equal parts.  One half was rinsed with sterile PBS and 
flash frozen in liquid nitrogen for use in mRNA expression analyses.  The other 
half was fixed in zinc fixative and embedded in paraffin for histologic evaluation.   
Histological Evaluation 
Cecal histologic sections were stained with hematoxylin and eosin (H&E) 
stain and scored for inflammatory lesions using a previously described 
protocol246,252,253.   In short, all cecal sections were scored in a blinded fashion 
and assigned a category score for each of the following: inflammation intensity (0 
= none, 1 = mild, 2 = moderate, 3 = severe); longitudinal extent of inflammation 
(0 = none, 1 = 1-2 small foci, 2 = patchy, 3 = diffuse); vertical extent of 
inflammation (0 = none, 1 = basal mucosal inflammation, 2 = full thickness 
mucosal inflammation, 3 = transmural inflammation); and hyperplasia (0 = none, 
1 = focal, 2 = patchy hyperplasia, 3 = diffuse hyperplasia).  The lesions scores 
depicted in figures are the sum of the four category scores; any lesions score 
greater than 2 were decreased by 2 to minimize inflation of scores by 
inflammation alone, which is described by three of the four categories evaluated.   
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RNA Isolation and Reverse Transcription 
Frozen cecal sections were thawed in TRIzol (Invitrogen, Carlsbad, CA) 
and homogenized using a Tissuelyser (Qiagen, Valencia, CA).  Total RNA was 
isolated per manufacturer’s (Invitrogen) instructions.  Five micrograms of total 
RNA was reverse-transcribed using the Super Script II kit (Invitrogen, Carlsbad, 
CA) utilizing the manufacturer’s oligo(dT) primer protocol.  The resultant cDNA 
was diluted to a final concentration of 20 ng/L. 
Real-Time PCR 
Real-time quantitative PCR was performed either with a Roche Light 
Cycler 2.0 or a Qiagen Rotor-Gene Q using Qiagen Quanti-tect SYBR Green 
(Qiagen, Valencia, CA).  The run conditions used for real-time PCR have been 
previously described 25 and primers can be found in Table 2-2.  
Statistical Analysis 
Two-tailed Student’s T tests, one-way ANOVAs with Dunnett’s post-hoc 
tests and Chi-Squared tests were performed using SigmaPlot 11.0 (Systat 
Software Inc., San Jose, CA).  When appropriate, Log2 transformations were 
used to correct for failures in normality.   Non-parametric analysis, Mann-Whitney 
Rank Sum Test and Kruskal-Wallis One Way Analysis of Variance on Ranks 
were used when failures in normality could not be corrected for by a Log2 
transformation.   p values < 0.05 were regarded as significant.   For lesion score 
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analysis of knockout mice, preliminary studies revealed that mean lesion scores 
of wild type, ERα+/-, and ERβ+/- mice did not differ statistically.  These groups 
were therefore combined as controls.  All graphs and dot plots were generated 
using GraphPad Prism 5.0 software (GraphPad Prism Software Inc., La Jolla, 
CA). 
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Figure 2-1. Estrogen treatment decreases disease severity and the expression of pro-
inflammatory cytokines and chemokines.   
(a) Representative histologic images of ceca from ovariectomized A/J mice sacrificed 90 days 
after Helicobacter hepaticus inoculation and implantation with a subcutaneous pellet containing 
either (top) placebo or (bottom) 17β-estradiol (1.5 mg/pellet).  (b) Cecal lesion scores of placebo 
(circles) and estradiol (squares) treated mice (n = 8, 8 respectively).  Each point represents the 
lesion score for an individual animal.  Mean lesion scores in the estrogen-treated mice are 
significantly lower than in the placebo-treated mice.  Lesion score data analyzed with a Mann-
Whitney Rank Sum Test; horizontal lines represent mean lesion score for each group and error 
bars correspond with s.d.   (c) Real-time quantitative PCR measurements of cecal cytokine and 
chemokine mRNA expression levels in mice receiving placebo or estrogen treatment (n = 8).  IL-
12/23 p40 (left), IFN-γ (middle) and CXCL9 (right) mRNA expression was normalized to the 
expression of the housekeeping gene HPRT.  For all three cytokines, IL-12/23 p40, IFN-γ and 
CXCL9, mice receiving estrogen treatment had significantly lower mRNA expression levels than 
mice receiving placebo treatment.  All mRNA expression data analyzed by two-tailed Student’s t 
tests and presented as group means ± s.d.      
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Figure 2-2. Absence of ERα expression decreases disease severity and mRNA expression 
of IFN-γ and CXCL9.   
A/J female mice deficient for either ERα or ERβ expression and heterozygous/wild type littermate 
controls were inoculated with H. hepaticus and evaluated 3 months post-inoculation.  (a) Cecal 
lesion scores of inoculated ERα (squares), ERβ (triangles) and control (circles) mice (n = 20, 11, 
and 37 respectively); each point represents the lesion score for an individual animal.  ERα-/- mice 
with normal ERβ expression had significantly lower lesion scores when compared to controls.  
Lesion score data analyzed with a Kruskal-Wallis one way ANOVA on ranks with a Dunnett’s 
post-hoc analysis.  Horizontal bars represent group means ± s.d.   (b) Percentage of animals with 
severe cecal inflammation (lesion score ≥ 6) within each genotype group.  The percentage of 
severe disease was significantly lower in ERα-/- mice when compared to controls and ERβ-/- mice.  
Data analyzed with chi-squared analysis.   (c) Real-time quantitative PCR measurements of cecal 
cytokine and chemokine mRNA expression levels in mice deficient for ERα or ERβ and littermate 
controls (n = 13, 9, and 27 respectively).  IL-12/23 p40 (left), IFN-γ (middle) and CXCL9 (right) 
mRNA expression levels were all normalized to HPRT. Expression of CXCL9, but not IFN-γ and 
IL-12/23 p40 were significantly less in ERα-/- mice when compared to control mice.  Additionally, a 
trend of decreased IFN-γ expression was noted in the ERα-/- mice. Data analyzed with one-way 
ANOVAs with Student-Newman-Keuls post-hoc tests; all data presented as group means ± s.d.. 
  
56 
 
Figure 2-3.  Treatment with an ERβ agonist decreases disease severity and the expression 
of pro-inflammatory cytokines.   
Female A/J mice were ovariectomized, administered continuous-release pellets containing a 
placebo, ERα agonist (PPT) or ERβ agonist (DPN), inoculated with H. hepaticus, and necropsied 
three months later. (a)  Cecal lesion scores of mice treated with a placebo (circles), PPT 
(squares) or DPN (triangles) pellet (n = 19, 22, and 21 respectively).  Points represent the lesion 
scores of individual animals. Administration of the ERβ agonist significantly reduced the mean 
lesion scores when compared to the placebo- and ERα agonist-treated mice.  Data analyzed by 
one-way ANOVA with a Student-Newman-Keuls post-hoc test; data presented as group means ± 
s.d (b) Depiction of the percentage of mice with severe disease (lesion score ≥ 6).  The incidence 
of severe disease in mice treated with DPN was significantly less than the control and PPT-
treated mice. Data analyzed with chi-squared analysis.  (c) Real-time quantitative PCR 
measurements of cecal mRNA expression levels in mice treated with an ERα agonist, ERβ 
agonist, or placebo control (n = 8, 9, and 9 respectively).  IL-12/23 p40 (left), IFN-γ (middle) and 
CXCL9 (right) mRNA expression levels are normalized to HPRT expression. Expression of IL-
12/23 p40 and CXCL9 is significantly lower in ERβ agonist-treated mice when compared to 
placebo-treated mice.  A trend of decreased IFN-γ expression was noted in the ERβ agonist-
treated mice.   Data analyzed with one-way ANOVA with a Dunnett’s post-hoc test (control = 
placebo treated mice); data presented as group means ± s.d.    
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Figure 2-4 Lack of ER signaling in CD4+ cellular populations does not alter cecal 
inflammation or cytokine and chemokine expression.   
(a) Cecal lesion scores in female H. hepaticus-inoculated RAG2-/- mice adoptively transferred 
ERα-/- (n = 8) or ERβ-/- (n = 9) CD4+ lymphocytes.  As a control group, RAG-/- female mice were 
adoptively transferred wild type CD4+ lymphocytes (n = 20).  Points represent the lesion scores of 
individual animals in each experimental group and horizontal bars indicate mean lesion scores; 
error bars correlate with s.d.  No significant differences in lesion scores were noted between any 
of the experimental groups.  (b-d) Real-time quantitative PCR measurements of cecal cytokine 
and chemokine mRNA expression levels in RAG2-/- mice adoptively transferred CD4+ 
lymphocytes deficient for ERα or ERβ expression.  IL-12/23 p40 (b), IFN-γ (c) and CXCL9 (d) 
mRNA expression levels were normalized to HPRT mRNA expression and data is represented as 
group means ± s.d. No differences in expression were noted.  All data analyzed by one-way 
ANOVA and presented as group means ± SD.      
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Figure 2-5. ERβ signaling on non-CD4+ cellular populations reduces cecal inflammation 
and IFN-γ expression.   
(a) Cecal lesion scores in female H. hepaticus-inoculated ERα-/-RAG2-/- (n = 11) (circles) or 
ERβ-/-RAG2-/- (n = 13) (squares) female mice adoptively transferred wild type CD4+ 
lymphocytes.  As a control group (triangles), RAG-/- female mice were adoptively transferred wild 
type CD4+ lymphocytes (n = 20).  Points represent the lesion scores of individual animals in each 
experimental group and horizontal bars indicate mean lesion scores. The adoptive transfer of WT 
CD4+ lymphocytes into ERα-/-RAG2-/- recipients significantly reduced the mean cecal lesion 
scores when compared to the control group.  Lesion score data analyzed with a Kruskal-Wallis 
one way ANOVA on ranks with a Dunnett’s post-hoc analysis.  Horizontal bars represent group 
means ± s.d.   (b-d) Real-time quantitative PCR measurements of cecal cytokine and chemokine 
mRNA expression levels in RAG2-/- mice deficient for either ERα or ERβ and adoptively 
transferred wild type CD4+ lymphocytes.  IL-12/23 p40 (b), IFN-γ (c) and CXCL9 (d) mRNA 
expression levels are normalized to HPRT expression. Expression of IFN-γ is significantly lower 
in both experimental groups in which mice dually deficient for RAG2 and either ERα or ERβ 
received wild type CD4+ lymphocytes.  All data analyzed by one-way ANOVA with a Dunnett’s 
post-hoc test (RAG2-/- mice adoptively transferred WT CD4+ used as controls); all data presented 
as group means ± s.d.  
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Table 2-1.  Genotyping PCR Primers, Products, & Annealing Temperatures.  
PCR 
Primers 
Forward (5’-3’) Reverse (5’-3’) Fragment 
size (bp) 
Annealing 
Temp (0C) 
ER α WT TCTACGGCCAGTCGGGCATC TAGGCGACACGCTGTTGAGC
TG 
102 66 
ER β WT TGACAATGGCTGTGTTCTCTGCTC TTAAAGTTAAACGCCAGCCCA
CCG 
566 66 
neo 
cassette 
5’-TGCCTGCTCTTTACTGAAGGCTCT-3’ α – 363 
β - 430 
66 
RAG2 
WT 
GGGAGGACACTCACTTGCCAGTA AGTCAGGAGTCTCCATCTCAC
TGA 
263 62 
neo 
cassette 
5’-CGGCCGGAGAACCTGCGTGCAA-3’ 350 62 
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Table 2-2. Real-time PCR Primers & Annealing Temperatures 
PCR 
Primers 
Forward (5’-3’) Reverse (5’-3’) Annealing Temp 
(0C) 
HPRT GTAATGATCAGTCAACGGGGGAC CCAGCAAGCTTGCAACCTTAACCA 60 
CXCL9 ACTCGGCAAATGTGAAGAAG CCCATTAAGATTCAGGGTGC 58 
IFN-γ GCCATCAGCAACAACATAAGC TGGGACAATCTCTTCCCCAC 58 
IL-12/23 
p40 
ACTCACATCTGCTGCTCCAC GGGAACTGCTACTGCTCTTGA 60 
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Chapter 3 - Trichuris muris therapy in a Helicobacter 
hepaticus-induced IBD mouse model 
Introduction 
The development of an Inflammatory Bowel Disease (IBD) such as 
Crohn’s disease (CD) or Ulcerative Colitis (UC) is a multifaceted process driven 
by an individual’s mucosal immune system.   The disruption in mucosal 
homeostasis appears to be driven by the complex interactions of an individual’s 
immune system, the environment in which they live, their genetic predisposition 
to disease development, and their microbiota3,13,67,106,216.   
 Due to the complexity of the events which lead to the development of IBD, 
attempts to develop an effective pharmaceutical treatment for patients have been 
less than ideal.  Traditional pharmaceuticals treatments for IBD patients include, 
but are not limited to: aminosalicylates ( 5-ASA derivatives), corticosteroids 
(prednisolone, prednisone), immune  modulators (thioprines, methotrexate, 
cyclosporine A), antibiotics (metronidazole, ciprofloxacin) and biological therapies 
(Adalimumab, Certolizumab pegol, Infliximab and Natalizumab)4,211,212.  
Unfortunately, remission rates reported with these treatments are widely 
variable211,215 and can be difficult to interpret due to IBD’s unpredictable cyclic 
patterns of exacerbation and remission4.    Also, many IBD clinical trials lack 
evaluation of a true placebo group, which furthers complicates the ability to 
identify the true efficacy of proposed  treatments215.    The lack of effective 
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pharmaceuticals for some patients is not surprising considering that IBDs 
develop through a variety of interactions, many of which are potentially unique to 
each individual.  The concept of personalized medicine in which therapeutics are 
tailored to individuals using biomarker and genetic analysis may help pair 
patients with the most effective therapeutics208-210.   Overall, the need for 
additional treatment options is highlighted by the high surgical recession rates 
found among IBD patients: 20-30% of UC patients and 70-80% of CD patients 
will undergo a surgical resection during their lifetimes as a result of uncontrolled 
disease4. 
 Due to the infectiveness of traditional treatment regimens, a need for 
novel treatment options has been identified122,208,212.  In an attempt to produce 
non-traditional therapies, risk factors involved in disease development, such as 
an individual’s environment, were scrutinized.  Historically  IBDs are 
predominantly diagnosed within the developed regions of North America and 
Europe18.   The importance of environment, rather than genetic predispositions 
been examined epidemiologically by evaluating the diagnosis rates of IBD in first 
and second generation immigrants in Europe originally from regions of the world 
with a traditionally low IBD diagnosis rate.  A study done by Carr et al. examined 
the rate of UC in first and second generation Asians that had immigrated to 
Europe and demonstrated that the incidence of UC in the immigrant populations 
normalized to the indigenous European population after only one generation99.   
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The importance of exposure to environmental risk factors in combination 
with a genetic predisposition was further highlighted by the finding that some 
Asian populations actually had a higher potential to develop IBD than the 
indigenous European population following immigration and exposure to novel 
environmental factors present in western cultures308.  When examining the 
influence of westernization on IBD development, one must also consider what is 
being lost within these environments97.   The exposure to helminths has been 
identified as an immunological event which could potentially protect from disease 
development within developing regions of the world93-96,100,309.   
Elliott et al. proposed an IBD hygiene hypothesis in the 1990s that 
suggested children would be predisposed to the development of immune-related 
diseases, such as IBD, if their immune system lacked appropriate antigen 
exposure during development93.   Since then, the hygiene hypothesis and IBD 
development has been extensively examined and considered94-97.  As previously 
mentioned, one aspect of westernized living which has been identified in the 
minimization of antigen exposure is the eradication of gastrointestinal 
parasites95,96.   In the early 1900s the Rockefeller Foundation’s International 
Health Board (formally the Rockefeller Sanitary Commission) began improving 
living conditions in and outside of the United States with programs that 
encouraged routine deworming of citizens, particularly schoolchildren310.   Today, 
organization such as the World Health Organization (WHO), World Health 
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Assembly and United Nations Children’s Fund (UNICEF) are working to improve 
accessibility to anthelmintics in developing regions of the world310.    
With the increased emphasis on decreasing helminth exposure, it is 
interesting that recent reports have shown increased IBD diagnosis rates in 
regions such as Asia, Africa and South America37.   A recent report by Chu et al. 
demonstrated that in South Africa, where western hygiene standards are being 
integrated into everyday life for some citizens, exposure to helminths during 
childhood appears to be protective against IBD development100.  The authors 
also demonstrated that environmental conditions such as shared housing and 
consumption of raw meat both of which have the potential to increase helminth 
exposure were protective in disease development, while  urban living and 
parental tertiary education was associated with IBDs100.    
In individual patients diagnosed with an IBD, the issue of pre-exposure to 
helminths is a moot point as this variable cannot be changed.  However, it has 
been speculated that exposure to helminths, even after disease development, 
may be beneficial due to the interactive nature of the TH1/TH2/TH17 signaling 
pathways active in IBDs and helminth infections223,225,231,311.   Following migration 
from the thymus, native CD4+ cells can be driven toward TH1, TH2 or TH17 
effector cell differentiation by IL-12, IL-4 and IL-6/TGFβ, respectively14,109-112.  As 
each of these differentiation pathways are suspected to act in a negative fashion 
on the others114,312, the TH1/TH17 response in CD potentially could be minimized 
by the induction of TH2 mediated inflammation by helminth exposure14,113,114.      
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Our laboratory utilizes a microbial driven IBD model in which A/J mice  
develop a lymphocytic infiltrative histologic disease that is detectable in the 
cecum25 three-months after gastric administration of Helicobacter hepaticus.  
Additionally, these mice have significantly elevated cecal mRNA gene expression 
of  IL-12/23 p40, IFN-γ and IL-1025,252-254.  The mechanism by which H. hepaticus 
induces disease is unknown however, one hypothesis is that once established in 
the cecum, helicobacters act as a provocateur instigating an immune response 
against certain endogenous microbiota248,249.  While data from Citrobacter 
rodentium IBD models suggests helminth therapy exacerbates disease313,314, 
there is need to further evaluate the efficacy of helminth therapy in an IBD model 
triggered by bacteria.    
As it is reasonable to speculate that inflammation instigated by an 
opportunistic member of the microbiota, such as H. hepaticus, may respond 
differently to the presence of helminths we sought to investigate the effects of 
Trichuris muris in the H. hepaticus IBD model.  T. muris was chosen for 
evaluation as it is closely related to Trichuris suis, the helminth utilized in the 
human trials36,37 and because it localizes to the cecum315, the site of inflammation 
in this model.  Our data demonstrates that T. muris is not only ineffective at 
reversing inflammation induced by H. hepaticus in the A/J mouse, but actually 
acutely exacerbates disease severity.  Furthermore, our findings demonstrate 
that the immune response necessary to expel T. muris is affected by TH1 
inflammation, such as that seen in the H. hepaticus IBD model.  In conclusion, 
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our data presents evidence that helminth therapeutics in IBD patients should be 
used with caution as there is a potential to cause exacerbation of disease and 
persistence of helminth colonization if disease is due to a microbiota driven TH1 
inflammation.  .    
Results 
A/J mice mount a TH2 cytokine response following exposure to T. muris 
which correlates with worm expulsion.   
Some mouse strains have been demonstrated to mount an inappropriate 
TH1 immune response to T. muris which results in chronic colonization by the 
parasite316.  Prior to evaluating T. muris’s therapeutic potential, the A/J mouse’s 
ability to mount a TH2 immune response must be confirmed.  As worm expulsion 
has been linked to a TH2 cytokine response, this was initially utilized to evaluate 
the immune response to the helminth.  Five-month old female mice were 
inoculated with T. muris ova. Mice (n=4/time point) were necropsied at either 
twelve or twenty-eight day post-inoculation and examined for the presence larvae 
or adult worms, respectively.  As shown in Figure 3-1A, at twelve days post-
inoculation live larvae (Figure 3-1B) were detected in the cecal digests of all four 
mice.  At twenty-eight day post-inoculation, one mouse (25%) had detectable 
adult worms at necropsy (<10 worms).   
The results from this experiment suggested that the A/J mouse mounts a 
TH2 cytokine response when exposured to T. muris based on the overall 
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resistance to worm colonization.  To best evaluate if the TH2 immune response to 
T. muris is capable of blunting or reversing the TH1 mediated inflammation 
induced by H. hepaticus, the immune response needs to be further defined.   To 
accomplish this, four-month old female A/J mice were inoculated with T. muris 
ova or PBS (vehicle control).  Five mice were necropsied every week starting one 
week post-inoculation and continuing for a total of six weeks (Figure 3-2A).  At 
necropsy, mice were evaluated for the appropriate life stage of T. muris (larvae at 
weeks 1-3 and adults at weeks 4-6).  Live T. muris larvae were detected in all T. 
muris inoculated mice at the week 1 and 2 necropsy time points; 4 of the 5 mice 
examined at week 3 had live larvae.  Adult worms were not found in any mice at 
week 4 and 6, however two mice evaluated at week 5 had adult worms (<10 
worms/mouse) (Figure 3-2B).    In addition, mRNA analyses of inflammatory 
cytokines were completed for: IL-12/23 p40, IFN-γ, IL-10, IL-4, IL-5, IL-6 and IL-
13.   mRNA expression of IL-4 and IL-13 was significantly elevated in T. muris 
inoculated mice when compared to PBS inoculated mice beginning at week 2 
and continued through week 6.  The expression of IL-5 was elevated at weeks 2-
3 and the expression of IL-6 was elevated between weeks 3-5.    IL-10 and IFN-γ 
mRNA expression was elevated at week 1, however both returned to the level of 
PBS inoculated mice by the weeks 3 and 5 necropsy time points, respectively.  
Expression of IL-12/23 p40 mRNA was elevated in T. muris inoculated mice only 
at the week 2 time point.  Collectively these data demonstrate that two weeks 
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following exposure to T. muris A/J mice have mounted a TH2 cytokine response 
which correlates with helminth expulsion.  
T. muris acutely exacerbates Helicobacter hepaticus induced mucosal 
inflammation.  
Our laboratory has previously demonstrated that three months following H. 
hepaticus inoculation A/J mice develop a TH1 driven mucosal inflammation which 
recapitulates several histologic aspects of CD.  As it is now known that A/J mice 
mount a TH2 response when exposed to T.muris, we sought to evaluate the 
therapeutic effects of this helminth in our model of IBD.  To accomplish this, A/J 
mice, 3-4 weeks of age, were inoculated with either brucella broth (sham) or H. 
hepaticus.  Three months following these inoculations mice were treated with 
either live T. muris ova or PBS (vehicle control).  This resulted in a total of four 
experimental groups (n = 8 mice/group): H.  hepaticus(-) T.muris(-), H. 
hepaticus(-) T.muris(+), H. hepaticus(+) T.muris(-), and H. hepaticus(+) 
T.muris(+).  Mice from each group were evaluated 3 weeks after treatment with 
either PBS or T. muris ova for changes in histologic disease, presence of 
histologically detectable T. muris and mRNA expression of: IL-12/23 p40, IFN-γ, 
IL-10, IL-4, IL-5, IL-6, IL-13, IL-17a and IP-10.  
Cecal lesion scores were significantly elevated in the H. hepaticus 
inoculated mice treated with T. muris when compared to H. hepaticus inoculated 
mice treated with PBS (Figure 3-3A).   Representative histologic images of mice 
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from all four experimental groups are depicted in Figure 3-3B.  During histologic 
evaluation of cecal sections, the presence of histologic T. muris was 
documented.  75% of the H. hepaticus inoculated mice treated with T. muris had 
histologically detectable helminths (Figure 3-3B, arrow heads); T. muris was not 
detected histologically in any of the other experimental groups. 
The mRNA gene expression of cytokines thought to be involved in H. 
hepaticus induced inflammation (IL-12/23 p40, IFN-γ, IL-17a and IL-10) and the 
immune response to helminths (IL-4, IL-5, IL-6, IL-13 and IP-10) were evaluated.   
Significant elevations in gene expression of in IFN-γ, IL-4, IL-5, IL-6, IL-12/23 
p40, IL-13, and IP-10 were seen within the H. hepaticus inoculated mice when T. 
muris ova and PBS treated mice were compared (Figure 3-4).  Although the A/J 
mice mounted the appropriate TH2 immune response following T. muris treatment 
it failed to counteract the ongoing TH1 inflammation and ultimately exacerbated 
disease severity.   
Exposure to T. muris has no long-term effects on Helicobacter hepaticus 
induced mucosal inflammation.  
To evaluate the long-term effects of T. muris exposure on H. hepaticus-
induced inflammation, mice were inoculated and treated as described for the 
previous experiment.  In short, mice were inoculated with either brucella broth 
(sham) or H. hepaticus and then treated with either live T. muris ova or PBS 
(vehicle control) three months later.  As with the previous experiment, there were 
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four experimental groups (n = 8 mice/group): H.  hepaticus(-) T.muris(-), H. 
hepaticus(-) T.muris(+), H.  hepaticus(+) T.muris(-), and H. hepaticus(+) 
T.muris(+).  Mice from each group were evaluated 8 weeks after PBS or T. muris 
ova treatment for severity of histologic disease, the presence of histologically 
detectable T. muris, the presence of adult worms in the cecum lumen and mRNA 
expression of: IL-12/23 p40, IFN-γ, IL-10, IL-4, IL-5, IL-6, IL-13, IL-17a, and IP-
10.  
Evaluation of cecal lesion scores revealed no significant differences in 
disease severity when H. hepaticus inoculated mice treated with T. muris were 
compared to H. hepaticus inoculated mice treated with PBS (Figure 3-5A). As 
with the previous group, histologic sections were evaluated for the presence of T. 
muris. One mouse in the H. hepaticus inoculated, T. muris treated experimental 
group had detectable helminths histologically.  To further evaluate the effect of H. 
hepaticus on the development of adult worms, the ceca of all mice necropsied 
were evaluated for adult worms.  Two of the mice inoculated with H. hepaticus 
and later treated with T. muris were found to have live T. muris adult worms 
within the cecum.  The number of adult worms found in the two mice varied 
greatly, one mouse had 1 live worm and the other had 24 live worms. (Figure 3-
5B) None of the other mice evaluated had either histologically detectable or live 
T. muris within the cecum.   
In regards to cecal cytokine mRNA expression, when H. hepaticus 
inoculated mice treated with T. muris were compared to those treated with PBS 
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the expression of IL-12/23 p40 and IL-10 was significantly decreased and the 
expression of IL-4, IL-5 and IL-13 was significantly elevated (Figure 3-5C).  
Ultimately, despite the chronic elevation of TH2 cytokine mRNA expression and 
the decreased IL-12/23 p40 mRNA expression, T. muris treatment did not alter 
H. hepaticus-induced disease severity.   
Discussion 
As previously discussed, the rate of intestinal resection for UC and CD 
patients is 20-30% and 70-80%, respectively4.  These statistics, in combination 
with the reported remission rates for the pharmaceutical agents currently 
available for the treatment of IBDs211,215, suggest a need for evaluation of non-
traditional therapies, such as helminth ova.  A variety of gastrointestinal parasites 
have been shown to have protective capacities in disease development in murine 
IBD models such as TNBS-induced colitis317,318, DNBS-induced colitis319,320, 
DSS-induced colitis321,322, C57BL/6 IL-10-/- mice93 and cell transfer-induced 
colitis323-325.   Additionally, data has been produced which demonstrates the 
capabilities of helminth derived antigens, such as killed eggs326-328 and helminth 
derived proteins329-335, to inhibit colitis development.  While these correlations 
certainly do not imply causation, the findings in animal models of IBD are also 
consistent with the hygiene hypothesis’s theory that exposure to gastrointestinal 
parasites can be protective for IBD development. 
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Research utilizing animal models of IBD has also yielded preliminary 
evidence that helminths can reverse ongoing colitis in both C57BL/6 IL-10-/- 
mice277,336 and cell transfer-induced colitis337. Preliminary data from clinical trials 
conducted in human patients with active IBD have demonstrated that treatment 
with T. suis can cause a decrease in disease related symptoms and/ or induce 
remission rates in approximately 70% of patients227,228,338.   
The efficacy of helminth therapeutics to reverse inflammation in mouse 
IBD models is contradictory as the literature includes studies that demonstrate 
improvement of disease severity with helminth treatments, as well as studies that  
demonstrate exacerbation of colitis following helminth exposure313,314,339-341.  The 
variable responses to helminth therapy between mouse IBD models could be due 
to differences in the mechanism by which disease is induced and supports the 
need for helminth therapeutics to be further evaluated.   
H. hepaticus induces mucosal inflammation in the cecum of A/J mice 
approximately three months post-inoculation.  Although it is unknown how the 
addition of H. hepaticus to the microbiota induces disease development, it is 
suspected that it triggers an inflammatory reaction to the endogenous 
microbiota248,249.   Furthermore, its presence is suspected to be pivotal in other 
IBD models240, highlighting potential pro-inflammatory effects on the immune 
system.   As previously stated, T. muris was selected for evaluation as a 
therapeutic agent because it localizes to the  cecum315 where H. hepaticus 
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induced inflammation occurs and, most importantly, is related to T. suis,  the 
helminth currently being used in human IBD clinical trials36,37. 
Early on, scientists recognized a variability in resistance to T. muris  as 
susceptibility in mice could be manipulated with selective breeding342 and thus 
was attributed to a genetic influence316,343,344.   Mouse strains with a BALB 
genetic background are generally resistant to T. muris, while those on a B10 or 
AKR genetic background are generally susceptible344,345.   The immune response 
which develops following  helminth exposure has been extensively 
documented198,346-351 and it now know that the induction of a TH1 mediated 
immune response results in T. muris colonization while the induction of a TH2 
mediated immune response is protective316.   Although helminth expulsion 
correlates with expression of the TH2 cytokine IL-4352, the action is ultimately 
dependent upon the downstream production of IL-13353,354.  The involvement of 
IL-5, also produced by activated lymphocytes, has also been suggested as its 
expression is up-regulated during the response to T. muris355,356 .       
As the A/J mouse strain used in our H. hepaticus IBD model is genetically 
related to the BALB mouse it was suspected that these mice would mount a 
protective TH2 immune response following T. muris infection.   However, before 
utilizing a helminth therapeutically in the A/J mouse, this speculation had to be 
confirmed.  The results demonstrated in Figure 3-2 confirm that A/J mice 
generate a TH2 immune response to T. muris that, in general, results in expulsion 
of the worm.  Of all the mice evaluated for the presence of adult worms (4 weeks 
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post inoculation and beyond), only three had live T. muris adult worms within the 
cecum.   Of importance is the fact that the three mice had a reduced worm 
burden (<10) compared to that typically seen in susceptible mouse stains (>100 
worms).  Collectively these data indicate that when exposed to T. muris, A/J mice 
mount an immune response dominated by TH2 cytokines.      
The ultimate goal of these studies is to evaluate the therapeutic potential 
of T. muris to reverse TH1 mediated inflammation induced by H. hepaticus.  To 
best accomplish this, the peak production periods of TH2 cytokines were 
identified, as they would have the best potential to decrease IL-12/IFN-γ driven 
TH1 inflammation14,113,114 and ultimately decrease disease severity.  Four month 
old female A/J mice were inoculated with T. muris and subsets of 5 mice were 
necropsied weekly for 6 weeks.  mRNA expression of IL-4 and IL-13 were 
significantly elevated within 2 weeks of T. muris ova inoculation (Figure 3-2C).  
Interestingly these cytokines remained elevated through the week 6 time point, 
suggesting that even after clearance of the worms a TH2 cytokine response 
persists.  This finding was not entirely unexpected as the TH2 responses which 
develops following exposure to helminths has been shown to prevent the 
development of colitis18,47-55 in mouse IBD models and thought to be protective in 
human IBD development100.  As IL-5 has also been shown to be integral for 
expulsion of T.muris355,356, the elevation of IL-5 seen during weeks 2 and 3 in the 
T. muris treated mice was not unexpected.  As IL-6 expression, in combination 
with TGFβ, has been linked to the induction of TH17 inflammatory 
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responses14,109-112, now known to play a role in CD14,113,114, it was not surprising 
that this cytokine was also up-regulated.    Additionally, epithelial cells have been 
shown to express elevated levels of IL-6 following exposure to T. suis357.  The 
elevation in IL-6 levels documented between weeks 3 and 5 could be due to 
either epithelial cell production and/or the induction of a TH17 cytokine response.   
The elevation in mRNA expression detected of the non-TH2 cytokines, IL-
10, IL-12/23 p40 and IFN-γ at weeks 1-2, week 2 and weeks 1-4, respectively, 
were relatively short lived in comparison.  Increased expression of these 
cytokines are typically observed in susceptible mouse strains316 however, 
clearance of T. muris  was documented in a majority of these mice.  As TH1 
responses often occur following exposure to intracellular microbes, not 
helminths, it is possible that these elevations of mRNA expression occur as a 
secondary effect to T. muris exposure.  Upon arrival at the cecum T. muris ova 
hatch into the L1 larval stage, penetrate the epithelium at the base of the crypts 
and undergo 4 larval molts within the epithelial layer before emerging into the 
lumen of the cecum343,358.  It is logical to suspect that the initial invasion of the 
mucosa by T. muris larvae and the entrance of adult worms into the cecal lumen 
could cause a temporary breach in the epithelium, which normally serves as a  
barrier between the microbiota and the immune system189.  This could result in a 
brief up regulation of  a TH1 immune response involving IL-12/23 p40 and IFN-γ. 
The immediate IFN-γ response could be due to the up-regulation of this cytokine 
by epithelial cells as this has been shown to occur within 24 hours of T. muris 
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exposure in mice359.   IL-10 is an anti-inflammatory cytokine known have the 
ability to down regulate both TH1 and TH2 mediated inflammation14,147.  As T 
regulatory cells have been shown to be involved in the immune response 
required for helminth clearance360,361, it is possible that the elevations in IL-10 are 
due to an increase T regulatory cell activity.  Alternatively, either epithelial cells or 
macrophages could be responsible for the IL-10 elevations, as both of these cell 
types have been documented to produce the IL-10 in response to antigens362,363.  
To evaluate the therapeutic potential of a helminth to reverse TH1 driven 
inflammation, A/J mice with ongoing H. hepaticus induced-inflammation were 
treated with T. muris ova and evaluated at one of two time points.  As human 
trials have reported some adverse clinical signs during the first months of T. suis 
therapy229, despite the long term benefit of disease remission227,228,338, it is 
important to evaluate changes in disease severity at both an acute and chronic 
time point following T. muris treatment.  Week 3 post-treatment was chosen for 
the short-term evaluation time point as changes in disease severity could 
potentially be caused by the up regulation of the anti-inflammatory cytokine IL-10 
and the TH2 cytokines IL-4 and IL-13.  The second time point was chosen to 
evaluate the long term effects of helminth therapy.   
Interestingly, at three weeks post-T. muris treatment disease was  
exacerbated in the H. hepaticus inoculated mice (Figure 3-3A).  This finding may 
simply be a side effect of the inflammatory response involved in helminth 
clearance316,358 as it coincides with the reports that helminth therapy in humans 
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can cause adverse clinical signs229.  The findings at the week 8 time point (Figure 
3-5A) support this hypothesis, as no long term effects on disease were observed.  
When the lesion scores of mice treated with T. muris ova were compared to 
those treated with PBS, no significant differences in cecal lesion scores were 
found within the H. hepaticus inoculation group.   
Next, the ability of T. muris treatment to alter H. hepaticus induced 
cytokine mRNA expression was evaluated.  Significant elevations were found for 
all cytokines, with the exception of IL-10 and IL-17a, when comparisons were 
made between H. hepaticus inoculated mice treated with T. muris and PBS at the 
three week time point.  Interestingly, when the same comparisons were made at 
the 8 week time point, IL-4, IL-5 and IL-13 remained elevated while IL-12/23 p40 
and IL-10 expression were significantly decreased.  As previously discussed, 
despite decreased mRNA expression of these cytokines, there was not a 
significant reduction in disease severity (Figure 3-5A).   
These observations are contrary to reports in other mouse models of 
IBD277,336,337 in which helminth exposure can suppress ongoing disease.  These 
data do, however, agree with the findings in the Citrobacter rodentium model of 
IBD, in which treatment with helminths increased histologic disease313,314. The 
discrepancy between these findings may be due to differences in disease 
induction between the mouse models being examined.   For example, reversal of 
disease following helminth therapy appears to be limited to animal models 
induced by a disruption of the epithelium (TNBS, DSS and DNBS), the adoptive 
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transfer of T cells into an immunocompromised mouse or the use of a genetically 
modified mouse (C57BL/6 IL-10-/-).  Both the C. rodentium and H. hepaticus 
models rely on a bacteria for the induction of disease.  Ultimately, these data 
demonstrated that, despite the induction of a TH2 predominated cytokine 
response to T. muris, the ongoing TH1 mediated inflammation induced by H. 
hepaticus in the A/J mouse was ultimately unaltered after an acute period of 
exacerbated disease severity.   
In addition to the finding that T. muris is incapable of reversing H. 
hepaticus-induced inflammation, we demonstrated that the immune response to 
T. muris is altered by an ongoing TH1 inflammation. During evaluation of disease, 
the presence of T. muris could be detected histologically as indicated by the 
arrows in Figure 3-3B.  Interestingly, when this was examined at the week 3 time 
point, a significant difference in T. muris detection was found between mice 
inoculated with H. hepaticus and treated with T. muris and mice inoculated with 
brucella broth and treated with T. muris. As the immune modulation capabilities 
of Helicobacter spp.255,261,364,365 have been documented it is not surprising that H. 
hepaticus could delay the clearance of T. muris.   
Comparisons between T. muris treated mice that had previously been 
inoculated with brucella broth or H. hepaticus allowed for evaluation of any 
effects an ongoing TH1 inflammatory process may have on the immune response 
to T. muris.  At 3 weeks post-inoculation, significant elevations in IFN-γ, IL-6, IL-
10, IL-12/23 p40, and IP-10 were found in T. muris treated mice previously 
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inoculated with H. hepaticus, which exceeded the expression levels causes by T. 
muris alone.  The same was found at the week 8 time point with the addition of 
significant elevations for IL-4, IL-5, IL-13 and IL-17a. The previous data 
presented in Figure 3-3C suggested that H. hepaticus inoculated mice have 
delayed clearance of T. muris as indicated by the significant increase of 
histologically detectable T. muris larvae.  IP-10 has been demonstrated to inhibit 
the increased turnover of epithelial cells caused by IL-13366,367 and neutralization 
of IP-10 has been shown to decrease colitis in other mouse models of IBD366,368; 
the up-regulation of IP-10 by H. hepaticus could potentially explain the delayed 
clearance of T. muris in these mice.  Furthermore, the expression of IFN-γ and 
associated cytokines such as IL-12 have been identified as being up-regulated in 
mice susceptible to T. muris infection343.  The previous induction of these 
cytokines by H. hepaticus could be interfering with worm expulsion.    
While several mouse models of IBD have demonstrated the therapeutic 
effects of helminth treatments, our data highlights an important consideration 
when using helminth based therapeutics in human patients – microbiota driven 
inflammation. The influence of the microbiota have been well documented in both 
IBD patients77,78 and in mouse models79-81 of IBD, and in general, have been 
shown to be integral in the  development of a functional immune system82.  As 
demonstrated by our data, the inverse situation in which inflammation driven by 
the microbiota could effect the immune response to worms, must also be 
considered.  Changes in the microbiota have been shown to be responsible for 
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delays in immune response to T. muris in B10Br mice treated with the probiotic 
Lactobacillus casei369.  T. muris burden has been shown to be decreased if 
antibiotics are given prior to helminth inoculation, suggesting the importance of 
an unaltered microbiota for helminth development370.  In this model, the immune 
response to H. hepaticus following its addition to the A/J mouse’s endogenous 
microbiota clearly affected not only the cytokine response, but also the severity of 
inflammation association with the presence T. muris and the timeframe in which 
the helminth was expelled.  In regards to the delayed expulsion in the H. 
hepaticus infected mice, we hypothesize this could be due to the significant 
elevation in IP-10, which inhibits IL-13 induced epithelial cell turn over108,109 and 
was found to be induced by H. hepaticus at both necropsy time points.   As 
depicted in Figure 3-7, instead of the helminth induced TH2 inflammation 
suppressing the H. hepaticus associated TH1/TH17 inflammation, the H. 
hepaticus associated TH1/TH17 inflammation interfered with the TH2 response 
required to expel T. muris.     
These data demonstrate that TH1/TH17 inflammation instigated by H. 
hepaticus, which serves as a model for IBD, is acutely exacerbated and 
chronically unaffected by treatment with T. muris, despite the induction of a 
protective TH2 cytokine response.   Additionally, we demonstrated that the ability 
to clear T. muris was delayed in the presence of a chronic TH1 inflammation.  
Overall our data suggests that helminth therapies should be used with caution 
when used to treat microbiota drivenTH1 inflammation.   
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Materials and Methods  
Mice 
This research described in this manuscript was approved by the University of 
Missouri’s Animal Care and Use Committee (ACUC) and performed in 
accordance with the Guide for the Care and Use of Laboratory Animals.   All wild 
type A/JCr mice used were obtained from Frederick National Laboratory for 
Cancer Research and either used directly in experiments or to create breeding 
pairs.  Pups from breeding pairs were used in experiments as described.   
Trichuris muris 
Trichuris muris inoculum was kindly provided by Dr. Joseph Urban of the 
United States Department of Agriculture (Beltsville, MD).  Mice were inoculated 
via gastric gavage with a volume (between 0.07 – 0.15 ml, dependent upon 
batch) of inoculum shown to result in a heavy worm burden (approximately 100 
adult worms) in a susceptible mouse strain.   
Helicobacter hepaticus 
The MU-94 Helicobacter hepaticus strain was cultured as previously 
described25,252.   Mice were inoculated at 3-4 weeks of age with 0.5 mL of culture 
broth which contains approximately 5 x 108 bacteria/ml.   One week later mice 
were re-inoculated with the same dose of H. hepaticus.  A H. hepaticus specific 
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PCR was utilized to confirmed colonization within one month of inoculation and 
again at necropsy247.    
Necropsy  
Following euthanasia through CO2 inhalation, the cecum was removed 
and cecal contents were collected.  The cecum was then longitudinally sectioned 
into two equal portions and used for two of the following: verification of T. muris 
presence, mRNA expression analysis or histologic examination.   
Verification of Trichuris muris larvae presence  
Ceca were rinsed in warm PBS to remove cecal contents and then placed 
in a 50-ml conical tube filled with 10 mls of 10 mM EDTA.  Following a two hour 
incubation in a 37⁰ C shaking incubator, tubes are vortexed on high speed for 15 
seconds and all contents poured into a petri dish.  The supernatant and cecal 
tissues are examined with an inverted microscope (40x) for larvae.  
Verification of Trichuris muris adult worm presence  
At necropsy, ceca were inspected with a dissecting microscope for the 
presence of adult worms.   
 Histologic Evaluation 
Cecal portions utilized for histologic evaluation were fixed in zinc fixative, 
paraffin embedded, sectioned and then stained with hematoxylin and eosin 
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(H&E).   Using a previously described protocol,246,252,253 the cecal sections were 
then scored for inflammatory lesions in a blinded fashion.  
Isolation of RNA and Reverse Transcription  
Cecal sections, stored at -80 ⁰C until processing, were thawed in TRIzol 
(Invitrogen, Carlsbad, CA) and homogenized with a Tissuelyser (Qiagen, 
Valencia, CA).  Isolation of RNA was performed per manufacturer’s (Invitrogen) 
instructions.  A Super Script II kit (Invitrogen) was next used to reverse-transcribe 
RNA (5 μg total/ sample) into cDNA (final concentration 20 ng/μL) following the 
oligo(dT) primer protocol provided by the manufacturer.   
Real Time PCR  
A Qiagen Rotor-Gene Q was used to perform real time quantitative PCR 
with Qigen Quanti-tect SYBR Green.  Table 3-1 contains the primers and 
annealing temperatures utilized.   Run conditions for HPRT, IFN-γ, IL-4, IL-10, IL-
12/23 p40, IL-17a and IP-10 have been previously published25,252,371.     
Statistical Analysis 
Two-way ANOVAs with Student-Newman-Keuls post-hoc tests and Fisher 
exact tests were performed using SigmaPlot 11.0 (Systat Software Inc., San 
Jose, CA).  Due to the exponential nature of real-time PCR, Log2 transformations 
were used to correct for failures in normality.  For all tests, p values < 0.05 were 
regarded as significant.   All graphs and dot plots were generated using either 
84 
 
SigmaPlot 11.0 or GraphPad Prism 5.0 software (GraphPad Prism Software Inc., 
La Jolla, CA).     
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Figure 3-1.  A/J mice expel Trichuris muris.   
Eight five-month old female A/J mice were gastrically gavaged with T. muris ova.  (A) Mice were 
sacrificed and evaluated for the presence of larvae at 12 days post-inoculation or adult worms at 
28 days post-inoculation (n = 4 / necropsy time point). Data is presented as total percentage of 
each experimental group with detectable T. muris larvae (white striped bars) or adult worms (gray 
striped bars).  (B) Images of T. muris larvae isolated from mice examined 12 days post-
inoculation.   
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Figure 3-2. A/J mice mount a protective TH2 immune response to Trichuris muris.  
Two groups of four-month old A/J mice (30 mice/group) were gastrically gavaged with either T. 
muris ova or PBS (vehicle control).  Five mice per group were necropsied weekly and examined 
for the presence of T. muris and IL-12/23 p40, IFN-γ, IL-10, IL-4, IL-5, IL-6 and IL-13 mRNA gene 
expression.  (A)  Experimental Design.  (B) Percentage of mice positive for T. muris at necropsy; 
weeks 1-3 were evaluated for the presence of larvae (white striped bars) and weeks 4-6 were 
evaluated for adult worms (white bars).  (C) mRNA analysis of cecal gene expression.  mRNA 
expression was significantly elevated in T. muris (gray bars) treated mice when compared to PBS 
control (black bars) treated mice as indicated.  All data was analyzed with a two-way ANOVA with 
Student-Newman-Keuls post-hoc test; p ≤ 0.05 considered significant and indicated by lower 
case letters.  Error bars represent ± S.D. 
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Figure 3-3. Treatment with Trichuris muris exacerbates intestinal inflammation.   
3-4 week old female A/J mice were inoculated with either H. hepaticus or brucella broth (control). 
Three months later the  mice were treated with either T.  muris ova or PBS.  (A) Cecal lesion 
scores of mice from all four experimental groups three weeks post-treatment.  Data was analyzed 
with a two-way ANOVA with Student-Newman-Keuls post-hoc test; p ≤ 0.05 considered 
significant and indicated by horizontal capped lines.  Error bars represent ± S.D. (B) 
Representative depictions of inflammation from all four experimental groups.  Black arrowheads 
indicate T. muris cross-sections.  (C) During examination of cecal histology the presence or 
absence of T. muris was recorded. Data from mice treated with T. muris analyzed with a Fisher 
exact test; p ≤ 0.05 considered significant and indicated by lower case letters. 
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Figure 3-4. Treatment with Trichuris muris significantly elevates TH1 and TH2 cytokine and 
chemokine expression. 
3-4 weeks old female A/J mice were inoculated with either H. hepaticus or brucella broth (control). Three 
months post-inoculation the same mice were treated with either Trichuris muris ova or PBS (vehicle control); 
three weeks later mice were sacrificed and mRNA expression in cecal tissue was evaluated with real-time 
PCR analysis. All data was analyzed with a two-way ANOVA with Student-Newman-Keuls post-hoc test; p ≤ 
0.05 considered significant and indicated by lower case letters.  Error bars represent ± S.D.   
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Figure 3-5.  Trichuris muris treatment does not abrogate H. hepaticus induced intestinal 
inflammation.   
3-4 week old female A/J mice were inoculated with either H. hepaticus or brucella broth (control). 
Three months post-inoculation the same mice were treated with either T.  muris ova or PBS; eight 
weeks later mice were sacrificed.  (A) Cecal lesion (B) Percentage of mice with T. muris 
detectable histologically and during necropsy. (C) Cecal mRNA gene expression evaluated with 
real-time PCR analysis. All data analyzed with a two-way ANOVA with Student-Newman-Keuls 
post-hoc tests or a Fisher exact test; p ≤ 0.05 considered significant and indicated by lower case 
letters.  Error bars represent ± S.D.  
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Figure 3-6.  The immune response to Trichuris muris is altered by ongoing TH1 
inflammation.  
  
91 
 
Table 3-1.  Real-time PCR primers and annealing temperatures.   
 Forward Reverse Anneal Temp (
0C) 
HPRT GTAATGATCAGTCAACGGGGGAC CCAGCAAGCTTGCAACCTTAACCA 60 
IFN-γ GCCATCAGCAACAACATAAGC TGGGACAATCTCTTCCCCAC 58 
IL-4 ATGGGTCTCAACCCCCAGCTAGT GCTCTTTAGGCTTTCCAGGAAGTC 57 
IL-5 TGACCGCCAAAAAGAGAAG GGTATCCCTTGCATTTGCAC 53.7 
IL-6 AGAGACTTCCATCCAGTTGC GAATTGCCATTGCACAACTCTT 54.5 
IL-10 CGGGAAGACAATAACTG CATTTCCGATAAGGCTTGG 58 
IL-12/23 
p40 ACTCACATCTGCTGCTCCAC GGGAACTGCTACTGCTCTTGA 60 
IL-13 ATCACACAAGACCAGACTCC GTTACAGAGGCCATGCAATATC 54 
IL-17a CAGAAGGCCCTCAGACTACC CTTTCCCTCCGCATTGACAC 56.6 
IP-10 TCCCCATCAGCACCATGAAC ACTTGAGCGAGGACTCAGAC 53 
	
	
	 	
92 
 
Chapter 4 – Depletion of natural and inducible Foxp3+ 
cell populations alters the immune response in a 
microbiota-dependent manner.    
Introduction 
Crohn’s Disease (CD) and Ulcerative Colitis (UC) are types of 
Inflammatory Bowel Diseases (IBDs) which affect approximately 1.5 million 
Americans. Regardless of the type of IBD, it is assumed that disease develops 
as the result of inappropriate interactions between an individual’s genetics, 
environment and microbiota which lead to an uncontrolled inflammatory 
response.  As IBDs are thought be the result of uncontrolled inflammation, it is 
logical to investigate the role of cellular subsets known to be capable of 
suppressing inflammatory reactions.  
The concept of a suppressive cell that can control the immune system has 
existed within the scientific community for decades138.  The existence of this 
cellular population was first implied in the mid-1900s when scientists observed 
that the removal of the thymus caused an uncontrolled immune response which 
resulted in massive autoimmunity139-142.  However, the concept of a T regulatory 
cell was not in the limelight of science until 1995 when Sakaguchi observed that 
CD4+CD25+ cells prevented the development of autoimmunity in athymic mice372.  
Since then, thousands of experiments attempting to characterize this cell 
population have been completed and published. One of the most important and 
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controversial concepts derived from these publications was discussed in 2003 by 
Bluestone and Abbas.  Upon reviewing the published literature, they proposed 
the novel idea that not one, but two distinct CD4+ regulatory cell populations, a 
natural and an inducible T regulatory cell, exist and although both have 
regulatory actions, they develop and function in different manners.143  As the 
distinction between inducible and natural T regulatory cells was made after the 
initial discovery of T regulatory cells, many of the early studies on T regulatory 
cells may actually reflect the synergistic effects of these two regulatory subsets.    
The existence and function of these two subsets of T regulatory cells has 
been extensively documented by the numerous reviews132,133,143-153.  Natural T 
regulatory cells arise in the thymus early in life, are programmed to recognize 
self-antigens373 and can suppress the actions of auto-reactive lymphocytes, 
which, if left unchecked, could cause the development of autoimmunity373.  The 
importance of natural T regulatory cells in preventing autoimmunity and their 
thymic origin has been extensively demonstrated in vivo through the use of the 
thymectomy model372,374,375.  Natural T regulatory cell’s suppressive abilities have 
been found to be cell-contact dependent376-378.   The ability of inducible T 
regulatory cells to develop from CD4+ naïve T cells in the periphery has been 
demonstrated by the development of T regulatory cells after either surgical 
thymectomy or the adoptive transfer of non-regulatory cells into a mouse lacking 
endogenous T regulatory cells154-158.  The exact mechanism by which they are 
induced in vivo is yet to be determined, but in vitro studies suggest that IL-10, 
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TGF-β and IL-2 are critical for their development and suppressive actions379-382.  
Additionally, it seems that specialized antigen presenting cells, such as CD103+ 
dendritic cells, may be required for inducible T regulatory cell induction in the 
periphery186-188. The requirement of CTLA-4 (Cytotoxic T-Lymphocyte Antigen 4), 
for peripheral induction also differentiates inducible T regulatory cells from their 
thymic-derived counterparts which do not require CTLA-4 for the development of 
suppressive abilities383,384.   
The most commonly used marker for T regulatory cell identification is 
Foxp3, a transcription factor that has been shown to control T regulatory cell 
development164,385.  Foxp3 is encoded on the X chromosome and genetic defects 
result in a fatal disorder known as IPEX (Immunodysregulation, 
Polyendocrinopathy, Enteropathy, X-linked) syndrome in humans159-162, and 
scurfy in mice134,386,387.  Although Foxp3 is, in general, accepted as a means to 
identify T regulatory cells, its use for in vitro and ex vivo studies are limited by its 
intracellular expression.   
As a means to study T regulatory cells, a variety of scientific methods 
have been developed to deplete mice of these cells including: anti-CD25 
antibody administration388,389, adoptive transfers in RAG1-/- and RAG2-/- knock-
out mice390,391, the development of transgenic mice targeting specific T regulatory 
cell related genes such as Foxp3134,386,392,393 and the use of surgical 
thymectomies374,375,394,395.  Of these, the surgical thymectomy is unique in that it 
anatomically depletes the body of natural T regulatory cells and results in 
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autoimmunity372,374, which can be reversed by the adoptive transfer of  
CD4+CD25+ cells375.  Inducible T regulatory cells are not affected by day-3 
neonatal thymectomies, as multiple groups have documented the development of 
a T regulatory cell population either after surgical thymectomy or when naïve T 
cells were adoptively transferred into mice lacking endogenous T cell 
populations154,155,157,158,396-398.   
Due to the therapeutic potential for T regulatory cells, protocols for the in 
vitro induction of these cells, from naïve T cell populations, have been described 
in the literature for cells isolated from both mice and humans 
169,379,380,382,383,399,400.  It has been shown that TGF-β is required for the 
development and maintenance of inducible T regulatory cells in the periphery 
169,379,380,383,401-403, and that surface-bound TGF-β may be important for T 
regulatory cell suppressive functions 168,404,405 in humans and mice.  In addition to 
TGF-β, IL-2 also appears to be required for the induction of T regulatory cells 
from a naïve CD4+ cellular population154,382,406,407.  The inducible T regulatory 
cell’s developmental independence from the thymus has been further 
documented in vivo by the peripheral expansion of T regulatory cells from naïve 
T cells after adoptive transfer to recipient animals154,408,409.   
Our laboratory utilizes a Helicobacter hepaticus-induced mucosal 
inflammation model which serves a for IBD model.  In this model, three months 
after inoculation with H. hepaticus, the ceca of A/J mice develop a lymphocytic 
infiltrative histologic disease25 and  have significant elevations in mRNA gene 
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expression of  IL-12/23 p40, IFN-γ and IL-1025,252-254.  It is hypothesized that once 
established in the cecum, Helicobacter spp. act as a provocateur which instigate 
immune responses against certain endogenous microbiota248,249.  The 
importance of T regulatory cells in the prevention of mucosal inflammation 
induced by H. hepaticus is suggested by the development of typhlitis in C57BL/6 
mice deficient for IL-10265,410.  While the C57BL/6 strain of mouse is known to be 
resistant to H. hepaticus induced disease25, removal of functional IL-10 renders 
these mice susceptible to disease265.  Furthermore, adoptive transfer 
experiments have demonstrated that only CD4+ cells with functional IL-10 
isolated from a donor previously infected with H. hepaticus have the ability to 
protect against H. hepaticus induced-disease development117.   As IL-10 is 
involved in the suppressive mechanism of T regulatory cells, it is logical to 
assume that these cells are involved in preventing inflammation following H. 
hepaticus exposure. 
As previously discussed, it is impossible to differentiate between the two 
subsets of T regulatory cells in vivo.  Instead, coordinated experiments which 
removed either just natural T regulatory cells or both subsets were utilized to 
dissect out the role of these cells in mucosal inflammation.  First, the protective 
capabilities of inducible T regulatory cells in this disease model were evaluated 
by utilizing neonatal thymectomies to remove natural T regulatory cell 
populations.  Next, both T regulatory cell subsets were removed utilizing 
C57BL/6- Foxp3DTR mice which allow for the depletion of all Foxp3+ cells 
97 
 
following injection with diphtheria toxin (DT).  This allowed us to evaluate the role 
of both T regulatory cells populations in the prevention of H. hepaticus induced 
disease development.   The results from these experiments demonstrate that 
depletion of natural and inducible T regulatory cells had no effect on the C57BL/6 
mouse strain’s resistance to H. hepaticus induced disease. Interestingly, 
however, the data suggests that in the C57BL/6 mouse, H. hepaticus causes a 
protective immune response, which potentially includes the development of 
inducible T regulatory cell population, which drives maintenance of mucosal 
homeostasis.   
Results   
Depletion of natural T regulatory cells results in decreased IFN-γ response 
to H. hepaticus in the C57BL/6 mouse four days post-inoculation  
C57BL/6 mice inoculated with H. hepaticus are resistant to the 
development of the TH1 inflammation seen in susceptible mouse strains.  When 
functional IL-10 is removed in this strain, disease develops following H. hepaticus 
inoculation, thus suggesting the importance of IL-10 and cells like T regulatory 
cells which utilize IL-10 to suppress inflammation.  These findings, in combination 
with published reports of the ability of adoptively transferred T regulatory cells to 
reverse H. hepaticus induced inflammation, prompted us to more thoroughly 
evaluate the role of these cells in the C57BL/6 mouse’s resistance to disease.   
To start, the capabilities of natural T regulatory cells to alter the acute response 
98 
 
to H. hepaticus were evaluated.  In short, C57BL/6DTR female mice were either 
thymectomized (removal of natural T regulatory cells) or sham thymectomized 
(control) three days following birth and then inoculated with either H. hepaticus or 
brucella broth at 3-4 weeks of age.  Four days after inoculation, the mice were 
necropsied and evaluated for mRNA expression of IL-12/23 p40, IFN-γ, IL-10, IL-
17a and IL-17f (Figure 4-1).  When H. hepaticus inoculated mice depleted of 
natural T regulatory cells (thymectomized) were compared to those with T 
regulatory cells (sham thymectomy) the only significant difference noted was a 
decrease in IFN-γ mRNA expression.  When the same comparison was made in 
brucella broth inoculated mice a significant decrease in IL-12/23 p40 mRNA 
expression and a significant increase in IL-10 mRNA expression was noted in the 
mice depleted of natural T regulatory cells.  When thymectomized mice 
inoculated with H. hepaticus were compared to those inoculated with brucella 
broth significant increases in IFN-γ, IL-12/23 p40, IL-17a and IL-17f were seen.  
Finally when control thymectomized mice inoculated with H. hepaticus were 
compared to those inoculated with brucella broth, significant elevations were 
noted in IFN-γ, IL-10, IL-17a and IL-17f.  The same experiment was repeated in 
male mice and, in general, similar trends were observed (Figure 4-5).  These 
data demonstrate that the initial IFN-γ response generated to H. hepaticus is 
suppressed in the absence of a natural T regulatory cell population.   
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Depletion of natural T regulatory cells does not result in H. hepaticus-
induced disease.  
Next we sought to determine if the absence of natural T regulatory cells 
would affect the C57BL/6 mouse’s resistance to the development of H. hepaticus 
induced disease.   To accomplish this, C57BL/6-Foxp3DTR female mice were 
either thymectomized or sham thymectomized three days following birth and then 
inoculated with either H. hepaticus or brucella broth at 3-4 weeks of age.  Ninety 
days after inoculation the mice were necropsied and evaluated for the 
development of cecal inflammation and mRNA expression of IL-12/23 p40, IFN-γ, 
IL-10, IL-17a and IL-17f.  When cecal inflammation was evaluated, no significant 
differences in disease severity were noted among the four groups, regardless of 
inoculum or natural T regulatory cell status (Figure 4-2A).  The same 
observations were made when male mice were evaluated (Figure 4-6A).   
When cecal mRNA expression in H. hepaticus inoculated mice depleted of 
natural T regulatory cells were compared to those with an intact natural T 
regulatory cell population no significant differences were noted in any of the 
cytokines evaluated.  When the same comparisons were made of brucella broth 
inoculated mice, IFN-γ was significantly elevated.  A significant decrease in the 
mRNA expression of IFN-γ and a significant increase in IL-10 mRNA expression 
were noted when H. hepaticus inoculated thymectomized mice were compared to 
brucella broth inoculated thymectomized mice.  When H. hepaticus mice with 
unaltered T regulatory cells populations were compared to their brucella broth 
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counterparts, a significant increase in IL-10 was detected. (Figure 4-2B)  As with 
the day 4 experiments, this experiment was repeated in male mice.  Similar 
trends were noted, with lack of disease development in all four treatment groups 
(Figure 4-6A).  In general, the trends observed for the cytokines in the female 
mice were also seen in the male mice. (Figure 4-6B)  Collectively the data from 
the experiments involving natural T regulatory cell depletion demonstrate the 
despite some changes in mRNA cytokine expression, the absence of natural T 
regulatory cells does not alter the C57Bl/6 mouse’s resistance to H. hepaticus 
induced disease.   
Acute depletion of Foxp3+ cells results in decreased IL-10 expression in H. 
hepaticus inoculated mice.   
The previous experiments demonstrate that natural T regulatory cells are 
not involved in the protective immune response which prevents the development 
of H. hepaticus induced disease in the C57BL/6 mouse.  The next logical step 
was to evaluate the role of inducible cells in the resistance to H. hepaticus 
induced disease.  As it is impossible to only deplete inducible T regulatory cells, 
the role of this cell population was extrapolated by comparing mice depleted of 
both T regulatory cells subsets (natural and inducible) to those only depleted of 
natural T regulatory cells.   First, the acute immune response to H. hepaticus was 
evaluated by treating 3-4 week old C57BL/6-Foxp3DTR mice with either diphtheria 
toxin (DT) or PBS (control), inoculating those mice with either H. hepaticus or 
brucella broth and then necropsying all mice 4 days post-inoculation. Again, the 
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expression of cytokine mRNAs were evaluated with real-time PCR (Figure 4-3).  
When H. hepaticus inoculated mice depleted of Foxp3+ cells were compared to 
those with intact T regulatory cell populations, a significant increase was noted in 
IL-12/23 p40 and a significant decrease was noted in IL-10.  When the same 
groups were compared within brucella broth inoculated mice, significant 
increases were noted in IL-12/23 p40, IFN-γ, IL-10 and IL-17a.  When H. 
hepaticus inoculated mice depleted of Foxp3+ cells were compared to brucella 
broth inoculated mice also depleted of this cell group, significant elevations were 
noted in IL-10 and IL-17a.  When comparisons were made between the control 
treatment mice inoculated with brucella broth or H. hepaticus, significant 
elevations were found for IFN-γ, IL-10, IL-17a and IL-17f.  The experiment was 
repeated in male mice and again similar trends were noted (Figure 4-5).  This 
experiment suggests that when Foxp3+ cells are removed in the presence of H. 
hepaticus, a more pro-inflammatory cytokine environment persists as IL-12/23 
p40 expression is up-regulated and the anti-inflammatory cytokine IL-10 is down 
regulated four days post-inoculation. .  
Depletion of Foxp3+ T regulatory cells did not change susceptibility to H. 
hepaticus induced disease.  
Finally, we sought to investigate if the pro-inflammatory immune response 
documented during the acute response to H. hepaticus would result in the 
development of disease.  As with the prior experiment, C57BL/6-Foxp3DTR mice 
were depleted of Foxp3+ cell populations with DT treatments and inoculated with 
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either H. hepaticus or brucella broth.  Ninety days post-inoculation mice were 
necropsied and their ceca used to evaluate the development of histologic 
disease and mRNA expression of IL-12/23 p40, IFN-γ, IL-10, IL-17a, and IL-17f.  
Interestingly, when histologic sections were evaluated a significant increase in 
disease was noted in female mice depleted of Foxp3+ cells and administered 
brucella broth, but not H. hepaticus.  In fact, when the mice depleted of Foxp3+ 
cells were compared between the two inoculation groups, those inoculated with 
brucella broth had more severe lesion scores than those inoculated with H. 
hepaticus. (Figure 4-4A) When the experiment was repeated with male mice, 
these differences were not noted (Figure 4-8A).   
 When cytokine mRNA expression was evaluated, minimal changes were 
seen.  No significant changes were seen among the four groups for IL-12/23 p40, 
IL-17a or Il-17f.  IFN-γ expression was elevated only when H. hepaticus 
inoculated, Foxp3+ depleted mice were compared to the H. hepaticus inoculated 
sham thymectomized mice.  Significant elevations in IL-10 were found within both 
T regulatory cell groups, depleted and intact, when H. hepaticus inoculated mice 
were compared to their brucella broth inoculated counterparts.  (Figure 4-4B)  
Similar trends were seen in the repeat experiment which utilized male mice 
(Figure 4-8B).  Collectively the experiments involving depletion of Foxp3+ T 
regulatory cells demonstrate that despite an acute pro-inflammatory response, 
the absence of these cells at the time of H. hepaticus inoculation does not alter 
the C57BL/6 mouse’s resistance to disease.   
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Discussion 
As the development of IBD is thought to be due to an inappropriate 
immune response to the bacterial flora, it is logical to assume that T regulatory 
cells, which are typically responsible for the regulation of the body’s immune 
responses, are involved.  Humans without functional Foxp3 lack T regulatory 
cells and many develop severe intestinal inflammation due to the uncontrolled 
infiltration of lymphocytes159-162.  In a similar fashion, mice without functional T 
regulatory cells have been shown to develop colitis163,164.   Although it has not 
been shown that those with IBD have dysfunctional T regulatory cells, it has been 
demonstrated that a decreased proportion of T regulatory cells are present in IBD 
patients compared to healthily controls165, which may be due to an increased rate 
of T regulatory cell apoptosis166.   It has been shown that T regulatory cell’s 
suppressive abilities are mediated by both IL-10 and TGFβ167-169 and that this cell 
subset is capable of both preventing and reversing colitis in mouse IBD 
models116-119,155,170-178.   
Experiments in IL-10-/- mice have demonstrated the importance of these T 
regulatory cells products in the prevention of colitis development.  For example, 
when C57BL/6 mice lack functional IL-10, they develop a chronic enterocolitis 
which is thought to be driven by members of the microbiota such as H. 
hepaticus411,412.  Furthermore, it has been shown that the protective abilities of T 
regulatory cells in adoptive transfer models of colitis are negated when IL-10 
signaling is not intact413.  As wild-type C57BL/6 mice do not develop disease 
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following inoculation with H. hepaticus25, it is logical to suspect that disease 
resistance in this strain is mediated in some fashion by T regulatory cells.   
First, we aimed to identify the T regulatory cell population responsible for 
resistance to H. hepaticus-induced disease in the C57BL/6 mouse.  While both 
populations are suppressive in nature, natural and inducible T regulatory cells 
have been shown to develop through different pathways132,133,143-153.  Natural T 
regulatory cells develop within the thymus and inducible T regulatory cells 
develop from CD4+ naïve T cells in the periphery154-158,127,128,138-148.   In the 
following experiments, neonatal thymectomies were utilized to permanently 
deplete natural T regulatory cells83,158,374,414, while still allowing for the 
development of an inducible T regulatory cell population21,30,100,101,415.  The use of 
a C57BL/6 mouse with a diphtheria toxin (DT) receptor linked to Foxp3 
expression (C57BL/6-Foxp3DTR) allowed for the temporary depletion of all Foxp3+ 
cell populations, including both natural and inducible T regulatory cells392.  
Injection with DT reduced T regulatory cell populations by 75% and 98% in the 
cecum and spleen, respectively, within 2 days following the last treatment (data 
not shown). It was at this time point that mice were inoculated to best evaluate 
the role of Foxp3+ T regulatory cells in the response to H. hepaticus.    
For both natural T regulatory cell and Foxp3+ T regulatory cell depletion, 
mice were evaluated at both an acute (4 day) and chronic (90 day) time point to 
access changes in mRNA expression of IL-12/23 p40, IFN-γ, IL-10, IL-17a and 
IL-17f.  These cytokines were chosen so as to evaluate both TH1 and TH17 driven 
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aspects of inflammation.   Human CD patients have been documented to have 
elevated TH1 and TH17 cytokines such as IFN-γ and IL-173,14-16,21,121.  
Furthermore mouse models of IBD involving H. hepaticus have demonstrated 
elevations in IL-12/23 p40, IFN-γ, IL-10 and IL-17a25,253,416. 
First, the role of natural T regulatory cells in the response to H. hepaticus 
was evaluated.  To accomplish this, H. hepaticus inoculated, thymectomized 
mice were compared to H. hepaticus inoculated, sham thymectomized mice. 
Evaluation of mRNA expression with real-time PCR at the acute time point (four 
days post-inoculation) revealed a significant decrease in IFN-γ expression in the 
thymectomized female mice compared to their respective controls (Figure 4-1).  
At the ninety day time point no significant differences in cecal cytokine mRNA 
expression were noted among female mice (Figure 4-2B).  The acute shift in 
mRNA expression of IFN-γ, although statistically significant, does not appear to 
be physiologically relevant as there were no differences in the development of 
histologic disease (Figure 4-2A).  These data suggest that natural T regulatory 
cells are not involved in the resistance to H. hepaticus induced disease. These 
findings were not entirely unexpected, as susceptibility to neonatal thymectomy-
induced autoimmunity has been reported to be strain dependent. The C57BL/6 
mouse is cited as a “resistant” strain417 and has been shown to only develop 
autoimmunity after complete removal of Foxp3+ cellular subsets164.   
These findings further support the importance of inducible T regulatory 
cells in C57BL/6 mouse and led to the evaluation of these cells. Unfortunately, 
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the selective depletion of inducible T regulatory cells is physiologically impossible 
with current techniques.  To evaluate the immune response without the influence 
of Foxp3+ regulatory T cells (natural and inducible), mice were treated with either 
diphtheria toxin or PBS (vehicle control) at 3-4 weeks of age and then inoculated 
with H. hepaticus two days later.  As with the prior experiment, mice were 
necropsied and evaluated either four or ninety days post inoculation.   Evaluation 
of cecal mRNA with real-time PCR at the early (4 day post-inoculation) time point 
revealed increased IL-12/23 p40 expression and decreased IL-10 expression 
when Foxp3+ female depleted mice were compared to controls (Figure 4-3).   
When H. hepaticus inoculated mice depleted of Foxp3+ cellular subsets 
were evaluated ninety days post-inoculation, the only shift observed in cytokine 
mRNA cytokine expression was a significant elevation of IFN-γ expression in 
female DT treated mice compared to controls (Figure 4-4B).  Despite the 
elevation in IFN-γ there were no differences in histologic lesions, and neither the 
DT treated nor control mice had an average lesion score which correlated with 
disease development in this model (Figure 4-4A).    
 Collectively these experiments demonstrate that depletion of neither 
natural nor inducible T regulatory cells at the time of H. hepaticus renders the 
C57BL/6 mouse susceptible to H. hepaticus induced inflammation.  These 
findings are contradictory to the implication derived from studies utilizing 
C57BL/6 IL-10-/- mice.  C57BL/6 mice which lack functional IL-10 develop 
disease when infected with H. hepaticus413,414, thus suggesting a possible role for 
107 
 
T regulatory cells in disease resistance.  The importance of T regulatory cells in 
disease resistance is further implied by studies which demonstrate that the 
adoptive transfer of T regulatory cells lacking functional IL-10 negates the typical 
protective properties of these cells413.   With this in mind, it must be considered, 
that the ability of the mice evaluated in this study to re-generate an inducible T 
regulatory cell population was not affected by the experimental protocols.  Unlike 
C57BL/6 IL-10-/- mice which have persistent loss of the cytokine’s anti-
inflammatory properties, the inducible T regulatory cell populations in these mice 
were only temporarily depleted.  The continued resistance in these mice to 
disease development could be due to the regeneration of an inducible T 
regulatory cell population.  These findings are in line with a previous study that 
demonstrated that protection from H. hepaticus induced disease following the 
adoptive transfer of T regulatory cells is dependent upon the H. hepaticus status 
of donor mice, which presumably drives the induction of an inducible T regulatory 
cell population117. 
To evaluate the role of these T regulatory cell populations in the general 
maintenance of gut homeostasis without the influences of a bacteria provocateur 
such as H. hepaticus, the comparisons made in H. hepaticus inoculated mice 
were repeated in those inoculated with brucella broth.  First we sought to 
evaluate the role of natural T regulatory cells in the immune response to the 
endogenous microbiota of the C57BL/6 mouse.  To accomplish this, mice 
depleted of natural T regulatory cells and inoculated with brucella broth were 
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compared to controls inoculated with brucella broth. Evaluation of mRNA 
cytokine expression with real-time PCR at the acute time point (four days post-
inoculation) revealed a significance decrease in IL-12/23 p40 expression and a 
significant increase in IL-10 expression when female mice depleted of natural T 
regulatory cells were compared to controls (Figure 4-1).  
When the same treatment groups of female mice were evaluated ninety-
days post-inoculation, there was a significant elevation in IFN-γ expression when 
thymectomized mice were compared to their control counterparts (Figure 4-2B).  
Interestingly, in the female mice, despite the elevation in IFN-γ expression, a 
cytokine associated with the T effector cell populations capable of disease 
induction25,253, no differences in disease severity were noted in the female mice 
(Figure 4-2A).   
Next the immune response to the microbiota, without the influence of 
Foxp3+ regulatory T cells (natural and inducible), was evaluated.  At 3-4 weeks of 
age C57BL/6-Foxp3DTR mice were treated with either diphtheria toxin or PBS 
(vehicle control) and then inoculated with H. hepaticus two days later.    
Evaluation of cecal mRNA with real-time PCR at the acute time point (four days 
post-inoculation) revealed a significance increases in IL-12/23 p40, IFN-γ, IL-10 
and IL-17a expression in female DT treated mice compared to controls (Figure 4-
3).  The acute elevation of cytokine mRNA expression when both natural and 
inducible T regulatory cells are depleted, but not when only natural T regulatory 
cells were depleted, suggests that inducible T regulatory cells are more involved 
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in controlling the immune response to the microbiota.  As it has been shown that 
development of this population of T regulatory cells is driven by the 
microbiota84,86, these findings are not surprising.   
At the late time point (90 days post inoculation), no significant differences 
in cecal mRNA expression of cytokines were found between the T regulatory cell 
depleted and control mice within the female mouse groups evaluated (Figure4-
4B). Interestingly, however there was a significant elevation in disease severity 
between female mice depleted of their Foxp3+ cellular subsets and the control 
mice (Figure 4-4A).  The lack of long term changes in mRNA expression 
following the depletion of Foxp3+, is most likely due to the regeneration of T 
regulatory cell populations.  Although mice depleted of their Foxp3+ cells had a 
significant elevation in lesions scores when compared to the control mice, the 
level of inflammation (mean = 4.4) is less severe than that typically seen in our 
IBD model25,252,253.  The development of this inflammation, although not severe, 
does point to the role of inducible T regulatory cells in establishing a threshold of 
physiologic inflammation early in life.  As inflammation developed only when both 
inducible and natural T regulatory cells were depleted, but not when natural T 
regulatory cells alone were depleted, this data further supports the importance of 
inducible, not natural, T regulatory cells in the maintenance of gut homeostasis.    
Interestingly, while our data did not demonstrate a lapse in protection from 
H. hepaticus induced inflammation when T regulatory cells are depleted, it did 
demonstrate that the removal of inducible T regulatory cells in the absence of H. 
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hepaticus resulted in an increased level of physiologic inflammation presumably 
driven by the microbiota.  To further investigate this finding, we evaluated the 
differences in mRNA cytokine expression and severity of inflammation in mice 
depleted of T regulatory cells and inoculated with either H. hepaticus or brucella 
broth.   
Four days after inoculation with either H. hepaticus or brucella broth 
removal of natural T regulatory cells resulted in elevated IFN-γ, IL-12/23 p40, IL-
17a and IL-17f mRNA expression in female mice inoculated with H. hepaticus 
(Figure 4-1).  At ninety-days post-inoculation depletion of natural T regulatory 
cells resulted in increased IL-10 and decreased IFN-γ mRNA expression when H. 
hepaticus inoculated female mice were compared their brucella broth inoculated 
counterparts (Figure 4-2B).  No differences in inflammation were found between 
the two inoculation groups when they were depleted of natural T regulatory cells, 
suggesting that despite  the shifts in IFN-γ a cytokine known to be up regulated in 
H. hepaticus driven inflammation25,253, natural T regulatory cells are not required 
for the C57BL/6 mouse’s protective immune response towards H. hepaticus 
(Figure 4-2A).   The elevated levels of IL-10 mRNA expression does, however, 
lend further support to the possibility that inducible T regulatory cells, which 
produce IL-10, are up-regulated in the H. hepaticus inoculated mice.  
Next the combined effects of H. hepaticus inoculation and the absence of 
Foxp3+ T regulatory cells were evaluated.  When female mice depleted of Foxp3+ 
cells were compared at four days post-inoculation, elevations in the mRNA 
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expression of both IL-10 and IL-17a were found in H. hepaticus inoculated mice 
(Figure 4-3).  At ninety days post-inoculation H. hepaticus inoculated mice 
depleted of Foxp3+ cells had a significant elevation in IL-10 mRNA expression 
compared to their brucella broth inoculated counterparts (Figure 4.4B).  This 
finding correlated with the significant decrease in histologic lesion scores seen in 
H. hepaticus mice depleted of Foxp3+ cellular populations when compared to 
those inoculated with brucella broth (Figure 4.4A).  It should be noted, however, 
that the lesion scores found in the DT treated, brucella broth inoculated mice are 
considered mild when compared to those typically seen in mice susceptible to 
the H. hepaticus model of IBD25,253.  The lack of inflammation in the H. hepaticus 
inoculated mice and the elevated levels of IL-10 mRNA expression further 
supports the hypothesis that this bacteria promotes the development of an 
inducible T regulatory cell population capable of suppressing inflammatory 
reactions in the gut.   
When data collected from male mice were evaluated in a similar fashion 
as the females, similar trends were identified overall.  The development of 
inflammation in the female mice, a finding not seen their male counterparts, may 
simply be due to female mice being more responsive to the microbiota than their 
male counterparts.  This finding supports a previous observation that male mice 
develop a less severe, inconsistent microbiota driven inflammation compared to 
their female counterparts252.   
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Collectively all of these experiments suggest the H. hepaticus supports the 
maintenance of mucosal homeostasis in the C57BL/6 mouse, possibly through 
the induction of an inducible T regulatory cell population.  These findings help 
explain why the addition of H. hepaticus to the microbiota of C57BL/6 mice 
prevents, rather than induces, the development of inflammation.  Without the 
presence of H. hepaticus, mice depleted of Foxp3+ T regulatory cells, but not 
natural T regulatory cells alone, developed a mild cecal inflammation further 
lending support to the ability of H. hepaticus to drive a protective immune 
response that ultimately helps maintain mucosal homeostasis.  
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Material’s and Methods 
Mice 
This study was conducted in accordance with the Guide for the Care and 
Use of Laboratory Animals and approved by the University of Missouri Animal 
Care and Use Committee.  A breeding pair of C57BL/6- Foxp3DTR was obtained 
from the laboratory of Alexander Y Rudensky (Department of Immunology, 
University of Washington, Seattle) and the offspring of these mice were utilized 
for all described experiments.    
Bacterial Culture 
 The cultivation of Helicobacter hepaticus strain MU-94 has been previously 
described25,252.  For inoculations, mice were gastrically gavaged with 0.5 ml of 
culture containing approximately 5 × 108 bacteria/ml. 2-4 weeks following 
inoculation and at the time of necropsy, colonization was confirmed with a H. 
hepaticus-specific PCR of feces 247. Brucella broth inoculations were utilized as 
the vehicle control for the H. hepaticus inoculum.   
Diptheria Toxin 
  Diphtheria toxin was purchased from Sigma (Saint Louis, MO) and all 
mice treated with diphtheria toxin received two1 μg intraperitoneal injections; all 
mice were monitored for weight loss and any sign of malaise.  Mice who lost 
more than 20% of their original body mass or who were exhibiting clinical signs 
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were immediately removed from the study and euthanized.   
Thymectomy 
  The surgical protocol utilized was adapted from the protocol published 
in the Current Protocols in Immunology374.  The pups were anesthetized by 
placing them on ice, with a plastic glove placed between the mice and the ice to 
prevent direct contact.  After anesthesia, the pups were placed in dorsal 
recumbency, secured with limb restraints and scrubbed with ethanol and 
chlorahexadine surgical scrub.  A skin incision was made from mid-sternum to 
the suprasternal notch and the thoracic cavity opened by cutting  the first 3 ribs at 
the site of sterna attachment. .  A pasteur pipette connected to a suction pump 
was then used to remove both thymic lobes and the skin incision closed with 
tissue glue.  All mice received 0.05 mg/kg buprenorphine subcutaneously for 
post-surgical analgesia.  At necropsy all mice were blindly evaluated for the 
presence of a thymus; any mouse with a thymic remnant was removed from the 
study.  
Necropsy  
For all experiments, ceca were removed and sectioned longitudinally into 
two equal parts.  For all experiments, one half was rinsed with sterile PBS and 
flash frozen in liquid nitrogen for use in mRNA expression analyses.  The other 
cecal half was either fixed in zinc fixative and embedded in paraffin for histologic 
evaluation.   
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Histological Evaluation 
Following staining with hematoxylin and eosin (H&E), cecal sections were 
evaluated for inflammatory lesions with a previously described protocol246,252,253.   
All cecal sections were blindly scored and given a category score for each of the 
following: inflammation intensity (0 = none, 1 = mild, 2 = moderate, 3 = severe); 
longitudinal extent of inflammation (0 = none, 1 = 1-2 small foci, 2 = patchy, 3 = 
diffuse); vertical extent of inflammation (0 = none, 1 = basal mucosal 
inflammation, 2 = full thickness mucosal inflammation, 3 = transmural 
inflammation); and hyperplasia (0 = none, 1 = focal, 2 = patchy hyperplasia, 3 = 
diffuse hyperplasia).  All of the lesions scores reported are the sum of the four 
category scores; any lesions score greater than 2 were decreased by 2 to 
minimize score inflation by inflammation, which is represented by three of the 
four categories evaluated.   
RNA Isolation and Reverse Transcription 
The ceca snap frozen for mRNA analysis were thawed in TRIzol 
(Invitrogen, Carlsbad, CA) and then homogenized with a Tissuelyser (Qiagen, 
Valencia, CA).  Per the manufacturer’s (Invitrogen) instructions, total RNA was 
isolated.  Five micrograms of the isolated RNA was reverse-transcribed using a 
Super Script II kit (Invitrogen, Carlsbad, CA) per the manufacturer’s oligo(dT) 
primer protocol.  All resulting cDNA was diluted to 20 ng/L.  
Real-Time PCR 
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Real-time quantitative PCR was performed with a Qiagen Rotor-Gene Q 
and Qiagen Quanti-tect SYBR Green (Qiagen, Valencia, CA).  All run conditions 
utilized for real-time PCR have been previously described25,371 and can be found 
in Table 4-1.  
Statistical Analysis 
Two-way ANOVAs with Student-Newman-Keuls post-hoc tests were 
performed using SigmaPlot 11.0 (Systat Software Inc., San Jose, CA).  Due to 
the exponential nature of real-time PCR, Log2 transformations were used to 
correct for failures in normality.   p values ≤ 0.05 are regarded as significant.   All 
graphs and dot plots were generated using either SigmaPlot 11.0 or GraphPad 
Prism 5.0 software (GraphPad Prism Software Inc., La Jolla, CA).   
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Figure 4-1.  Depletion of natural T regulatory cells in female mice results in decreased   
IFN-γ production in H. hepaticus inoculated mice.   
Female C57BL/6-Foxp3DTR mice were thymectomized (nTreg Depleted) or sham thymectomized 
(control) at three days of age to remove natural T regulatory cells and then administered H. 
hepaticus (Hh) or brucella broth (BB) at 3-4 weeks of age.  Four days later the mice were 
necropsied and ceca collected.   Real-time PCR was utilized to evaluate the mRNA expression of 
cytokines.  All cytokine expression normalized to the housekeeping gene HPRT and presented as 
mean ± S.D.  Two-way ANOVA with Student-Newman-Keuls post-hoc tests were utilized; p 
values ≤ 0.05 are regarded as significant and indicated by lowercase letters. .    
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Figure 4-2.  Depletion of natural T regulatory cells in female mice does not result in 
disease development following H. hepaticus inoculation.  
Female C57BL/6-Foxp3DTR mice were thymectomized (nTreg Depleted) or sham thymectomized 
(control) at three days of age to remove natural T regulatory cells and then administered H. 
hepaticus (Hh) or brucella broth (BB) at 3-4 weeks of age.  Ninety days later the mice were 
necropsied and ceca collected.  (A) Cecal inflammation was evaluated histologically; each point 
represents an individual mouse’s lesion score.  No significant differences were found between the 
four groups.  (B) Real-time PCR was utilized to evaluate the mRNA expression of cytokines.  All 
cytokine expression normalized to the housekeeping gene HPRT and presented as mean ± S.D.   
Two-way ANOVA with Student-Newman-Keuls post-hoc tests were utilized; p values ≤ 0.05 are 
regarded as significant and indicated by lowercase letters.    
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Figure 4-3.  mRNA expression of IL-10 is reduced following Foxp3+ cell population 
depletion in H. hepaticus inoculated female mice.    
Female C57BL/6-Foxp3DTR mice were administered diphtheria toxin (Treg depleted) or PBS 
(Cotnrol) at 3-4 weeks of age to remove natural T regulatory cells and then administered H. 
hepaticus (Hh) or brucella broth (BB) at 2 days following the last DT treatment.  Four days 
following inoculation, mice were necropsied and ceca collected.   Real-time PCR was utilized to 
evaluate the mRNA expression of cytokines.  All cytokine expression normalized to the 
housekeeping gene HPRT and presented as mean ± S.D.  Two-way ANOVA with Student-
Newman-Keuls post-hoc tests were utilized; p values ≤ 0.05 are regarded as significant and 
indicated by lowercase letters.  
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Figure 4-4. Depletion of Foxp3+ cells in female mice does not result in H. hepaticus-
induced disease development.  
Female C57BL/6-Foxp3DTR mice were administered diphtheria toxin (T reg depleted) to remove 
Foxp3+ cells (natural and inducible T regulatory cells) or PBS (control) at 3-4 weeks of age.  Two 
days following DT treatments, they were administered H. hepaticus (Hh) or brucella broth (BB). 
Ninety days post- inoculation, the mice were necropsied and ceca collected.  (A) Cecal 
inflammation was evaluated histologically; each point represents an individual mouse’s lesion 
score. (B) Real-time PCR was utilized to evaluate the mRNA expression of cytokines.  .  Two-way 
ANOVA with Student-Newman-Keuls post-hoc tests were utilized to evaluate all data; p values ≤ 
0.05 are regarded as significant and indicated by either horizontal capped bars (A) or lowercase 
letters (B).    
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Figure 4-5. Depletion of natural T regulatory cells in male mice results in decreased IFN-γ 
production in H. hepaticus inoculated mice.   
Male C57BL/6-Foxp3DTR mice were thymectomized (nTreg Depleted) or sham thymectomized 
(Control) at three days of age to remove natural T regulatory cells and then administered H. 
hepaticus (Hh) or brucella broth (BB) at 3-4 weeks of age.  Four days later the mice were 
necropsied and ceca collected.   Real-time PCR was utilized to evaluate the mRNA expression of 
cytokines.  All cytokine expression normalized to the housekeeping gene HPRT and presented as 
mean ± S.D.  Two-way ANOVA with Student-Newman-Keuls post-hoc tests were utilized; p 
values ≤ 0.05 are regarded as significant and indicated by lowercase letters.    
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Figure 4-6. Depletion of natural T regulatory cells in male mice does not result in disease 
development following H. hepaticus inoculation.  
Female C57BL/6-Foxp3DTR mice were thymectomized (nTreg Depleted) or sham thymectomized 
(control) at three days of age to remove natural T regulatory cells and then administered H. 
hepaticus (Hh) or brucella broth (BB) at 3-4 weeks of age.  Ninety days later the mice were 
necropsied and ceca collected.  (A) Cecal inflammation was evaluated histologically.  Each point 
represents an individual mouse’s lesion score and is presented as mean ± S.D.  (B) Real-time 
PCR was utilized to evaluate the mRNA expression of cytokines.  All cytokine expression 
normalized to the housekeeping gene HPRT and presented as mean ± S.D.   Two-way ANOVA 
with Student-Newman-Keuls post-hoc tests were utilized to evaluate all data; p values ≤ 0.05 are 
regarded as significant and indicated by lowercase letters. .    
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Figure 4-7. IL-10 mRNA expression levels are reduced in H. hepaticus inoculated male 
mice depleted of Foxp3+ cell populations.    
Male C57BL/6-Foxp3DTR mice were administered diphtheria toxin (Treg depleted) or PBS (control) 
or at 3-4 weeks of age to remove natural T regulatory cells and then administered H. hepaticus 
(Hh) or brucella broth (BB) at 2 days following the last DT treatment.  Four days following 
inoculation, mice were necropsied and ceca collected.   Real-time PCR was utilized to evaluate 
the mRNA expression of cytokines.  All cytokine expression normalized to the housekeeping 
gene HPRT and presented as mean ± S.D.  Two-way ANOVA with Student-Newman-Keuls post-
hoc tests were utilized; p values ≤ 0.05 are regarded as significant and indicated by lowercase 
letters.    
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Figure 4-8.  Depletion of Foxp3+ cells in male mice does not result in disease development. 
Male C57BL/6-Foxp3DTR mice were either administered PBS (Control) or diphtheria toxin (Treg 
Depleted) to remove Foxp3+ cells (natural and inducible T regulatory cells) at 3-4 weeks of age.  
Two days following DT treatments, they were administered H. hepaticus (Hh) or brucella broth 
(BB). Ninety days post- inoculation, the mice were necropsied and ceca collected.  (A) Cecal 
inflammation was evaluated histologically and no significant differences were found. Each point 
represents an individual mouse’s lesion score; data presented as mean ± S.D.  (B) Real-time 
PCR was utilized to evaluate the mRNA expression of cytokines.  All cytokine expression 
normalized to the housekeeping gene HPRT and presented as mean ± S.D.  Two-way ANOVA 
with Student-Newman-Keuls post-hoc tests were utilized; p values ≤ 0.05 are regarded as 
significant and indicated by lowercase letters. .  
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Table 4-1.  Real-time PCR primers and annealing temperatures.   
 Forward Reverse Anneal Temp (
0C) 
HPRT GTAATGATCAGTCAACGGGGGAC CCAGCAAGCTTGCAACCTTAACCA 60 
IFN-γ GCCATCAGCAACAACATAAGC TGGGACAATCTCTTCCCCAC 58 
IL-10 CGGGAAGACAATAACTG CATTTCCGATAAGGCTTGG 58 
IL-12/23 
p40 ACTCACATCTGCTGCTCCAC GGGAACTGCTACTGCTCTTGA 60 
IL-17a CAGAAGGCCCTCAGACTACC CTTTCCCTCCGCATTGACAC 56.6 
IL-17f ACTTGCCATTCTGAGGGAGG  
TGATGCAGCCTGAGTGTCTG 
 57.1 
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Chapter 5 - The Forgotten Projects  
 
Part I: Exploratory Research in TNBS-induced colitis with emphasis on the 
respective influences of gonadal sex hormones and previous infection with 
Helicobacter hepaticus. 
 
Part II: Preliminary investigations of the immune response to Trichuris muris in 
the young A/J mouse and the helminth’s ability to reverse H. hepaticus induced 
inflammation. 
 
Part III: Alternative explorations in the role of T regulatory cells in Helicobacter 
hepaticus induced inflammation.  
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Exploratory Research in TNBS-induced colitis with emphasis on 
the respective influences of gonadal sex hormones and previous 
infection with Helicobacter hepaticus. 
Introduction and Research Aims  
The documented influences of gonadal sex hormones in IBD have been 
extensively discussed in Chapters 1 and 2.  In short, females develop more 
autoimmune diseases than their male counterparts47-50 and the severity of 
disease in female IBD patients is higher than that seen in male IBD patients34. 
Additionally, a slight female sex bias has been reported for CD33.   The work 
presented here utilizes another IBD model in which TNBS (2,4,6-trinitrobenzene 
sulfonic acid) is administered intra-rectally and induces a colonic inflammation  
that histologically resembles CD418.   
When TNBS is administered in a solution of 50% ethanol into the lumen of 
the colon, it causes haptenization of colonic proteins, which are viewed as 
antigenic by the immune system.  A resulting inflammatory response develops 
within two weeks and is typically accompanied by diarrhea, rectal prolapse, 
abnormal hunched posture, anorexia and a scruffy hair coat.  Additionally, 
animals typically lose significant amounts of weight which correlate with 
mortality.418   Numerous studies utilizing TNBS have identified the importance of 
IL-12 and IFN-γ signaling in the development of this IBD model27,419-421.  
Furthermore, it has been repeatedly demonstrated that oral feeding of 
haptenized proteins negates the effects of rectally administered TNBS278,422-424.   
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The research presented here addresses two independent research aims.  
In the first, the ability of gondal sex hormones to modulate the development of 
TNBS-induced colitis was evaluated.  Female mice were ovariectomized, 
implanted with either an estrogen or placebo pellet and then administered either 
a high or low dose of TNBS.  Male mice were orchiectomized, implanted with 
either a testosterone or placebo pellet and administered the high dose of TNBS.  
Following TNBS administration, mice were weighed daily as a secondary means 
of evaluating disease development and then necropsied one week post-
administration.  Colons were collected and evaluated for the development of 
disease. The second experiment evaluated the effects of prior infection with H. 
hepaticus on the development of TNBS-induced colitis.  Ninety days following 
inoculation with H. hepaticus mice were administered TNBS and evaluated for 
the development of both colitis and thyphlitis.  Control mice received only 
H.hepaticus or only TNBS, along with the appropriate vehicle controls.  
Results and Discussion 
TNBS-induced colitis in the female A/J mouse is not modulated by 
estrogen signaling.   
5-6 week old A/JCr mice were ovariectomized and, during the surgery, a 
pellet containing either 17β estradiol or placebo was placed subcutaneously 
(n=10/treatment group).  Mice were administered 0.5 mg TNBS seven days post-
operatively and weighed daily for one week as a secondary indicator of disease.  
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At this point, mice were necropsied and the colon evaluated for histologic 
disease.  The scoring system utilized to evaluate colitis can be found in Figure 5-
1A;  images depicting the range of disease severity can be found in Figure 5-1B . 
As depicted in Figure 5-1C (top) there were no statistical differences in the lesion 
scores between the two treatments.  
To determine if the effects of estrogen signaling on TNBS-induced colitis 
were lost by the low concentration of TNBS used in the initial experiment (0.5 
mg), the experiment was repeated with a higher dose of TNBS (2.0 mg).  5-6 
week old A/JCr mice were ovariectomized and, during the surgery, a pellet 
containing either 17β estradiol or placebo placed subcutaneously 
(n=10/treatment group).  Mice were administered 2.0 mg TNBS 7 days post-
operatively and weighed daily for one week as a secondary indicator of disease.  
At this point, mice were necropsied and the colon evaluated for histologic 
disease.  Even with the higher dose of TNBS, there were no statistical 
differences between the test treatments (Figure 5-1C, middle).  
As stated, the mice from both experiments were weighed daily and the 
percent change in weight was calculated for each mouse.  For both experiments, 
no significant differences in weight gain/loss were noted between the placebo 
and estrogen treated groups (Figure 5-2A & B).   
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Despite estrogen’s proven immune-modulatory effects in prior 
experiments involving a TH1 mediated mouse model252, it does not appear to 
modulate TNBS-induced colitis in the A/J mouse.  However these results must be 
interpreted cautiously as the validity of this disease model in the A/J mouse has 
not been evaluated previously.  There is an identified strain susceptibility to 
TNBS induced-colitis and it was predicted that A/J mice would have a similar 
disease presentation as the closely related Balb/c mouse strain which is 
susceptible to disease induction418.   However, the overall disease severity seen 
in the female A/J mice treated with TNBS was lower than expected and did not 
significantly differ between the two TNBS doses administered, suggesting that 
the strain is not an ideal model for evaluation of estrogen signaling in TNBS-
induced colitis.   
TNBS-induced colitis in the male A/J mouse is not modulated by 
testosterone signaling.   
 Unlike other mouse models, many studies involving TNBS utilize male 
mice278,425-427 and the Current Protocols in Immunology  actually recommends the 
use of male SJL/J mice418.   As testosterone has been shown to be a natural 
immunosuppressive agent 428, we sought to determine if testosterone modulates 
the severity of TNBS-induced colitis.  To accomplish this, twenty 3-4 week old 
male A/JCr mice were orchiectomized.  During surgery, a pellet containing either 
5α-dihydrotestosterone or a placebo was placed subcutaneously (n=10/treatment 
group).  Mice were administered 2.0 mg TNBS seven days post-operatively and 
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weighed daily for one week as a secondary indicator of disease.  At this point, 
mice were necropsied and the colon evaluated for histologic disease.  There 
were no statistical differences between the severity of disease seen in the two 
treatment groups (Figure 5-1C, bottom).  As with the female mice, no significant 
differences in weight gain/loss were noted (Figure 5-2C).     
H. hepaticus colonization does not alter TNBS-induced colitis  
The IBD model used most frequently by our laboratory utilizes H. 
hepaticus to cause a TH1 type inflammatory response in the cecum ninety days 
post-inoculation.  Experiments involving flora and TNBS-induced colitis have 
demonstrated that the oral tolerance achievable in this model is limited to one’s 
own flora429.  Furthermore studies have shown probiotics to be protective against 
TNBS-induced colitis, suggesting a role for the microbiota in disease 
susceptibility430.  To evaluate the affect H. hepaticus has upon the development 
of TNBS colitis in the A/J mouse, 3-4 week females were inoculated with either 
brucella broth or H. hepaticus.  Three months post-inoculation, eight mice 
inoculated with H. hepaticus and seven mice inoculated with brucella broth were 
administered TNBS intracolonically.  As a control, eight additional mice 
previously inoculated with H. hepaticus were administered a solution of 50% 
ethanol intracolonically as a vehicle control for the TNBS treatment.  This 
resulted in three experimental groups: sham inoculated, TNBS treated (n=7); H. 
hepaticus inoculated, sham treated (n=8); and H. hepaticus inoculated, TNBS 
treated (n=8). These groups will be referred to as: TNBS, H. hepaticus and H. 
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hepaticus + TNBS in all further discussions, respectively.   Mice were weighed 
daily for one week and then necropsied.  The colon and the cecum were 
evaluated separately for disease severity.   
The cecal lesson scores of both the H. hepaticus + TNBS mice and the H. 
hepaticus mice were significantly elevated when compared to the TNBS treated 
mice. The colon lesson scores of the TNBS mice and the H. hepaticus + TNBS 
mice were significantly elevated when compared to the H. hepaticus mice. 
(Figure 5-3A).  The lack of colonic lesions in the H. hepaticus mice and cecal 
lesions in the TNBS mice suggest there is not an anatomical overlay of disease.  
This was further supported by the lack of differences in either cecal or colonic 
disease severity between the H. hepaticus + TNBS mice and either the H. 
hepaticus or TNBS treated mice.   Although both diseases produce a TH1 
mediated inflammatory response characterized by the production of IL-12/23 p40 
and IFN-γ, neither appeared to be exacerbated by the addition of the other.  The 
lack of interaction may be simply due to the lack of anatomical similarly, or may 
be due to the non-responsiveness of the A/J mouse strain in general to TNBS 
induced colitis.    
As mentioned, daily weights were taken to monitor a known secondary 
sign of TNBS-induced colitis418.  No significant differences in weight change were 
found between the groups (Figure 5-3B) 
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Conclusions 
 Despite the known genetic similarity of the A/J and BALB/c mouse strains, 
the lack of severe disease development suggests that the A/J mouse strain is not 
ideal for this IBD model.  Although our experimental results suggest that neither 
GSH or a prior infection with H. hepaticus is capable of modulating TNBS-
induced colitis, these results must be interpreted with caution as they may simply 
be a result of limited response to disease induction and the effects of either 
treatment may be lost due to the limited severity of disease presentation.  
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Materials & Methods 
Mice 
The University of Missouri’s Animal Care and Use Committee (ACUC) 
approved all experiments involving the use of animals.  All experiments were 
planned and performed in accordance with the Guide for the Care and Use of 
Laboratory Animals.   The A/J mice were obtained from Frederick National 
Laboratory for Cancer Research were used in experiments as described.   
Ovariectomy 
Mice were anesthetized with isoflurane, placed in ventral recumbency, 
clipped dorsally, and aseptically scrubbed.  A single longitudinal skin incision was 
made on the dorsal midline.  The ovaries were visualized, and following incision 
of the muscle wall, were removed.  Next, a continuous-release hormone pellet 
(described below) was inserted rostrally into the subcutaneous space between 
the scapulae through the initial incision and the incision closed with sterile skin 
staples.  Mice were given an intraperitoneal injection of buprenorphine for 
analgesia and recovered on a heating pad.  Seven to ten days post-operatively, 
the skin staples were removed.  At the time of necropsy, mice with detectable 
ovarian remnants were removed from the study.   
Orchiectomy  
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Male mice were anesthetized with isoflurane and placed in ventral 
recumbence.  Scrotal hair was removed with clippers and the scrotum prepped 
with alternating betadine and alcohol surgical scrubs.   The scrotum was incised 
with a scalpel and the testicle exteriorized and removed via gentle dissection 
from the testicular fat pad.  To prevent herniation of abdominal contents, the 
testicular fat pad was left intact and the scrotum sealed with tissue adhesive.  For 
placement of the continuous-release pellet, the dorsal thorax was clipped, and 
aseptically scrubbed.  A single longitudinal skin incision was made on the dorsal 
midline and the pellet placed subcutaneously. Following pellet placement the 
incision was closed sterile skin staples.  Mice were given buprenorphine IP for 
analgesia and recovered on a heating pad.  Seven to ten days post-operatively, 
the skin staples were removed. 
Compounds 
Female animals were administered a 90-day continuous-release hormone 
pellet containing either 1.5 mg 17β-estradiol (E2) or 1.5 mg placebo (Innovative 
Research of America, Sarasota, FL Catalog # NE-121 and NC-111, respectively). 
Male animals were administered a 21-day continuous-release hormone pellet 
containing either 10 mg 5α-dihydrotestosterone or 12.5 mg testosterone placebo 
(Innovative Research of America, Sarasota, FL Catalog #A-161 and NC-111, 
respectively).  At the time of necropsy, the presence of a pellet was confirmed 
and mice without a visible, intact pellet were removed from the study.  
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Induction of TNBS ((2,4,6-trinitrobenzene sulfonic acid) 
 Mice were lightly anesthetized with isoflurane.  TNBS (Sigma Chemical, 
St. Louis, MO), diluted in 50% ethanol was slowly administered into the lumen of 
the colon through the tip of a 3.5 french catheter inserted approximately 4 cm 
proximal to the anus.  Control mice received a solution of 50% ethanol.  For 
either TNBS dose, 0.5 or 2 mg, the total injection volume was 100μl.  Following 
TNBS administration, mice were kept in a vertical position for 30 seconds and 
then returned to their cages.  Animals were weighed daily and euthanized seven 
days post-treatment.  All mice were weighed daily and monitored for the 
development of colitis (diarrhea, rectal prolapse).  Any mouse which lost >20% 
starting body weight or developed clinical signs was removed from the study and 
euthanized. 
Helicobacter hepaticus 
The culture protocol for the MU-94 Helicobacter hepaticus strain has been 
previously described25,252.   At 3-4 weeks of age, mice were gastrically gavaged 
with 0.5 mL of culture broth.  The estimated concentration of H. hepaticus is 
approximately 5 x 108 bacteria/mL.  A previously described PCR assay was used 
to confirm colonization with H. hepaticus at necropsy247.    
Necropsy  
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CO2 inhalation was utilized to achieve euthanasia.  For all experiments, 
the cecum was removed and sectioned longitudinally into two equal parts.  One 
half was rinsed with sterile PBS and flash frozen in liquid nitrogen (these cecal 
sections were not utilized further).  The other half was fixed in 10% formalin and 
embedded in paraffin for histologic evaluation.  For those experiments involving 
H. hepaticus, cecal contents were collected to confirm H. hepaticus colonization.  
The colon was also removed, flushed with PBS and sectioned into three portions 
identified as: distal, middle and proximal.   These sections were then sectioned 
longitudinally - one half of each colon section was flash frozen in liquid nitrogen 
(these sections were not utilized further).  The other halves were fixed in 10% 
formalin and embedded in paraffin for histologic evaluation. 
Histological Evaluation 
Cecal histologic sections were stained with hematoxylin and eosin (H&E) 
stain and scored for inflammatory lesions using a previously described protocol 
246,252,253.   In short, all cecal sections were scored in a blinded fashion and 
assigned a category score for each of the following: inflammation intensity (0 = 
none, 1 = mild, 2 = moderate, 3 = severe); longitudinal extent of inflammation (0 
= none, 1 = 1-2 small foci, 2 = patchy, 3 = diffuse); vertical extent of inflammation 
(0 = none, 1 = basal mucosal inflammation, 2 = full thickness mucosal 
inflammation, 3 = transmural inflammation); and hyperplasia (0 = none, 1 = focal, 
2 = patchy hyperplasia, 3 = diffuse hyperplasia).  The lesions scores depicted in 
figures are the sum of the four category scores; any lesions score greater than 2 
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were decreased by 2 to minimize inflation of scores by inflammation alone, which 
is described by three of the four categories evaluated.   
The three colonic histologic sections collected were stained with H&E 
stain and individually scored for inflammation utilizing the rubric provided in figure 
5-2A which was adapted from the Current Protocols in Immunology418. Each 
section (distal, middle and proximal) was scored individually on a scale of 0-4 
(please see figure for corresponding pathology descriptions).   The scores from 
all three sections were then summed for an overall colonic lesion score 
(minimum = 0, maximum = 12).   
Statistical Analysis 
Student’s t-tests and one-way ANOVAs with a Student-Newman-Keuls 
post-hoc analysis were performed using SigmaPlot 11.0 (Systat Software Inc., 
San Jose, CA).  p values ≤ 0.05 were regarded as significant.   All graphs and 
dot plots were generated using either Microsoft Office Professional Plus 2010 
Excel software (Microsoft Corporation, Redmond, WA) or GraphPad Prism 5.0 
software (GraphPad Prism Software Inc., La Jolla, CA).    
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Figure 5-1. GSH signaling in the A/J mouse does not affect the development of TNBS-
induced colitis.   
(A) Rubric used to score colon sections.  (B) Histologic representations of disease severity.  
Corresponding lesion score indicated on individual images.  (C) Mice were ovariectomized and 
administered either an estrogen or placebo pellet. All mice were administered TNBS at either a 
low (0.5 mg) or high (2.0 mg) dose.   Seven days later the mice were necropsied and their colon’s 
accessed for disease development. Dot plots represent individual mice’s lesion scores of mice 
who received the low TNBS (top) and high TNBS (bottom) dose. (D)  Male mice were 
orchiectomized and administered either a testosterone or placebo pellet. All mice were 
administered a 2.0 mg dose of TNBS.   Seven days later the mice were necropsied and their 
colon’s accessed for disease development.  Lesion scores were compared with a t-test, no 
significant differences were found.  All data shown analyzed with a t-test; p ≤ 0.05 considered 
significant. No significant differences were found for any of the comparisons made.   
 
 
	
	
	
	
	
	
	
	
	
	
 
 
 
 
Colonic lesion scoring scale 
0 No evidence of inflammation.  
1 Low level of leukocyte infiltration with infiltration 
seen in <10% HPF.  No structural changes. 
2 Moderate leukocyte infiltration with infiltration seen 
in 10% to 25% HPF, crypt elongation, bowel wall 
thickening that does not extend beyond the 
mucosal layer, and no ulcerations.  
3 High level of leukocyte infiltration seen in 25% to 
50% HPF, crypt elongation, infiltration beyond the 
mucosal layer, thickening of the bowel wall and 
superficial ulcerations. 
4 Marked degree of transmural leukocyte infiltration 
seen in >50% HPF, elongated and distorted 
crypts, bowel-wall thickening, and extensive 
ulcerations.  
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Figure 5-2.  GSH do not affect TNBS-associated weight changes in the A/J mouse.   
(A)  Mice were ovariectomized and administered either an estrogen or placebo pellet. All mice 
were administered TNBS at either a low (0.5 mg) or high (2.0 mg) dose and weighed daily for 
seven days.  Average percentage of weight change was compared for both treatment groups.   
(B)  Male mice were orchiectomized and administered either a testosterone or placebo pellet. All 
mice were administered a 2.0 mg dose of TNBS and then weighed daily for seven days.  Average 
percentage of weight change was compared for both treatment groups.   All data shown analyzed 
with a t-test; p ≤ 0.05 considered significant.  Data plotted as mean percentage ± SD.  No 
significant differences were found for any of the comparisons made.   
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Figure 5-3. The development of typhlitis and colitis in mice previously inoculated with H. 
hepaticus and then administered TNBS.  
Ninety days following inoculation with H. hepaticus mice were administered TNBS (n=8) and 
evaluated for the development of both typhlitis (A) and colitis (B).  Control mice received only 
H.hepaticus (n = 8) or only TNBS (n=7), with the appropriate vehicle controls.  Dot plots indicate 
the lesion scores of individual mice, error bars indicate mean ± SD.   (C) Average percent weight 
loss of each treatment group from the day of TNBS treatment; presented as the mean percentage 
± SD.  All data shown analyzed with a one-way ANOVAs with a Student-Newman-Keuls post-hoc 
analysis; p ≤ 0.05 considered significant.  
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Preliminary investigations of the immune response to Trichuris 
muris in the young A/J mouse and the helminth’s ability to 
reverse H. hepaticus induced inflammation. 
Introduction and Research Aims  
Helminths are being considered as a therapeutic treatment option for IBD 
patients for several reasons.  First, the immune responses generated towards 
helminths for the purpose of worm clearance are typically TH2 in nature198,346-351.  
As TH1/TH17 immune responses are typically seen in CD patients14,113,114 , it has 
been speculated that the TH2 response induced by helminth exposure could 
counter balance an ongoing TH1 response and ultimately decrease inflammation.   
Second, regions of the world with an increased incidence of helminth infestations 
have a relatively low incidence of IBD diagnosis37,100.  In mouse models of IBD, 
pre-exposure to helminths prior to the administration of a trigger capable of 
causing IBD-like inflammation such as TNBS317,318, DNBS319,320, DSS321,322, and 
adoptive cell transfers323-325 has been shown to be protective.  Whether pre-
exposure to helminths during childhood development is crucial, is yet to be 
determined.  Furthermore, there has been published evidence supporting the 
ability of helminths to reverse inflammation seen in mouse models of IBD277,336,337 
and improve clinical signs in human IBD patients227,228.   Overall, these data 
suggest that helminths are capable of modulating future and ongoing immune 
responses.  We sought to determine if this was the case in the Helicobacter 
hepaticus model of IBD.   
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Previous studies have demonstrated that when A/J mice are administered 
H. hepaticus there is an immediate response to the bacterial addition to the 
microbiota  by four days post-inoculation characterized by elevations in mRNA 
gene expression of several cytokines such as IL-12/23 p40, IFN-γ and IL-1025.  
At ninety days post inoculation the elevations in gene expression persist, with the 
addition of histologic disease development which is localized to the cecum and 
characterized by lymphocytic infiltration of the lamina propria25,252-254.  T. muris is 
a whipworm of mice and was chosen for evaluation as a potential therapeutic in 
this model of IBD for two reasons.  First, it is related to the helminth, Trichuris 
suis, used in human therapeutic trials227,228 and second, because disease 
development in our H. hepaticus model occurs in the cecum, where these worms 
predominantly reside315.   
The projects described here provide a closer examination of the effects of 
exposure to T. muris during and after exposure to H. hepaticus, known to incite 
mucosal inflammation. First, the A/J mouse’s resistance to T. muris colonization 
was re-examined.  A previous experiment (Figure 3-1) had demonstrated that 5 
month old A/J mice are capable of expelling T. muris.   To confirm this is also 
true in a young mouse, the susceptibility of 4 week old A/J mice to T. muris 
colonization was investigated.  Next, a series of weekly necropsies were used to 
identify changes in cytokine expression following T. muris  exposure in a young 
mouse.   During the time course study, the presence of detectable T. muris was 
also documented.   Following these studies, the effects of T. muris exposure at 
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the time of H. hepaticus inoculation were examined at both four and ninety days 
post-inoculation.  Finally, the ability of T. muris to reverse ongoing disease 
induced by H. hepaticus was evaluated by administering the helminth to H. 
hepaticus infected mice.  Changes in histologic disease and mRNA gene 
expression were then analyzed at both 3 and 5.5 weeks post-helminth treatment.  
The findings in these later experiments, lead to the projects presented in  
Chapter 3.   
Results and Discussion 
Young A/J mice are capable of T. muris expulsion.  
To investigate the young A/J mouse’s susceptibility to T. muris, four week 
old female mice were inoculated with T. muris ova.   Four mice were then 
necropsied at either twelve or twenty-eight days post-inoculation.  At the time of 
necropsy mice were examined for either the presence larvae (12 day necropsy 
time point) or adult worms (28 day necropsy time point).  As shown in Figure 5-4, 
twelve days post-inoculation one-hundred percent (n=4) of the mice had 
detectable live larvae present in their cecal digests.  In contrast, by twenty-eight 
day post-inoculation none of the mice had adult T. muris within their ceca.   
These findings are consistent with those previously described in Chapter 3, when 
the susceptibility in a mature 5 month old A/J mouse was examined, and further 
support the findings that A/J mice are resistant to T. muris colonization.     
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Characterizing the immune response to T. muris in the young A/J mouse  
A/J mice were inoculated with T. muris ova or PBS (vehicle control) at 14 
days of age.  Eight mice (4 male and 4 female) from each inoculation group were 
necropsied at weeks 1, 2, 3, 4, 5 and 6 post-inoculation.  The week 14 necropsy 
time point consisted of 5 male and 3 female PBS inoculated mice and 7 male and 
3 female T. muris inoculated mice.  At necropsy the cecum was collected for 
cytokine mRNA analysis and examined for the presence of live T. muris.  Mice 
included in the week 1-3 necropsies were examined for larvae, while the mice 
included in the week 4-6 and 14 necropsies were examined for adult worms.    
As shown in Figure 5-5 all mice examined at weeks 1 and 2 were found to 
have live T. muris larvae.  At week 3, only three of the eight mice examined 
(62.5%) were positive for the helminth, suggesting the immune response 
required to clear the worms had begun by this time.  One mouse was found to 
have a worm burden of one adult worm at the week six time point.  Although this 
mouse did have an adult worm, it must be noted that the dose of T. muris ova 
given to the mice was sufficient to yield over 100 worms in a susceptible mouse 
strain.  After examining the data it was concluded that this experiment’s results 
concurred with the previously presented data and ultimately suggest that the A/J 
mouse is resistant to colonization by the helminth T. muris.   
 Analysis of mRNA expression was completed to further evaluate the 
immune response to T. muris in the young A/J mouse; all comparisons described 
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refer to mRNA expression levels in T. muris inoculated mice compared to the 
control PBS inoculated mice. As in the older mice (Figure 3-2), IL-12/23 p40 was 
elevated only at the week 2 necropsy time point. The expression of IFN-γ was 
elevated between weeks 1-4; this is one week longer than the IFN-γ expression 
pattern seen in the older A/J mice. Interestingly, the expression pattern of IL-10 
was dissimilar to that seen in the older mice in which a brief elevation was seen 
during weeks 1 and 2; in the young mice significant elevations were seen during 
weeks 3 and 5.  The cytokines associated with helminth clearance, IL-4 and IL-
13, were initially elevated at week 2 in the young and old mice, however the 
elevation in expression in young mice was shorter than that seen in older mice.  
IL-4 was elevated during weeks 2 and 3, while IL-13 was elevated during weeks 
2-4 and 6.  IL-5 expression was identical in the young and old mice – elevations 
were seen only at weeks 2 and 3.  Like IL-10, the elevations in IL-6 differed in the 
younger mice and occurred during weeks 2, 3 and 6.  
 In general, the cytokine expression seen in young A/J mice mirrored that 
documented in the mature A/J mice, with a few exceptions.  The discrepancies in 
IL-10 could be due to the development of inducible T regulatory cells towards the 
developing microbiota in the young mice.  It is plausible that the immediate IL-10 
response seen in the older mice (Figure 3-2) was generated by a population of 
established T regulatory cells; while the delayed IL-10 response could be due to 
the ongoing development of this cell subset in the younger mice.  This 
speculation is supported by the known involvement of T regulatory cells in 
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helminth clearance349,361 as well as the known induction of T regulatory cells in 
the periphery to endogenous microbiota84,117,145,431.    Overall, the general pattern 
of cytokine elevation is comparable between the two age groups evaluated in this 
experiment and the one described in Chapter 3. 
The immediate effects of co-exposure to T. muris and H. hepaticus  
To evaluate if the immediate immune response to H. hepaticus is altered 
by concurrent exposure to T. muris ova, 3-4 week old female A/J mice were 
inoculated with both agents (n=8).  Four days later, the mice were sacrificed and 
cecal mRNA gene expression of IFN-γ, IL-4, IL-5, IL-6, IL10, IL-12/23 p40 and IL-
13 was evaluated.  As a control, age matched A/J females were inoculated with 
H. hepaticus and PBS, the vehicle control for the T.  muris ova inoculum (n=8).  
When gene expression in H. hepaticus inoculated mice treated with T. 
muris ova were compared to PBS treated mice, no significant differences were 
found (Figure 5-6).  These data suggest that the initial cytokine response to H. 
hepaticus, typically defined by increased expression of IL-12/23 p40 and IFN-γ is 
not affected by the concurrent immune response to T. muris.  As we had 
previously demonstrated that exposure to T. muris does not elicit a change in 
either of these cytokines, this was not unexpected.   Furthermore, the previous 
experiment demonstrated elevations in the TH2 cytokines IL-4, IL-5, IL-6 and IL-
13 gene expression two week post-inoculation, which is well beyond the time 
point evaluated here (Figure 5-5).  Although it is reasonable to conclude that the 
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immediate response to H. hepaticus is not altered by the concurrent exposure to 
T. muris, the long term effects must be evaluated.   
The long term effects of co-exposure to T. muris and H. hepaticus 
Next we sought to evaluate if the immune response and subsequent 
disease development triggered by H. hepaticus is altered by a concurrent initial 
exposure to T. muris ova.  To accomplish this, groups of 3-4 week old female A/J 
mice were inoculated with H. hepaticus and either T. muris ova or PBS 
(n=8/group).  Ninety days later, the mice were sacrificed and cecal mRNA gene 
expression of IFN-γ, IL-4, IL-5, IL-6, IL10, IL-12/23 p40 and IL-13 was evaluated.  
To document if changes in H. hepaticus induced inflammation occurred following 
exposure to T. muris ova cecal, histology was evaluated.    
When the severity of H. hepaticus-induced disease was compared 
between mice treated with T. muris ova and PBS, no significant changes were 
found.  However, it must be noted that the disease severity seen in the H. 
hepaticus, PBS treated mice are lower than historically observed in this model; 
typically inoculation with H. hepaticus yields average lesion scores between 5-7.  
The most logical explanation for the dissimilarity between the current and past 
data, is the H. hepaticus culture used to inoculate the mice.  Although the mice 
were confirmed to be positive for H. hepaticus with PCR at the time of necropsy, 
the initial bacterial culture used for inoculation could have potentially been at a 
lower concentration or viability than normally used.  Unfortunately, the data must 
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be considered inconclusive to avoid missing changes potentially masked by a 
lack of disease severity.   
When gene expression of cytokines was compared between the two 
treatment groups, significant elevations in both IL-4 and IL-12/23 p40 were noted 
in the T. muris ova treated mice. Both of these findings were unexpected.  While 
the previous experiment clearly showed IL-4 to be initially elevated in response to 
T. muris ova exposure, the increase had subsided within four weeks post-
inoculation.  Considering the findings presented in Chapter 3 which demonstrate 
that H. hepaticus is capable of delaying T. muris exposure, it is reasonable that 
the persistence of IL-4 gene expression could simply be attributable to the 
delayed clearance of T. muris.   There were, however, no adult worms noted at 
necropsy or detected histologically.  The elevations in IL-12/23 p40 cannot, 
however, be explained by persistence of the helminth as none of the previous 
experiments demonstrated an IL-12/23 p40 response to T. muris.  Furthermore, 
elevations in IL-12/23 p40 in this model are typically associated with 
inflammation; as previously discussed the lesion scores in these mice were lower 
than typically seen in H. hepaticus infected A/J mice.  It is possible that the 
discrepancies noted here are simply due to an in-effective H. hepaticus culture 
and, as previously stated, the data must considered inconclusive.   
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The effects of T. muris treatment on H. hepaticus infected mice  
Overall, the investigation into the effects of prior and concurrent helminth 
infections and inflammatory triggers is merely academic as helminth therapies for 
IBD patients would only be administered following the onset of inflammation, 
making pre-exposure to helminths an impossibility.  Here it was done to 
document the immune response and susceptibility to T. muris in the A/J mouse, 
which had yet to be done in the literature.  Therefore, we next sought to instead 
focus on the therapeutic potential of T. muris to reverse H. hepaticus induced 
inflammation. To accomplish this all mice in this study were inoculated with H. 
hepaticus at 3-4 weeks of age.  Ninety days post inoculation the same mice were 
treated with either T. muris ova or PBS; animals treated with PBS serve as the 
control animals for all experiments described here.  Equal groups of mice from 
the two treatment groups were necropsied at either 3 or 5.5 weeks following 
treatment.  
 The severity of disease documented at both necropsy time points was 
more consistent with the disease severity seen in previous experiments involving 
experimentally inoculated H. hepaticus A/J mice.  A significant elevation in lesion 
scores were detected in T. muris ova treated mice when compared to PBS 
control treated mice at both time points (Figure 5-8A).  This data supports the 
findings in Chapter 3 which suggest T. muris ova therapeutics exacerbate 
ongoing microbial driven disease, rather than alleviating inflammation.  Also  
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consistent with the previously reported findings is the observation of live T. 
muris adults during the 5.5 week necropsy time point.  The data from H. 
hepaticus negative mice inoculated with T. muris presented in Figures 3-1 and 5-
3 demonstrate that both weanling and adult A/J mice are fairly capable of 
clearing T. muris infestations by 28 days (4 weeks).  The data from the current 
experiments show 60% of the mice treated with T. muris had live adult worms 
present at the 5.5 week time point.  Furthermore, when the rate of histologically 
detectable T. muris was scrutinized, over 50% of the T. muris treated mice had 
detectable helminths during both time points evaluated.  Together, with the data 
presented in Figure 3-5, these data suggest that the presence of H. hepaticus 
delays clearance of T. muris. 
   The mRNA gene expression of IFN-γ, IL-4, IL-5, IL-6, IL-10, IL-12/23 p40 
and IL-13 was compared between both treatment groups for each necropsy time 
point.  Comparisons in expression levels were not made between necropsy time 
points.  Significant elevations in IFN-γ, IL-4, IL-5, IL-6 and IL-13 were noted in the 
T. muris ova treated mice at both time points when compared to PBS treated 
controls.  An elevation in T. muris treated mice was also noted for IL-10, but only 
during the week 3 time point.  The elevations seen in TH2 cytokines (IL-4, IL-5 
and IL-13) are likely due to the persistence of T. muris discussed previously.  The 
literature has extensively documented the immune response in mice towards 
helminths346,348,350,432 and towards T.muris in particular316,344,351,355,356,358,359,433,434.  
Considering these reports and our findings reported in Figure 5-5, it is not 
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surprising that these cytokines were elevated at the 3 week time point, however it 
was unexpected that their elevation persisted through the 5-5 week necropsy 
time point.  The extended period of expression is most likely attributable to the 
persistence of T.muris in these H. hepaticus infected mice.  Once again, the data 
suggests that persistent T. muris colonization has detectable effects on cytokine 
mRNA expression.  
Conclusions 
These data provide further support for the findings presented in Chapter 3 
which suggest that the microbiota can alter the immune response to helminths.  
Inoculation with H. hepaticus has been demonstrated to delay the expulsion of 
the helminth T. muris.  Furthermore neither co-exposure to T. muris at the time of 
H. hepaticus inoculation or treatment with T. muris following the onset of 
inflammation improved disease severity.  In fact, the H. hepaticus induced 
disease was initially exacerbated following helminth treatment.  As stated in 
Chapter 3, these findings highlight the importance of the microbiota in the 
immune response and suggest that helminth therapies may not be appropriate 
for IBD patients with specific microbiota profiles.   
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Materials & Methods 
Mice 
The University of Missouri’s Animal Care and Use Committee (ACUC) 
approved all experiments involving the use of animals.  All experiments were 
planned and performed in accordance with the Guide for the Care and Use of 
Laboratory Animals.   The A/J mice  were obtained from Frederick National 
Laboratory for Cancer Research and either used to create breeding pairs or for 
experiments. The pups resulting from the created breeding pairs were used in 
experiments as described.   
Trichuris muris ova 
Dr. Joseph Urban of the United States Department of Agriculture 
(Beltsville, MD) kindly provided the Trichuris muris ova inoculum used in all the 
experiments.  The volume of inoculum was calculated to result in a heavy worm 
burden (approximately 100 adult worms) in a susceptible mouse strain.  Gastric 
gavage was used to inoculate mice with the appropriate volume (between 0.07 – 
0.15 ml, dependent upon batch) of inoculum.   
Helicobacter hepaticus 
The culture protocol for the MU-94 Helicobacter hepaticus strain has been 
previously described25,252.   At 3-4 weeks of age, mice were gastrically gavaged 
with 0.5 mL of culture broth.  The estimated concentration of H. hepaticus  is 
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approximately 5 x 108 bacteria/mL.  A PCR assay was used to confirm 
colonization with H. hepaticus at necropsy247.    
Necropsy  
CO2 inhalation was utilized to achieve euthanasia.  The cecum was then 
removed, cecal contents collected and sectioned longitudinally.  The two cecal 
portions was used for two of the following, dependent upon the experiemnt: 
verification of T. muris larvae or adult worms, examination of histologic disease 
or cytokine mRNA expression analysis.   
Verification of T. muris  
To evaluate for the presence of T. muris larvae, warm PBS was used to 
rinse cecal section of all cecal contents and debris.  The sections were then 
placed in a 50 ml conical tube containing 10 mls of 10 mM EDTA and left in a 
shaking incubator for two hours at 37° C.  Following this incubation tubes were 
vortexed at high speed for 15 seconds.  Next, the digested cecum and all 
associated fluids poured into a petri dish and examined with an inverted 
microscope (40x) for live, moving larvae.  
To check for adult T. muris worms, the cecum was examined at necropsy 
for adult worms, which can be visualized without the aid of microscopy.  To 
further evaluate the cecum for worms, the cecum was placed in warm PBS and 
evaluated with a dissecting microscope.   
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Histologic Evaluation 
Cecal portions designated for histologic evaluation were paraffin 
embedded following fixation with zinc fixative.   Sections were stained with 
Hematoxylin and eosin (H&E) stain and blinded scored for inflammatory lesions 
using a previously described protocol246,252,253.   
Isolation of RNA and Reverse Transcription  
Cecal sections were stored at -80° C until processing.  To begin RNA 
isolation, cecal sections were thawed in TRIzol (Invitrogen, Carlsbad, CA) and 
then homogenized with a Tissuelyser (Qiagen, Valencia, CA).  RNA isolation was 
done per the manufacturer’s (Invitrogen) instructions.  An Invitrogen Super Script 
II kit was used to reverse-transcribe RNA (5 μg total/ sample) into cDNA (final 
concentration 20 ng/μL) per  the oligo(dT) primer protocol provided.   
Real Time PCR  
Real time quantitative PCR with Qigen Quanti-tect SYBR Green was done 
with a Qiagen Rotor-Gene Q.    Table 3.1 contains the primers and annealing 
temperatures utilized.   Run conditions for HPRT, IFN-γ, IL-4, IL-10 and IL-12/23 
p40 had been previously published25,252.     
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Statistical Analysis 
Student’s t-tests and two-way ANOVA with Student-Newman-Keuls post-
hoc test were performed using SigmaPlot 11.0 (Systat Software Inc., San Jose, 
CA).  Due to the exponential nature of real-time PCR, Log2 transformations were 
used to correct for failures in normality. p values ≤ 0.05 were regarded as 
significant.   All graphs and dot plots were generated using either SigmaPlot 11.0 
or GraphPad Prism 5.0 software (GraphPad Prism Software Inc., La Jolla, CA).   
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Figure 5-4. The percentage of mice positive for T. muris at 12 and 28 days post-
inoculation.  
4 week old A/J female mice were gastrically gavaged with T. muris ova.  Mice were sacrificed and 
examined for the presence of T. muris at one of the two time points.  Mice necropsied 12 days 
post inoculated were examined for larvae, while the mice necropsied at day 28 were examined for 
adult worms.  
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Figure 5-5. The immune response to Trichuris muris in the 14 day old A/J mouse.  
A/J mice were gastrically gavaged with either T. muris ova or PBS (vehicle control) at 14 days of 
age.  Eight mice from each inoculation group were necropsied each week and their ceca 
evaluated for mRNA expression and examined for the presence of T. muris.  (A)  Mice sacrificed 
at the week 1-3 time points were evaluated for the presence of larvae (white striped bars) and 
mice sacrificed at the week 4-6 time points were evaluated for adult worms (gray striped bars).  
(B)  IFN-γ,  IL-4, IL-5, IL-6, IL-10, IL-12/23 p40 and IL-13 expression was significantly elevated in 
T. muris (gray bars) treated mice when compared to PBS control (black bars) treated mice.  All 
data was analyzed with a two-way ANOVA with Student-Newman-Keuls post-hoc test; p ≤ 0.05 
considered significant.  Error bars represent ± S.D. 
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Figure 5-6. Co-inoculation with T. muris does not alter the initial immune response to H. 
hepaticus.  
3-4 week old A/J mice were inoculated with H. hepaticus and either T. muris ova or PBS (control).  
Mice necropsied four days post-inoculation and the ceca collected for the mRNA gene expression 
analysis of IFN-γ, IL-4, IL-5, IL-6, IL-10, IL-12/23 p40 and IL-13.  No significant differences were 
found between the T. muris ova and PBS inoculated mice.  All data was analyzed with a student’s 
t-test; p ≤ 0.05 considered significant.  Error bars represent ± S.D. 
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Figure 5-7. Co-inoculation with T. muris has minimal effects on the persistent immune 
response to H. hepaticus.  
3-4 week old A/J mice were co-inoculated with H. hepaticus and either T. muris ova or PBS 
(control).  Mice were necropsied ninety days post-inoculation and the ceca collected for histologic 
disease evaluation and mRNA gene expression analysis of IFN-γ, IL-4, IL-5, IL-6, IL-10, IL-12/23 
p40 and IL-13.  (A) No significant differences in disease severity were found between the T. muris 
ova (squares) and PBS (circles) inoculated mice. (B) Gene expression of IL-4 and IL-12/23 p40 
were significantly elevated in the mice inoculated with T. muris ova (Gray bars) compared to 
those inoculated with PBS (black bars).  No significant differences were found for any of the other 
cytokines evaluated.    All data was analyzed with a student’s t-test; p ≤ 0.05 considered 
significant.  Dot plots represent individual mice.  Error bars represent ± S.D. 
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Figure 5-8. Treatment of H. hepaticus induced inflammation with T. muris ova exacerbates 
disease.  
3-4 week old A/J mice were inoculated with H. hepaticus.  Ninety days later the mice were treated 
with either T. muris ova or PBS (control).  Mice were necropsied either 3 or 5.5 weeks following 
treatment and the ceca collected for both histologic disease evaluation and mRNA gene 
expression. (A)  At both time points, significant elevations in disease severity were found in mice 
treated with T. muris (squares) when compared to those treated with PBS (circles).  (B)  Sixty 
percent of the mice treated with T. muris and necropsied at the 5.5 week time point (gray 
checker), had visible adult worms in the cecum at necropsy. (C) During histologic evaluation, the 
percent of mice with histologically detectable T. muris was tabulated.  (D) The level of gene 
expression in the ceca of T. muris treated mice were compared to PBS treated mice separately 
for each necropsy time point.  Data for each time-point was analyzed with a student’s t-test; p ≤ 
0.05 considered significant.  Dot plots represents an individual mice.  Error bars represent ± S.D. 
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Alternative explorations in the role of T regulatory cells in 
Helicobacter hepaticus induced inflammation.  
Introduction and Research Aims  
 The role of T regulatory cells in the regulation of immune responses in 
general has been extensively discussed in Chapter 4.  The novel data presented 
and discussed there suggests that inducible T regulatory cells in particular are 
involved in the management of inflammatory responses driven by H. hepaticus.  
The studies presented here explore the role of T regulatory cells defined by the 
expression of either CD25 or CD45RB in inflammation induced by the bacterium 
H. hepaticus, and should be considered a prequel to those experiments 
presented in Chapter 4.    
 As previously discussed, the lack of an extracellular marker that is 
exclusive to T regulatory cells is one of the greatest challenges of working with 
this cellular subset.  Because of this, data generated from studies using a 
specific marker to identify T regulatory cells for targeted depletion or adoptive 
transfer must be carefully considered as other cell types may be unintentionally 
manipulated and ultimately affect the disease or condition being studied.  The 
studies presented here utilize CD25 and CD45RB as markers for T regulatory 
cell identification.   
CD25 seemed to be a logical marker for T regulatory cells after Sakaguchi 
and Asano demonstrated the suppressive abilities of CD4+CD25+ cells372,375; 
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however, subsequent research demonstrated that the expression of CD25 is 
found on almost all activated T cells, not just T regulatory cells435.  Several other 
extracellular markers were linked to T regulatory cells including: CTLA-4, CD45, 
CD62L and GITR131,143,436,437; however, it soon became apparent that there is not 
a unique surface marker available that can be used to distinguish the two 
subsets of T regulatory cells from one another or from other CD4+ T cells.  To 
further complicate the study of T regulatory cells, combinations of these markers 
are often used to identify T regulatory cells and, because all laboratories do not 
use the same combinations to isolate and evaluate the suppressive capabilities 
of T regulatory cells, the literature is often confusing and difficult to interpret.   
CD25 was identified as a marker for T regulatory cells shortly after the 
discovery of a regulatory lymphocyte subset.  CD25 is a part of the receptor for 
IL-2438, which was first identified as a proliferation factor for T lymphocytes439. 
This maker is convenient for the study of T regulatory cells, because unlike 
Foxp3, it is expressed externally on the cell thus allowing for the live isolation of 
CD25+ cells with flow cytometry or magnetic bead separation.  Adoptive transfer 
experiments have demonstrated that the transfer of CD4+CD25- cells to mice 
which lack an endogenous T cell population results in disease development.  
Interestingly, the co-transfer of CD4+CD25+ cells prevents disease 
development155,173,174,178.   
CD45RB is another external marker that has been utilized to differentiate 
T regulatory cells.  In adoptive transfer experiments, it has been shown that cell 
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populations with low levels of CD45RB expression have the capability to 
suppress inflammation, while the adoptive transfer of cells with high expression 
of this marker cause disease development116,119,155,173,174,178.  Unfortunately due 
to the physiologic distinction between high and low expression of CD45RB, cell 
populations must be isolated using flow cytometry based cell separation.   
Several of CD25 and CD45RB based adoptive transfer based experiments 
have looked at the importance of H. hepaticus infection in the development of 
disease in these models.  The results have been contradictory – while some 
models suggest that the adoptively transferred cells do not need prior exposure 
to H. hepaticus118, others clearly demonstrate the opposite117.  Furthermore, 
several groups have demonstrated that the recipient mouse must be colonized 
with H. hepaticus for the induction of disease following an adoptive transfer89.  Of 
note is the unknown H. hepaticus status of the mice utilized in many published 
studies utilizing adoptive transfer.  
 For the following experiments, adoptive transfer and antibody depletion 
techniques were utilized to either remove or supplement the T regulatory cell 
populations in the A/J and C57BL/6 mouse strains which are known to be 
susceptible and resistant, respectively, to H. hepaticus induced inflammation.  
Additional experiments utilizing flow cytometery allowed for the characterization 
of T regulatory cell populations in the cecum of these mice.     
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Results and Discussion 
Chapter 5 Part IIIA: Characterization of T regulatory cell populations in the 
A/J mouse  
Inoculation with H. hepaticus does not alter the percentage of 
CD4+CD25+FoxP3+ T regulatory cells in the A/J mouse  
 As administration of H. hepaticus in A/J mice results in the development of 
typhlitis approximately 90 days later, it is reasonable to suspect that either the T 
regulatory cells induced by the bacteria are unable to control inflammation or H. 
hepaticus exposure simply does not result in the induction of a T regulatory cell 
population.   To investigate this, the T regulatory cell populations, here defined as 
CD4+CD25+FoxP3+ cells, found within the spleen and the cecum were evaluated.  
The cecal T regulatory cell populations were evaluated following independent 
isolation of intraepithelial (IEL) and lamina propria (LPL) lymphocytes.   
 Forty 3-4 week old A/J mice were gastrically gavaged with H. hepaticus; 
four months later these mice were grouped into four groups of ten, necropsied 
and the ceca and spleens collected for analysis.  Three groups of age matched 
H. hepaticus negative A/J mice were also necropsied and their tissues used as 
controls (n = 5 mice/group).   The cells isolated from the spleen, IEL and LPL 
were stained with CD4, CD25 and Foxp3 fluorochromes and analyzed via flow 
cytometry.  The data presented in Figure 5-9 demonstrates the percentage of 
CD25+ cells which are CD4+Foxp3+.   
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 As demonstrated in Figure 5-9 no significant differences in the percentage 
of CD4+ CD25+Foxp3+ cells were found between the H. hepaticus and control 
inoculated mice.  This data suggests that inoculation with H. hepaticus does not 
result in a detectable change in the number of CD4+CD25+Foxp3+ cells.  It does 
not, however, provide any insight on if T regulatory cells are induced following 
exposure to H. hepaticus – it is plausible that the T regulatory cell population 
induced by H. hepaticus is negligible when considering all of the other T 
regulatory cells within the three cellular compartments evaluated.     
Chapter 5 Part IIIB: Depletion of CD25+ Cell Populations in the A/J and 
C57BL/6 Mouse   
1 mg of anti-CD25 significantly decreases the percentage of CD4+CD25+ 
splenocytes in the A/J and C57BL/6 mouse.   
 An antibody targeting CD25 can be utilized to deplete T regulatory cells in 
the mouse388,389.  As previously discussed, however its use is limited to the pre-
inflammatory period, as T effector cells have been shown to upregulate the 
expression of CD25 following activation and thus could also be depleted with this 
antibody.  Before any experiments utilizing this antibody can be completed, an 
effective dosage regime must be established.  As it is possible, although unlikely, 
that A/J and C57BL/6 mice will require different doses of anti-CD25 to achieve 
optimal depletion of CD25+ cells, this pilot study was completed to ensure 
maximal depletion of cells in both strains.  
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Twelve female A/J and twelve female C57BL/6 mice 3-4 weeks of age 
were utilized for this study.  The mice from each strain were divided into four 
equal groups, with three mice per group.  Three of the groups underwent an 
experimental dosing regimen, while the fourth mouse group acted as the control 
and was not treated.  Mice in the experimental groups received one of the 
following treatments: one treatment of 1 mg, two treatments of 1 mg  or two 
treatments of 0.5 mg (Figure 5-10B).   All treatments were administered by 
intraperitoneal (IP) injection; those groups given antibody twice were treated 
every three days.  All mice were necropsied and evaluated three days following 
the last treatment.  For an experimental timeline, see Figure 5-10A.   
At necropsy, mice were euthanized and spleens were collected for cell 
population evaluation.  The splenic cells isolated were stained for CD4 and CD25 
and evaluated with flow cytometry.  As shown in Figure 5-10C a significant 
decrease in the percentage of CD4+CD25+ occurred in both strains with all three 
treatment regimens.  No significant differences between the A/J and C57BL/6 
mouse strains were found for either the percentage of CD4+CD25+ cells in the 
control groups or in the responses seen in the experimental groups.   
Because no differences were seen between the three treatment regimens, 
the regimen utilizing the lowest dose and smallest number of treatments was 
chosen.  For all subsequent experiments, unless otherwise noted, mice were 
treated once with 1 mg of anti-CD25 antibody IP to accomplish depletion of 
CD25+ cellular subsets.   
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anti-CD25 antibody administration prior to H. hepaticus inoculation may 
deplete other cell types in addition to CD25+ T regulatory cells.  
While A/J mice are known to develop lesions three-months following H. 
hepaticus administration, C57BL/6 mice administered the same dose of H. 
hepaticus are resistant to disease development.   The extracellular marker, 
CD25, is known to be associated with a T regulatory cell subset.  As previously 
discussed, the adoptive transfer (AT) of CD4+CD25+ cells has been shown to 
suppress the development of colitis caused by the AT of CD4+CD25- 
cells155,173,174,178.  CD25 is the receptor for IL-2, which is a cytokine associated 
with lymphocyte proliferation439.  Interestingly, CD25 is up-regulated on activated 
T effector cells following an immune stimulus435.  
The utilization of an anti-CD25 antibody will allow for the selection 
depletion of CD25+ cells; however because both T regulatory and T effector cells 
will express CD25 following antigen stimulation, the timing of antibody 
administration must be considered to avoid depletion of both cell types.   By 
administering the anti-CD25 antibody prior to antigen stimulation T regulatory 
cells, but not the T effecter cell populations initiated by the presence of H. 
hepaticus, will be depleted.  
The overall aim of this project is to determine the role of T regulatory cells, 
defined here as a CD4+CD25+ cellular subset, in the development of H. hepaticus 
induced inflammation.  To accomplish this, both a resistant and susceptible 
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mouse strain, C57BL/6 and A/J respectively, were administered anti-CD25 
antibody and then three days later, were gastrically gavaged with H. hepaticus.  
At the time of H. hepaticus administration it is assumed, based on the previous 
study depicted in Figure 5-10, that the T regulatory cell population has been 
significantly depleted and that the immune response initiated by the presence of 
H. hepaticus will develop without the full suppressive influences of a T regulatory 
cell population. As a control, both A/J and C57BL/6 mice were administered rat 
IgG, the isotype control of the anti-CD25 antibody, in the same manner as those 
mice treated with the depletion antibody and similarly inoculated with H. 
hepaticus.  Groups of mice were necropsied at 4, 45 and 90 days post-
inoculation.  Those mice necropsied at day 4 were utilized to verify the depletion 
of CD25+ cells in addition to evaluation of mRNA gene expression of IP-10, MIG 
and IL-12/23 p40.  Those mice necropsied at 45 and 90 days post inoculation 
were also evaluated for the mRNA gene expression of these there cytokines, as 
well as the expression of IL-10.  Additionally, the ceca of the mice necropsied at 
the two later time points were evaluated for the development of inflammation.  
 Four days following inoculation with H. hepaticus  five mice from each of 
the four groups (A/J mice administered anti-CD25, A/J mice administered the IgG 
isotype control, C57BL/6 mice administered anti-CD25 and C5BL/6 mice 
administered the IgG isotype control) were necropsied and their spleens and 
ceca collected for evaluation.  To evaluate the depletion of CD25+ cells, the five 
mice from each group were split into two sub-groups, one with two and one with 
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three mice.  The splenocytes from these mice were pooled and strained for CD4 
and CD25.  A representation of the staining patterns seen for the anti-CD25 and 
IgG isotype treated mice can be found in Figure 5-11A.  On average, for the 
isotype control treated mice, 2.7% (range 2.1% – 3.4%) of all splenocytes were 
CD4+CD25+ compared to the anti-CD25 treated mice in which on average 1.3% 
(1.0% – 1.6%) of all splenocytes were  CD4+CD25+.  It should be noted that the 
percentage of CD4+CD25+ cells seen in the control groups here are slightly lower 
than those presented in Figure 5-10C, in which the range of CD4+CD25+  was 
3.4% to 6.5%.  This variation may be simply due to the low animal numbers 
evaluated in these studies.  Ultimately, the data allows for the conclusion that a 
significant depletion of CD25+ cells occurred with the administration of anti-CD25 
antibody and was still detectable six days following antibody administration.   
 Those mice necropsied 45 and 90 days post-H. hepaticus inoculation 
were evaluated for the development of typhlitis. As expected, at the early time 
point, the average lesions scores seen were below those considered as diseased 
in this model and there were no significant differences between the average 
lesion scores of the four treatment groups.  As disease induced by H. hepaticus 
is not typically seen until 90 days post inoculation, the development of or 
changes in disease was not necessarily expected.  However, as it was plausible 
that the absence of T regulatory cells during the initial response to H. hepaticus 
could result in the accelerated development of disease, it was necessary to 
evaluate inflammation at this early time point. (Figure 5-11B) 
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 As previously seen in this model, at the 90 day necropsy time point, the 
A/J mice, regardless of antibody treatment, developed cecal inflammation while 
the C57BL/6 mice did not.  There were no significant differences between lesion 
scores of the A/J mice administered anti-CD25 and the control isotype antibody; 
the same was observed in the C57BL/6 mice.  Interestingly, there were 
significant differences between the A/J and C57BL/6 mice administered anti-
CD25, but not those administered the IgG control antibody.  Again, the low n for 
each of the treatment groups combined with the individual variability in disease 
development of this model may be contributing to the lack of significant 
differences between the treatment groups, especially in the case of the IgG 
treated mice.  
 As previously stated mRNA analysis of several cytokines was evaluated at 
all three necropsy time points.  No significant differences were detected in the 
mRNA gene expression of IP-10, MIG or IL-12/23 p40 at the day 4 necropsy 
time-point (Figure 5-11C)  At the day 45 time point these three cytokines and IL-
10, were significantly elevated in the A/J mice when compared to C57BL/6 mice 
within both antibody treatment groups.  Furthermore A/J mice who received the 
anti-CD25 antibody had a significantly lower mRNA expression of IL-10, IP-10 
and MIG when compared to the A/J control mice.  At the day 90 time point the 
trends in MIG expression were the same as that seen at day 45.  For both IP-10 
and IL-10 the only significant difference identified was an elevation in mRNA 
gene expression in the A/J mice administered the IgG control antibody when 
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compared to C57BL/6 control mice.  Interestingly, when IL-12/23 p40 was 
evaluated at this time point in addition to the significant increases in mRNA gene 
expression in A/J mice compared to the C57BL/6 mice within both antibody 
treatment groups, there was a significant increase in IL-12/23 p40 expression in 
the control A/J mice compared to the aCD25 treated A/J mice.   
 The differences in mRNA cytokine gene expression at the two later time 
points within the IgG treated A/J and C57BL/6 mice were not unexpected; 
previous publications have demonstrated a significant elevation in these 
cytokines in A/J mice compared to C57BL/6 mice inoculated with H. hepaticus25.  
The decrease mRNA expression of IL-10 in the CD25 antibody treated A/Js 
compared to the control antibody treated antibodies at the day 45 time point 
could be due to a decreased number of T regulatory cells, which produce IL-10, 
however the decreased expression of the pro-inflammatory cytokines IP-10, MIG 
and IL-12/23 p40 could indicate that T effector cells, known to produce or induce 
the expression of these cytokines, were also depleted with the administration of 
the anti-CD25 antibody.  
 As previously discussed activated T effector cells upregulate the 
expression of CD25, and thus could be susceptible to depletion by the antibody 
utilized in this study.  The flow data presented in Figure 5-11A suggests that the 
depletion of CD25+ cells persisted at least six days post antibody administration 
and thus, it is rationale to hypothesize that residual anti-CD25 antibody may have 
affected the T effector cell population induced by the introduction of H. hepaticus.  
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The suppressed pro-inflammatory mRNA gene expression in the anti-CD25 
antibody treated mice lends further support to this hypothesis.  Before any further 
experiments could be completed, a kinetics study to evaluate the duration of 
CD25+ depletion in both A/J and C57BL/6 mice must be completed.   
Identification of the time-point at which anti-CD25 antibody achieves 
maximum depletion of CD25+ cells.  
 The data from the previous experiment has lead us to believe that the 
ability of the anti-CD25 antibody to deplete CD25+ cells extends belong three 
days.  Furthermore, the residual effects of the anti-CD25 treatment is suspected 
to have depleted CD4+CD25+ T regulatory cells, as well as activated CD25+ T 
effector cells which developed in response to H. hepaticus exposure. The 
experiments described here attempt to document the duration of depletion 
following a single 1 mg dose of anti-CD25.   Unfortunately immediately following 
the previously described experiment it was realized that the anti-CD25 antibody 
utilized was being administered at a less concentrated dose than originally 
intended.  This was due to the presence of IgG in the FBS used in cell culture for 
antibody production; it was estimated that almost half of the IgG in the anti-CD25 
isolates was not the intended antibody (data not shown).  For this reason, 
subsequent experiments will be completed at a dosing regimen of one 0.5 mg 
treatment of anti-CD25.  In addition to evaluating the residual effects of anti-
CD25 antibody administration these experiments will confirm that the new dose 
of anti-CD25 antibody is sufficient for cellular depletion.   
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To accomplish this, A/J and C57BL/6 mice were administered 0.5 mg anti-
CD25 antibody IP; mice not administered anti-CD25 were used as controls. On 
days 5, 7, 9 and 11 post-antibody three anti-CD25 treated and one control mouse 
was euthanized and spleens collected for flow cytometry analysis.  Isolated 
splenocytes were stained for CD4, CD25 and Foxp3; cells were initially gated on 
CD4 expression and then the co-expression of CD25 and Foxp3. To allow for 
easier interruption of the data, the percentage of CD4+CD25+Foxp3+ cells 
obtained were normalized to the percentage seen in the control mouse.  In short, 
the control mouse’s percentage of triple positive cells became the baseline to 
which the experimental, anti-CD25 treated mice were compared.  A/J and 
C57BL/6 mice were analyzed separately.   
As shown in Figure 5-12A, in both strains and at all four time points, those 
mice administered anti-CD25 had a reduced level of CD4+CD25+Foxp3+ 
compared to the control mice.  As this experiment suggests that suppression of 
CD25+ cells extends beyond 11 days post-administration, the experiment was 
repeated as described below.  
Again A/J and C57BL/6 mice were administered 0.5 mg anti-CD25 
antibody IP; mice not administered anti-CD25 were used as controls. At days 3, 
9, 11, 13, 15 17 and 19 post-antibody administration mice were euthanized and 
spleen again collected for flow cytometry analysis.  The same staining, gating 
and analysis protocol described in the previous experiment was followed. The 
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day 3 time point was included to ensure an initial depletion of CD25+ did indeed 
occur in both mouse strains.  
Subsequent studies will again aim to evaluate the immune response to H. 
hepaticus when T regulatory cells are depleted, but without altering the resultant 
T effector cell populations.  Thus it is necessary to identify the time period 
immediately before CD25+ populations begin to return in an attempt to have both 
a decreased CD4+CD25+ T regulatory population and minimal antibody affects 
upon developing T effector cell populations.  Figure 5-12B depicts the depletion 
of CD25+ cells in the A/J mouse.  From this data it was concluded that by day 15 
post-injection some of the mice had begun to regain their CD25+ cell populations.  
At the previous time point, however, the proportion of CD4+CD25+FoxP3+ cells in 
the antibody treated mice was still depressed compared to the control mouse.  
Interestingly in the C57BL/6 mouse (Figure 5-12C) the threshold for CD25 
depletion appeared to be around 9 days post-inoculation.  By the day 11 time-
point the portion of CD4+CD25+Foxp3+   cells in the antibody treated mice was 
fairly similar to the control mice.   
Based on these results it was determined that the optimal time for H. 
hepaticus administration following anti-CD25 antibody treatment would be 13 and 
9 days post-treatment for the A/J and C57BL/6 mouse strains, respectively.  
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The administration of anti-CD25 antibody had short-term, but lacked long 
term effects on H. hepaticus induced inflammation.   
 In light of these recent findings, the original experiment in which anti-CD25 
antibody was utilized to deplete CD25+ cells was repeated.  However instead of 
administering antibody 3 days prior to H. hepaticus inoculation, the mice received 
antibody treatments according to the findings just discussed.  A/J mice were 
administered 0.5 mg anti-CD25 or the rat IgG isotype control 14 days before H. 
hepaticus inoculation.  The C57BL/6 mice were administered their antibody 
treatments 9 days prior to H. hepaticus inoculation.   
 Flow cytometry was used to confirm that CD4+CD25+Foxp3+ cell 
populations were detected at the time of H. hepaticus inoculation (data not 
shown).  Lesion scores were evaluated at 45 and 90 days post-H. hepaticus 
inoculation.  At the day 45 necropsy time point significant decreases in LS were 
noted when mice treated with anti-CD25 where compared to control, IgG treated 
mice; this trend was observed within both the A/J and C57BL/6 mice (Figure 5-
13A). By the 90 day time point these differences were no longer observed, 
however control A/J mice had significantly higher lesion scores than the control 
C57BL/6 mice.  Interestingly there were no differences in inflammation noted 
between the A/J and C57BL/6 mice administered anti-CD25.   
 The decreased histologic disease in both mouse strain groups treated with 
anti-CD25 could still be the result of residual anti-CD25 antibody depleting T 
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effector cells capable of causing disease. As the IgG treated A/J mice developed 
significantly increased disease compared to the C57BL/6 controls at the day 90 
time point, there is no reason to suspect the H. hepaticus inoculum administered 
failed to produce disease.  There were, however no statistical differences 
between the two A/J treatment groups suggesting that lacking T regulatory cells 
at the time of H. hepaticus does not affect disease development in the A/J 
mouse.  Interestingly, there were no differences in lesion scores between the A/J 
and C57BL/6 mice administered anti-CD25 (Figure 5-13A).  This could suggest 
that lack of T regulatory cells at the time of H. hepaticus administration in the 
C57BL/6 mouse makes the strain more susceptible to disease, however this 
cannot be definitely concluded to the lack of significant differences between 
these mice and those administered the control antibody.   
 Due to the lack of significant conclusions drawn from the lesions scores, 
which ultimately are the indicator of disease, mRNA gene analysis of IL-12/23 
p30, MIG and IP-10 was completed only for the A/J mice necropsied at the day 
45 and 90 time points (Figure 5-13B). At the 45 day necropsy time point mice 
administered anti-CD25 had significantly decreased mRNA expression of three 
cytokines/chemokines examined when compared to those mice administered the 
control antibody.  At the 90 day time point, no significant differences were 
identified between the A/J mice administered anti-CD25 and control antibodies.    
The decreased pro-inflammatory mRNA expression at the day 45 time point 
further supports the lesion score observation that anti-CD25 antibody does 
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indeed have residual effects on disease progression, but  ultimately does not 
affect disease development.  
Due to the suspicion that the use of anti-CD25 antibody is affecting the T 
effector cell response to H. hepaticus, it will not be used for T regulatory cell 
depletion in further studies.  The use of neonatal thymectomies and diphtheria 
toxin (DT) administration in C57BL/6-Foxp3DTR were used to further evaluate the 
role of T regulatory cell in H. hepaticus induced-inflammation.   
Chapter 5 Part IIIC: The Adoptive Transfer of T regulatory cells  
The adoptive transfer of CD4+CD25+ T cells from H. hepaticus naive A/J 
mice does not reverse H. hepaticus induced-inflammation. 
These experiments sought to evaluate the ability of CD4+CD25+ T 
regulatory cells to reverse existing Helicobacter hepaticus induced inflammation. 
To accomplish this, A/J mice were inoculated with H. hepaticus and, three 
months later, adoptively transferred 1 x 106 CD4+C25+ T regulatory cells weekly 
for either 2 or 3 total transfers.  The transferred cells were isolated from 4-6 week 
old, naïve A/J mice.  Three days following the last adoptive transfer, mice were 
necropsied and their ceca collected for histologic evaluation.  Evaluation of lesion 
scores revealed (Figure 5-14) no significant differences between any of the three 
treatment groups.   
This data suggests that in this experiment the adoptive transfer of 
CD4+CD25+ T cells is not capable of reversing H. hepaticus induced disease.  
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These results are contradictory to published experiments which demonstrate that 
the adoptive transfer of T regulatory cells are capable of reversing 
colitis155,173,174,178.  The discrepancy between this data and that previously 
published by other laboratories may be due to the H. hepaticus status of the 
donor mice, the age of the donor mice and or a combination of both.    
Neither the adoptive transfer of CD4+CD25- or CD4+CD25+ cell populations 
effects the development of H. hepaticus induced disease.  
The previous experiment evaluated the ability of CD4+CD25+ cell 
populations to reverse H. hepaticus induced inflammation in the A/J mouse.  In 
those experiments adoptive transfers were completed when inflammation had 
already developed and did not evaluate the protective ability of these cells to 
prevent disease development. The experiment presented here, in addition to 
including non-treated controls and the adoptive transfer of CD4+CD25-, mice are 
treated prior to, during and at the development of H. hepaticus-induced 
inflammation.  This experiment sought to better evaluate both the curative and 
preventative properties of CD4+CD25+ T regulatory cells in this inflammatory 
model.  In addition, the potential for CD4+CD25-  T effector cells to exacerbate 
disease will be evaluated.   
To accomplish these goals 3-4 week A/J mice were inoculated with H. 
hepaticus.  The same mice received adoptive transfers of either 1 million  
CD4+CD25+ or CD4+CD25- cells weekly for three weeks starting one, two or 
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three months post-H. hepaticus inoculation.  Control mice were inoculated with 
H. hepaticus but received no cellular transfers.  Mice administered cells one 
month following inoculation are referred to as “Group 1”, mice administered cells 
two months following inoculations are referred to as “Group 2” and mice 
administered cells three months following inoculations are referred to as “Group 
3.”   All cells used in adoptive transfers were isolated from six week old H. 
hepaticus free A/J mice.  Three days following Group 3’s third adoptive transfer, 
all mice in the study were necropsied.  At the time of necropsy ceca were 
collected for histologic evaluation and mRNA gene expression analysis of MIG, 
IP-10, IL-12/23 p40 and IL-10.   
As shown in Figure 5-15A no significant differences were found between 
the disease severities of any two treatment groups.  It should be noted, however 
that the disease seen in these mice is slightly less severe than that normally 
seen following H. hepaticus administration. When considering the mRNA gene 
expression, no significant differences were found in either MIG or IP-10 (Figure 
5-15B).  Significant decreases in IL-12/23 p40 expression were seen in those 
mice adoptively transferred CD4+CD25- T effector cells in groups 1 and 2 
compared to those in group 3.  This finding was contrary to the hypothesis that 
the transfer of T effector cells would cause increased disease, accompanied by 
increased expression of IL-12/23 p40.  Mice in group 1 adoptively transferred 
CD4+CD25- cells had elevated IL-10 gene expression compared to all the other 
mice in Group 1 as well as the mice in groups 2 and 3 transferred CD4+CD25- 
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cells.  This finding was unexpected and could potentially be due to the induction 
of induced T regulatory cells from the transferred CD4+CD25- cell populations; 
however the lack of effect on disease development would suggest that if the 
elevations in mRNA cytokine expression were due to T regulatory cells, this cell 
population ultimately had minimal effects on disease development.   
 The lack of disease alteration in this experiment and those described in 
Figure 5-14 following the adoptive transfer of either CD25- or CD25+ cells 
suggests that the addition of these two cell groups does not alter the progression 
of H. hepaticus induced inflammation in the A/J mouse.  It does not, however, 
mean that these cells are not involved in the prevention or development of H. 
hepaticus induced inflammation.   
The adoptive transfer of CD4+CD25+ cells causes significant elevations in 
histologic disease.  
To further investigate the role of these two cell groups, A/J mice with a 
deficiency in RAG2 were utilized.  As these mice lack functional T and B cells, 
specific T cell populations can be adoptively transferred and their role in the 
development of inflammation more thoroughly examined.  While the protective 
effects of CD4+CD25+ have been demonstrated in the C57BL/6 RAG2-/- mouse 
adoptive transfer model of colitis117,178 this mouse strain is resistant to the 
development of H. hepaticus25.  As the discrepancy in susceptibly between A/J 
and C57BL/6 mice to H. hepaticus-induced inflammation may be due to T 
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regulatory cell function, it is important to evaluate the ability of T regulatory cells 
to suppress inflammation in general in the A/J mouse.   
As with the previous experiments, this experiment aims to determine the 
role of T regulatory cells (CD4+CD25+) in the development of inflammation in the 
A/J mouse.  To accomplish this 8-12 week old A/J RAG2-/- mice (A.129S6(B6)-
Rag2tm1Fwa) were adoptively transferred 5 x 105 CD4+CD25- or CD4+CD25+ or a 1 
to 2 ratio of these cells (2.5 x 105 CD4+CD25-: 1.25 x 105  CD4+CD25+ ).  Twelve 
weeks later these mice were necropsied and cecal inflammation evaluated.  This 
experiment was completed with female donors/female recipients, male 
donors/male recipients and female donors/male recipients.  Each experimental 
group contained 3-5 mice per group.   
As demonstrated in Figure 5-16A, in RAG2-/- female mice the adoptive 
transfer of CD4+CD25+ cells from female A/J donors caused disease that was 
significantly more severe than that seen in the other two cell treatment groups.  
This was surprising, as the CD4+CD25+ cellular subset was originally predicted to 
contain T regulatory cells, which were predicted to suppress, not exacerbate 
disease.  In the C57BL/6 adoptive transfer models previously cited, this subset of 
cells was capable of suppressing inflammation compared to the adoptive transfer 
of CD4+CD25-.  As the opposite was seen here, it is logical to speculate if the 
population of cells isolated here in the A/J mouse contained a higher proportion 
of T effector cells, which would also be expressing CD25+.  When comparisons 
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were made in the male to male and female to male adoptive transfer no 
differences in lesion scores were noted (Figure 5-16B & C). 
Based on this experiment and the previous experiments described in this 
chapter, CD25 does not appear to be the optimal extracellular marker for the 
isolation or depletion of T regulatory cells.  All further experiments exploring the 
ability of T regulatory cells to alter disease development will utilize CD45RB 
expression as the criteria for isolation of the T regulatory and T effector cell 
populations adoptively transferred.    
The adoptive transfer of cells sorted on CD45RB expression does not alter 
H. hepaticus disease development.  
 As an alternative to CD25, CD45RB was chosen for the selection of T 
regulatory and effector cells.  CD45 is known to be highly up-regulated on T 
effectors cells (CD45RBhigh), while T regulatory cells have minimal levels of 
expression (CD45RBlow).  As cell selection is based on degree of expression, 
rather than simply expression or lack of expression a different method of cellular 
isolation was utilized than that used in previous experiments.  Isolated 
lymphocytes were stained for CD4 and CD45RB, then flow cytometry was used 
to sort CD4+CD45RBhigh and CD4+CD45RBlow cellular subsets.  To ensure the 
development of disease in these mice, all mice were inoculated with H. 
hepaticus.   
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 8-12 week old male mice were inoculated with H. hepaticus and then 
adoptively transferred 5 x 105 CD4+CD45RBhigh cells, 5 x 105 CD4+CD45RBlow  
cells or a ratio of 1:2 of both cellular subsets (2.5 x 105  CD4+CD45RBhigh  cells: 
1.25 x 105 CD4+CD45RBlow).  12 weeks later the mice were necropsied and ceca 
collected for evaluation of inflammation.  As shown in Figure 5-17 no significant 
differences were found between the three groups, although there is a trend of 
elevated disease noted in those mice adoptively transferred T effector cells 
(CD4+CD45RBhigh).  It should be noted, however that following the adoptive 
transfers, it was found that the cell isolates were contaminated with bacteria.  All 
mice were monitored for weight loss, a secondary skin of systemic bacteremia, 
however none of mice were noted to loss more than 20% of their body weight 
(data not shown).   
Conclusions 
Ultimately, it was determined that neither the use of anti-CD25 antibody nor 
the adoptive transfer of either CD25+ or CD45RBlow cells was effective at 
specifically selecting a T regulatory cell population.  These findings led to the 
experiments described in Chapter 4 which utilized both neonatal thymectomies 
and DT administration in the C57BL/6-Foxp3DTR mice to further evaluate the roles 
of natural and inducible T regulatory cells in H. hepaticus induced-inflammation.   
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Materials & Methods 
Mice 
The University of Missouri’s Animal Care and Use Committee (ACUC) 
approved all experiments involving the use of animals.  All experiments were 
planned and performed in accordance with the Guide for the Care and Use of 
Laboratory Animals.   The A/J  and C57BL/6 mice  were obtained from Frederick 
National Laboratory for Cancer Research.  
Helicobacter hepaticus 
The culture protocol for the MU-94 Helicobacter hepaticus strain has been 
previously described25,252.   At 3-4 weeks of age, mice were gastrically gavaged 
with 0.5 mL of culture broth.  The estimated concentration of H. hepaticus is 
approximately 5 x 108 bacteria/mL.  A PCR assay was used to confirm 
colonization with H. hepaticus at necropsy247.    
Necropsy  
Following euthanasia through CO2 inhalation, ceca were removed and 
cecal contents and feces collected for verification of H. hepaticus colonization.  
The cecum was then longitudinally sectioned into two equal portions and used for 
mRNA expression analysis and histologic examination.   
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Splenocyte Isolation  
Following removal from the mouse, the spleen is placed in a petri dish 
containing 2 ml complete RPMI-10 and left on ice until processing. The spleen is 
then minced with a scalpel blade.  Each piece is thoroughly flushed by drawing 
up the media into a 5 ml syringe and expelling it through a 20G needle into each 
piece.  The supernatant and remaining spleen pieces are transferred to a 70 μm 
cell strainer affixed atop a 15 ml conical tube.  The plunger of the previously used 
5 ml syringe is then used to pulverize the remaining spleen pieces in the cell 
strainer until only fibrous tissue remains.  The cell strainer is rinsed with 5 
additional mls of RPMI-10. 
To remove red blood cells, BD Pharm LyseTM buffer is used per 
manufactures protocol (BD Biosciences, San Jose, CA).   The suspension is then 
centrifuged at 200 g for 5 minutes. The resulting cell pellet is suspended in 1 ml 
staining buffer (Biolegend, San Diego, CA) and the passed over a clean 70 μm 
cell strainer.  Cells are counted using trypsin blue and a hemacytometer and, 
following centrifugation at 350 x g for 5 minute, suspended at the desired 
concentration in cold staining buffer.    
IEL and LPL isolation 
Following removal from the mouse, the cecum is cleaned of all cecal 
contents, stripped of all fat and mesenteric tissue and placed in a petri dish 
containing 5 mls of cold RPMI + 5% FBS.  The cecum is then evaluated and all 
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peyers patches are dissected out.  The cecum is then rinsed in fresh media and 
cut into 0.5 – 1.0 cm pieces.  First, to isolate IELs, cecal pieces are placed in a 
250 ml Erlenmyer flask containing 25 mls of RPMI + 5% FBS + 1 mM DTT and  
shook at 200 rpm, 37° C for 20 minutes.  Next, the supernatant was filtered 
through a nylon mesh into a 50 ml conical tube and centrifuged at 1200-1400 
rpm for 10 minutes. The cecal tissue collected in the nylon mesh is set aside for 
LPL isolation. The resulting cell pellet is then suspended in 3 mls of RPMI + 5% 
FBS.  These steps (filter, centrifuge, suspend) are repeated twice for a total of 
three repetitions.  Lympholyte® M (Cedarlane Laboratories Limited, Hornby, 
Ontario, Canada), per the manufactures instructions, is used to isolate viable 
cells which is the IEL fraction used for the described experiments.    
To isolate the LPLs, the cecal tissue previously collected is minced with a 
razor blade, suspended in 25 mls of RPMI + 5% PBS + 100 units/mls 
collagenase and placed in a 250 Erlenmyer flask.  The suspension is shook at 
37° C at 200 rpm for 1 hour and then decanted through nylon mesh into a 50 ml 
conical tube and spun at 1400 rpm for 10 minutes.  Lympholyte-M (Cedarlane 
Laboratories Limited), per the manufactures instructions, is used to isolate viable 
cells which serves as the LPL fraction used for the described experiments.    
Cell Staining, Analysis and Sorting  
Cells isolated from the spleen and ceca were stained for CD4, CD25 and 
Foxp3 utilizing a Mouse Regulatory T Cell Staining Kit (eBioscience, San Diego, 
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CA) per the manufactures instructions, along with the recommended isotype 
controls. For cell sorting, PE-conjugated CD45RB and FITC-conjugated CD4 
antibodies were used per manufactures instructions (eBioscience) along with 
recommended isotype control.  Following staining, cells were washed, 
suspended in an appropriate volume of staining buffer and analyzed with either a 
FACScan or FACSCalibur flow cytometer (BD Biosciences). A FACSdiva flow 
cytometer was used for all CD4/CD45RB cell sorts.  For all experiments, side 
and forward scatter used to exclude dead cells and all gates were set upon 
isotype controls.   
Magnetic Bead Isolation  
CD4+CD25+ T cells were isolated from the spleens of donor mice.  First 
CD4+ T cells were negatively selected using a CD4+ T Cell Isolation Kit per 
manufactures instructions (Miltenyi Biotec, Auburn, CA) and purified with either a 
Miltenyi Biotec autoMACSTM cell separator or an LS Column/MidiMACSTM 
Separator (Miltenyi Biotect). Then, from the isolated CD4+ cellular subset, CD25+ 
cells were positively selected using a CD25 Microbead Kit per manufactures 
instructions (Miltenyi Biotec) and purified in the same fashion as the first isolate.   
Adoptive Transfer of lymphocytes 
After isolation with either flow cytomery or magnetic bead separation, T 
cells were suspended in sterile PBS and 100 μl injected into the tail vein of 
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recipient mice.  All mice were monitored for weight loss; loss of more than 20% of 
the starting body weight resulted in removal from the study.  
anti-CD25 antibody production and administration  
PC61 cells were generously donated by Dr. Habib Zaghouani.  Cells were 
grown in an UltraDOMA serum-free hybridoma media (Cambrex Bio Science 
Walkersville, Inc., Walkersvile, MD) + 10% FCS at 37° C.  Cell suspensions are 
centrifuged at 3000 RPM and the supernatant passed through Whatman 20.0 cm 
filter paper (GE Healthcare, Piscataway, NJ); if necessary supernatant was 
frozen and stored at -20° C until isolation. HiTRAP IgG columns (GE Healthcare) 
were used per manufacture’s protocol for antibody isolation.  All isolated fractions 
were dialyzed in PBS overnight and then concentrations determined using 
spectrophotometery (280nm); if necessary Amicon ® Ultra-15 centrifugal filter 
devices (Millipore, Billerica, MA) were used per manufacturer’s instructions to 
concentrate antibody fractions. For the last experiment, anti-CD25 antibody (PC-
61.5.3) was purchased from BioXCell (West Lebanon, NH).  The isotype control 
rat IgG used in all experiments was purchased from Sigma-Aldrich (Saint Louis, 
MO).  Anti-CD25 and control IgG antibodies were administered to all mice IP with 
a 25G needle.   
Isolation of RNA and Reverse Transcription  
Cecal sections were stored at -80° C until processing.  To begin RNA 
isolation, cecal sections were thawed in TRIzol (Invitrogen, Carlsbad, CA) and 
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then homogenized with a Tissuelyser (Qiagen, Valencia, CA).  RNA isolation was 
done per the manufacturer’s (Invitrogen) instructions.  An Invitrogen Super Script 
II kit was used to reverse-transcribe RNA (5 μg total/ sample) into cDNA (final 
concentration 20 ng/μL) per  the oligo(dT) primer protocol provided.   
Real Time PCR  
Real time quantitative PCR with Qigen Quanti-tect SYBR Green was done 
with a Qiagen Rotor-Gene Q.    Table 4-1 contains the primers and annealing 
temperatures utilized.   Run conditions for HPRT, MIG, IP-10, IL-10 and IL-12/23 
p40 had been previously published25,252. 
Histologic Evaluation 
At necropsy, cecal portions utilized for histologic evaluation were fixed in 
zinc fixative, paraffin embedded and then stained with hematoxylin and eosin 
(H&E) stain.   Using a previously described protocol246,252,253, the cecal sections 
were then scored for inflammatory lesions in a blinded fashion.  
Statistical Analysis 
Student’s t-tests, two-way ANOVA with a Student-Newman-Keuls post-
hoc analysis and two-way ANOVA with a Student-Newman-Keuls post-hoc 
analysis were performed using SigmaPlot 11.0 (Systat Software Inc., San Jose, 
CA).  When appropriate, Log2 transformations were used to correct for failures in 
normality.   p values ≤ 0.05 were regarded as significant.   All graphs and dot 
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plots were generated using either SigmaPlot 11.0 or GraphPad Prism 5.0 
software (GraphPad Prism Software Inc., La Jolla, CA).   
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Figure 5-9.  H. hepaticus does not alter the percentage of CD25+ which are CD4+FoxP3+.   
Pooled splenic, IEL and LPL samples from A/J mice inoculated with H. hepaticus at 3-4 weeks of 
age were collected four months post-inoculation (n= 10 mice/group).  Three groups of age 
matched A/J mice (H. hepaticus free) were used as controls.  Data presented the percentage of 
CD25+ also CD4+Foxp3+; bars indicate group means ± SD.   Data statistically analyzed with 
student t-tests; p ≤ 0.05 considered statistically significant.     
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Figure 5-10.  1 mg of anti-CD25 antibody administered IP is sufficient to deplete CD25+ 
cellular populations in the A/J and C57BL/6 mouse.   
(A) 3-4 week old A/J and C57BL/6 mice were administered one of the four treatment regimens 
listed. (B) To allow for necropsy of all mice on the same day, antibody was administered as 
outlined.  (C) Following necropsy splenocytes were isolated and stained for CD4 and CD25.  
Following evaluation with flow cytometry, the percentage of CD4+CD25+ cells for all four 
treatment groups was determined; mice within each group were individually evaluated. Data 
statistically analyzed with a two-way ANOVA with a Student-Newman-Keuls post-hoc analysis; p 
≤ 0.05 considered statistically significant.     
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Figure 5-11. Administration of anti-CD25 antibody potentially depletes T effector cells 
generated in response to H. hepaticus.  
15 A/J and 15 C57BL/6 mice were treated with 1 mg anti-CD25 antibody IP 3 days prior to 
inoculation with H. hepaticus.  The same number of control mice were treated in the same 
manner with 1 mg rat IgG isotype control antibody.  (A)  Four days post-inoculation 5 mice from 
each group (20 total) were necropsied and evaluated for the presence of CD4+CD25+ cells; 
images are representative of those seen within the two treatment groups.     A significant 
decrease this cell population was noted in the anti-CD25 treated mice when compared to the 
controls. (B)  At 45 and 90 days post-inoculation the remaining mice were necropsied (n=5 for 
each group at each time point) and evaluated for the development of cecal inflammation.  Each 
dot plot represents the lesion score of an individual mouse. (C)  Mice necropsied at the 45 and 90 
day time points were evaluated for the mRNA expression of IP-10, MIG, IL-12/23 p40 and IL-10. 
Data statistically analyzed with either a student’s t-test or a two-way ANOVA with a Student-
Newman-Keuls post-hoc analysis; p ≤ 0.05 considered statistically significant.  All data presented 
as mean ± S.D..  
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Figure 5-12.  0.5 mg of anti-CD25 antibody suppresses CD25+ cell populations for 9 days in 
the C57BL/6 mouse and 13 days in the A/J mouse.   
A/J and C57BL/6 mice were treated with 0.5 mg anti-CD25 antibody IP.  Mice were necropsied on 
the indicated days and splenocytes isolated and evaluated for the expression of CD4, CD25 and 
Foxp3.  Data from experimental mice is normalized to the control mouse for each time point.  (A) 
CD4+CD25+Foxp3+ expression was evaluated at 5, 7, 9 and 11 days post-antibody administration.  
(B) CD4+CD25+Foxp3+  expression was evaluated at 3, 9, 11, 13, 15, 17 and 19 days post-
antibody administration.     
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Figure 5-13.  Administration of anti-CD25 has no long term effects on H. hepaticus 
induced-disease development in the A/J mouse.   
A/J mice were treated with 0.5 mg anti-CD25 antibody IP 13 days prior to inoculation with H. 
hepaticus.  C57BL/6 mice were treated with 1 mg anti-CD25 antibody IP 9 days prior to 
inoculation with H. hepaticus.   A/J and C57BL/6 control mice were treated with 0.5 mg rat IgG 
isotype control antibody prior to inoculation.  (A)  At 45 and 90 days post-inoculation mice were 
necropsied (n= 5, 10 per group for the 45 and 90 day necropsy time points, respectively) and 
evaluated for the development of cecal inflammation. (C)  A/J mice necropsied at both time points 
were evaluated for the mRNA expression of IL-12/23 p40, MIG and IP-10.  All data statistically 
analyzed with a two-way ANOVA with a Student-Newman-Keuls post-hoc analysis; p ≤ 0.05 
considered statistically significant. Each dot plot represents the lesion score of an individual 
mouse; error bars indicate mean ± S.D.. 
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Figure 5-14. The adoptive transfer of CD4+CD25+ cells does not reverse H. hepaticus 
induced inflammation.   
3-4 week old female A/J mice were inoculated with H. hepaticus; ninety days later the mice were 
administered either 0, 2 or 3 treatments of 1 x 106 CD4+CD25+ cells intravenously.  Treatments 
were done once every seven days.  Three days following the last adoptive transfer for the mice 
which received three treatments, all mice were necropsied and ceca evaluated for histologic 
disease.  Each dot plot represents the lesion score of an individual mouse.  Data statistically 
analyzed with a one-way ANOVA; p ≤ 0.05 considered statistically significant.  No significant 
differences were identified.   
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Figure 5-15. The adoptive transfer of CD4+CD25+ during disease development does not 
ultimately inflammation severity.   
3-4 week A/J mice were inoculated with H. hepaticus.  The same mice received adoptive 
transfers of either CD4+CD25+ or CD4+CD25- cells weekly for three weeks starting one (group 
one), two (group two) or three (group 3) months post-H. hepaticus inoculation.  Control mice were 
inoculated with H. hepaticus but received no cellular transfers.  All cells used in adoptive transfers 
were isolated from 6 week old A/J mice.  Three days following group 3’s third adoptive transfer, 
all mice in the study were necropsied.  (A) Cecal histologic lesion scores of experimental and 
control mice.  (B)  mRNA gene expression analysis of MIG, IP-10, IL-12/23 p40 and IL-10.  .  
Each dot plot represents the lesion score of an individual mouse.  All data statistically analyzed 
with a two-way ANOVA with a Student-Newman-Keuls post-hoc analysis; p ≤ 0.05 considered 
statistically significant. All data presented as mean ± S.D.. 
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Figure 5-16. The adoptive transfer of CD4+CD25+ cells exacerbates disease.    
8-12 week old A/J RAG2-/- mice were adoptively transferred CD4+CD25- or CD4+CD25+ or a 1 to 2 
ratio of these cells.  12 weeks later these mice were necropsied and cecal inflammation 
evaluated.  These adoptive transfer groups were completed with (A) female donors/female 
recipients (n = 4, 4 and 3), (B) male donors/male recipients (n = 3, 3 and 3) and (C) female 
donors/male recipients (n = 4, 4 and 5). Data statistically analyzed with a one-way ANOVA; p ≤ 
0.05 considered statistically significant. Each dot plot represents the lesion score of an individual 
mouse; error bars indicate mean ± S.D.. 
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Figure 5-17. The adoptive transfer of CD4+CD45RBlow T regulatory cells does not 
significantly decrease inflammation.  
8-12 week old male A/J RAG2-/- mice were inoculated with H. hepaticus and then adoptively 
transferred CD4+CD25- or CD4+CD25+ or a 1 to 2 ratio of these cells from naïve male A/J mice.  
12 weeks later these mice were necropsied and cecal inflammation evaluated.  Each dot plot 
represents the lesion score of an individual mouse.  Data statistically analyzed with a one-way 
ANOVA; p ≤ 0.05 considered statistically significant.  Each dot plot represents the lesion score of 
an individual mouse; error bars indicate mean ± S.D.. 
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